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Background 
This first chapter of the thesis outlines the background of both economic 
evaluation (EE) and coronary heart disease (CHD). In the first (1) part the 
general aim of performing EEs and elementary concepts of EEs are de-
scribed. In the second (2) part CHD is introduced and its treatment op-
tions are described. In parts 3 and 4 the epidemiology and the eco-
nomic burden of CHD are described. Finally, the aim and the thesis out-
line are summarized in part 5. 
1 Economic evaluations in healthcare 
Over the past decades a rapid increase of medical care costs was ob-
served in western countries due to technological developments and 
ageing populations. At the same time there was increasing pressure of 
national governments on budgets and an awareness that limits must be 
set to the growth of healthcare costs. EEs were introduced as a tool to 
inform decision-makers (e.g., Minister of Public Health, insurance com-
panies, management, professionals and individual healthcare providers) 
on the efficiency or cost-effectiveness of a specific healthcare program. 
EEs aims to answer the following two questions; 'Is the new treatment 
worth doing compared to what we could do with the same resources?', 
and 'Are we satisfied with the way healthcare resources (required to 
make the treatment available to those who benefit from it) are spent'? 
(Drummond, 1996). 
An EE can be defined as the comparative analysis of alternative courses 
of action in terms of both costs and consequences. The basic framework 
of any EE is to identify, measure, value and compare costs and conse-
quences of alternative treatments considered (Drummond, 1996). The 
decision making process of the use of specific healthcare technology is 
not only based on its cost-effectiveness, but also on its efficacy (can the 
new treatment work?), effectiveness (does it work?), and availability (is it 
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reaching those who need it?). The latter three aspects are not the pri-
mary subject of EEs (Drummond, 1996) and need to be assessed in addi-
tional evaluations. 
Framing is a theoretical framework, which can be used to develop an 
EE. Framing can be defined as a series of decisions that collectively de-
fine and describe the EE study to be undertaken (Gold, 1996). In other 
words, moving from a general idea to concrete details it is necessary to 
design an EE study leading to the calculation of a cost-effectiveness ra-
tio that is informative to the decision making context. The important as-
pects of framing will be briefly discussed below. 
The first important aspect of framing an EE is defining the study objective 
and the target audience. In other words, which particular healthcare 
program will be the objective of the study, and who are the persons that 
make the decisions about the particular healthcare programs (an ex-
ample of the objective can be: what is the cost-effectiveness of a spe-
cific type of fast-track treatment compared to care as usual; an exam-
ple of the audience can be: general managers of the intensive care 
units). 
The second aspect is choosing the correct type of analysis for the EE. 
Three types of full EEs and five types of partial EEs can be distinguished. In 
a full EE both the costs and consequences of alternative treatments or 
services are evaluated. The first type of full EE is the cost-effectiveness 
analysis (CEA). All relevant costs and health gains (for instance reduction 
of blood pressure, decrease in the number of myocardial infarctions) are 
measured. The second type of full EE is the cost-utility analysis (CUA), a 
special form of CEA analysis. The effects are expressed in the preference 
for the health state reached (like Quality Adjusted Life Years (QALYs). 
QALYs are a combined measure of quality of life and duration of life. The 
third type full EE is the cost benefit analysis (CBA). Both costs and effects 
are expressed in monetary terms. 
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In addition there are five types of partial EEs (Drummond, 1996). In three 
types of partial EEs no comparison of alternatives is being made (that is, 
a single service or program is being evaluated). They are named: out-
come description (only the consequences of program or service are ex-
amined), cost description (only the costs are investigated), and the 
combination of the two previous ones, a cost-outcome description 
(Drummond, 1996). The two other types of partial EEs are efficacy or ef-
fectiveness evaluation and cost analysis. In both evaluation situations 
two or more alternatives are compared, but the costs and outcomes of 
each alternative treatment are not examined simultaneously. In efficacy 
or effectiveness evaluation only the outcomes and in cost analysis only 
the costs are examined. 
A third aspect of framing an EE is choosing the relevant type of perspec-
tive. There are several perspectives, which can be chosen. First a societal 
perspective, which is recommended by the Dutch and the international 
pharmaco-economic guideline (ISPOR, 2008). In this type of perspective 
all relevant costs are taken into account: direct medical costs, direct 
non-medical costs, and indirect costs. Direct medical costs are all costs 
that are part of the healthcare sector, and are related to detection, 
treatment and rehabilitation of health impairment or its effect (for in-
stance, costs of blood samples, drugs, general practitioner). Direct non-
medical care costs are associated with provision of medical services out-
side the healthcare sector (for instance, out-of-pocket expenses, costs of 
informal care). Indirect costs are productivity costs: costs related to ab-
sence of work due to illness and treatment. Another perspective that 
can be used is the decision makers' perspective. For instance, the hospi-
tal perspective (costs only related to the hospital are accounted for and 
the healthcare insurer's perspectives (costs of care which the insurer 
pays). Furthermore, the patient perspective can be chosen. All relevant 
costs for the patient are calculated (e.g. travel and waiting times, out-of-
pocket expenses of drugs). 
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The fourth aspect is defining the intervention, the comparison treatment 
and the target population. All three should be described in detail. The 
target population is the population for whom the treatment is intended 
and is mostly defined by eligibility criteria. 
The fifth aspect is defining the boundaries and the time horizon. The 
boundaries are those aspects that are not primary related to the scope 
of the study. These aspects should not be incorporated in the analysis, 
like the influences on quality of life of family members and costs made 
by those relatives due to illness of the patients under study. The time hori-
zon for the EE is the period of time over which costs and benefits are 
likely to differ between the alternative options being compared (Scul-
pher, 2006). This can be, for instance, the duration of patients' lives. If the 
appropriate time horizon extends beyond the availability of data, a 
mathematical modelling of costs and consequences might be unavoid-
able (Buxton, 1997). 
2 Coronary heart disease 
The term cardiovascular disease (CVD) covers a number of different dis-
eases, which affect the heart. Coronary heart disease (CHD) (or coro-
nary artery disease (CAD) or ischemic heart diseases (IHD) (ICD-10 120-
125) are the type of CVD caused by atherosclerosis causing a shortage 
of oxygen in the heart muscle due to a reduction in blood supply. CHD 
can be divided into an acute (heart attack or myocardial infarction) 
and a chronic form (angina pectoris). Acute myocardial Infarction (AMI 
or Ml), more commonly known as a heart attack, is a medical condition 
that occurs when the blood supply to a part of the heart is interrupted. 
The resulting ischemia or oxygen shortage causes damage and potential 
death of heart tissue. Angina pectoris, commonly known as angina, is 
chest pain due to ischemia (a lack of blood and hence oxygen supply) 
of the heart muscle, generally due to obstruction or spasm of the coro-
nary arteries. 
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For both Ml and angina pectoris the most common invasive treatment 
intervention to restore blood supply in the heart are the percutaneous 
coronary interventions (PCI) and coronary artery bypass grafting surgery 
(CABG) (Scholte op Reimer, 2006). Patients who undergo CABG-surgery 
can be stratified by risk of the development of postoperative complica-
tions. By means of a risk stratification system based on Parsonnet (Par-
sonnet, 1989) and Society of Thoracic Surgeons criteria (STS, 2003), low-
risk CABG patients can be identified as those patients who fulfill the fol-
lowing criteria: stable cardiological hemodynamic condition (not having 
a cardiogenic shock, no need for inotropic therapy, no need for in-
traaortic balloon pump, and no ongoing or recent myocardial infarc-
tion), not older than 78 years, an ejection fraction of more than 30% and 
not requiring hemodialysis or having pulmonary hypertension. 
High-risk CABG patients are all CABG patients who do not fulfill the 
above-mentioned criteria or CABG patients who also undergo valve re-
placements or valve repair surgery. In 2001 approximately 80% of the pa-
tients with CHD undergoing CABG-surgery in the Netherlands could be 
classified as low-risk (based on an estimate of the Summit database of 
the department of Cardio Thoracic Surgery of the University Hospital of 
Maastricht). The average length of hospital stay for Dutch CABG patients 
between 2005 and 2007 was 11.6 days (Prismant, 2008). After surgery pa-
tients are admitted to the intensive care unit for monitoring the essential 
organ functions (like cardiac output, fluid balance). 
3 Epidemiology of coronary heart disease 
Quantification of the burden of illness of CHD is important for healthcare 
planning, policy decisions and resource allocation for research. CHD is 
the most common heart disease in the Netherlands. In 2003 more than 
675,000 people were diagnosed CHD. The prevalence of CHD in the 
United States of America (US) was 13.2 million in 2003. Data from the 
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Health Survey in the United Kingdom (UK) in 2006 show a prevalence of 
CHD of 6.5% in men and 4.0% in women (BHF, 2008). 
The annual incidence of CHD in the Netherlands in 2003 was 51.0 per 
1,000 men and 32.5 per 1,000 women (RIVM, 2008b). The estimated inci-
dence in the US of Ml is 600,000 new attacks and 320,000 recurrent at-
tacks annually (AHA, 2008). The incidence of Ml varies in the United 
Kingdom, but on average the incidence rate for men aged between 30 
and 69 is about 600 per 100,000, and for women about 200 per 100,000 
(BHF, 2008). 
In the Netherlands, in the last three years (2005-2007), on a yearly basis 
almost 9,000 patients with CHD underwent CABG-surgery and more than 
35,000 CHD patients underwent a PCI (Prismant, 2008). In the US in 2005 
469,000 CABG-surgeries were performed (AHA, 2008). 
CVD was for both men and women the most important cause of death 
in the Netherlands in 2004. More than 45,000 people died due to CVD, 
which is 33% of all causes of death. One third of these deaths was due to 
CHDs (NHS, 2006). CHD caused 451,326 deaths in the United States of 
America in 2004 (AHA, 2008). CHD causes over 94,000 deaths a year in 
the UK: this is approximately one in five deaths in men and one in seven 
deaths in women (BHF, 2008). These figures indicate that CHD is not only 
a health problem that affects both men and women, but it is also the 
number one cause of death in the Netherlands, the US and the UK. 
4 Costs of illness 
The costs of illness illustrate the economic burden of a disease in a spe-
cific country. The total healthcare costs due to CHD were estimated in 
2005 at €1.251 million in the Netherlands (RIVM, 2008a). In the US the total 
direct and indirect costs of CVD are estimated at $448.1 billion (AHA, 
i 
2008). Overall CHD is estimated to cost the UK economy over £9.0 billion 
a year (in 2006). Of the total cost of CHD to the UK, around 36% is due to 
direct healthcare costs, 43% to productivity losses, and 21% to the infor-
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mal care of people with CHD (BHF, 2008). CHD is estimated to cost the 
European Union over €49 billion a year. Around 48% of the total costs of 
CHD in the European Union are due to direct healthcare costs, 34% to 
productivity losses and 18% to the informal care of people with CHD 
(BHF, 2008). These figures show that the total healthcare costs of CHD are 
substantial for both the European Union and the US. 
5 Aim and outline of the thesis 
The aim of this thesis is twofold. The first part of the thesis focuses on the 
evaluation of short-stay intensive care treatment (SSIC). The second part 
deals with methodological aspects of measuring the outcomes as part 
of an EE of SSIC, more specifically, the measurement and analysis in 
quality of life of CABG patients. 
Part 1: Evaluation of short-stay intensive care treatment 
The first objective of this thesis is to evaluate the clinical effectiveness, 
quality of life and cost-effectiveness of the short-stay intensive care 
treatment for low-risk CABG patients. 
The second chapter comprises a systematic review of all randomized 
clinical trials published from 1966 to 2004 in low-risk coronary artery by-
pass patients who evaluated fast-track treatments. Furthermore, a meta-
regression analysis will be performed to evaluate the impact of these 
types of intensive care treatments on the number of hours of intensive 
care and hospital stay. In addition, the methodological quality of trials, 
including the economic evaluation performed alongside, will be as-
sessed. 
Chapter 3 contains the clinical effectiveness and cost-effectiveness of 
the randomised controlled clinical equivalence trial evaluating the short-
stay intensive care treatment protocol in low-risk CABG patients. In this 
study overnight intensive care stay (care as usual) will be compared with 
discharge from intensive care within 8 hours (SSIC). 
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In the fourth chapter the disease specific, generic and domain specific 
quality of life of the CABG patients receiving SSIC treatment will be 
evaluated until one year after surgery. The first four hundred patients 
who also participate in the trial (chapter 3) participate in this quality of 
life study. 
Part 2: Methodological aspects of measurement and analysis of quality 
of life 
The second objective of this thesis is the improvement of measurement 
and analysis of quality of life when evaluating interventions in CABG pa-
tients. 
In chapter 5 the psychometric proportions of a generic (EQ-5D) and a 
disease specific (MILQ) quality of life measure will be assessed. Therefore, 
the item completion rate, the discriminative validity, the predictive valid-
ity, the criterion validity and the test-retest reliability of both question-
naires will be examined. 
In the sixth chapter, the impact of imbalances in baseline utility in QALY 
calculations will be examined. Five different methods for the calculation 
of QALYs will be discussed. The data of the economic evaluation of the 
SSIC treatment will be used to demonstrate the impact of the various 
correction methods on the study outcomes. 
Chapter 7 gives an overview of the thesis. The main findings will be sum-
marized, discussed and recommendations for further research will be 
given. 
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C H A P T E R 
Does fast-track treatment lead to a decrease 
of intensive care unit and hospital length of 
stay in coronary artery bypass patients? 
A meta-regression of randomised clinical trials 
Critical Care Medicine 2006; 34 (6): 1624-34 
Ghislaine van Mastrigt 
Jos Maessen 
John Heijmans 
Hans Severens 
Martin Prins 
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Abstract 
Objective: Evaluation of randomised controlled clinical trials studying 
fast-track treatment in low-risk coronary artery bypass grafting patients. 
Design: Meta-regression. 
Patients: Low-risk coronary artery bypass grafting patients. 
Interventions: Fast-track treatments including (high or low) anesthetic 
dose, normothermia - vs. hypothermia and extubation protocol (within or 
after 8 hours). 
Measurements: Number of hours intensive care unit stay, number of days 
of hospital stay, prevalence of myocardial infarction, and death. Fur-
thermore, quality of life and cost evaluations were evaluated. The epi-
demiological and economic qualities of the different trials were also as-
sessed. 
Main results: A total of 27 studies evaluating fast-track treatment were 
identified, of which 12 studies were with major and 15 were without major 
differences in extubation protocol or anesthetic treatment or both. The 
use of an early extubation protocol (P-value =.000) but not the use of low 
anesthetic dose (P-value =.394) or normothermic temperature man-
agement (P-value =.552) resulted in a decrease of the total intensive 
care unit stay of low-risk coronary artery bypass grafting patients. Early 
extubation was found to be an important determinant of the total hospi-
tal stay for these patients. An influence of the type of fast-track treat-
ment on mortality or the prevalence of postoperative myocardial infarc-
tion was not observed. In general, the epidemiological and economic 
qualities of included studies were moderate. 
Conclusions: Although fast-track anesthetics and normothermic tem-
perature management facilitate early extubation, the introduction of an 
early extubation protocol seems essential to decrease intensive care unit 
and hospital stay in low-risk coronary artery bypass grafting patients. 
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Introduction 
Rising medical costs mandate a close look at our practices to assess the 
possibility of costs savings without comprising the quality of care (vander 
Salm & Blair, 1984). As coronary artery bypass grafting (CABG) is a costly 
and common procedure, this treatment merits attention. The intensive 
care unit (ICU) stay is an important cost component of the total cost of 
recovery after CABG (Cheng, 1996b). Hence, earlier discharge to lower-
care facility would decrease the cost of hospitalization of CABG patients. 
CABG patients with a low Parsonnet score (Parsonnet, 1989) who stay in 
ICU facilities have low risk for postoperative complications and are there-
fore candidates for a decrease of ICU length of stay and, hence, are 
eligible for fast-track treatment. This includes not only fast-track anesthet-
ics, but also normothermic temperature management and the use of 
weaning protocols that make early extubation possible. Several reviews 
performed so far have demonstrated the safety for elements of fast-track 
treatment, for instance early vs. late extubation (Hawkes, 2003; Meade, 
2001) or low vs. high use of opioids (Myles, 2003; Myles, 2002). 
Due to the heterogeneity of the interventions, we sought to investigate 
the combined effect of the above-mentioned elements after CABG sur-
gery on the decrease of ICU and hospital stay, and for this purpose, we 
used a meta-regression technique (Thompson & Higgins, 2002). Further-
more, we systematically reviewed the studies on reported quality of life 
and costs. 
27 
Chapter 2 
Materials and Methods 
Selection criteria 
All randomised clinical trials of low-risk, adult (age >18 years) CABG pa-
tients that evaluated fast-track treatments and reporting ICU stay were 
eligible for inclusion. Studies were excluded if the patient sample in-
cluded a majority of non-CABG patients or if a majority of patients were 
considered to have a high risk for complications. High-risk was defined 
as: age > 78 years, ejection fraction of <30%, stage 3 obesity, hemodialy-
sis, pulmonary hypertension, recent cardiovascular accident (<1 month), 
recent myocardial infarction (Ml; <24 hrs before CABG), cardiogenic 
shock, need for inotropic therapy, ongoing infarction or the need for in-
traaortic balloon pump (Priestley, 2002). Abstracts and reviews were also 
excluded. 
Search strategy 
A systematic search for all relevant trials published from 1966 until 
through October 2004 was performed. Studies were identified through 
MEDLINE and Cochrane databases using, for instance the following 
terms: coronary artery bypass surgery, randomised controlled clinical 
trial, fast-track, early extubation and ICU Stay. The complete search 
strategy is provided in Appendix 1. References lists were screened for 
additional relevant publications. 
Classification of interventions 
The interventions of the different studies were independently assessed by 
two reviewers (GvM, JH) and disagreement was resolved by discussion. 
The types of interventions were categorized first, by type and dose of 
anesthetics (high dose: fentanyl >15pg/kg, sufentanil >3pg/kg, alfentanil 
>60pg/kg (Ahonen, 2000), low dose: fentanyl <15pg/kg, sufentanil <2-
3|jg/kg, alfentanil<60|jg/kg (Ahonen, 2000) or remifentanyl), second by 
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temperature management during cardiopulmonary bypass (nor-
mothermia (>35°C) or hypothermia (<35°C)) and third, by extubation 
protocol (the intention to extubate a patient within or after 8 hours post-
operatively). 
Outcome measures 
The primary outcome measure was length of ICU stay (in hours). The 
other outcomes were hospital stay (days), Ml, death, quality of life (QoL) 
and costs. 
For this study, the Ml definition of the trials needed to contain the follow-
ing aspects: a typical rise and gradual fall (troponin) or more rapid rise 
and fall (CK-MB) with at least one of the following criteria: ischemic 
symptoms, development of pathologic Q waves on the echocardio-
gram or echocardiographic changes of ischemia ST depres-
sion/elevation or t-wave inversion (Alpert, 2000). 
Methodological quality of the studies 
The articles were not blinded for authors, institution or journal. The three 
assessed methods of methodological qualities were: allocation con-
cealment (unclear and adequate), blinding of person or persons decid-
ing on the length of ICU stay (adequate, unclear) and the use of inten-
tion-to-treat analysis for the primary outcome ICU stay. Uncertainties 
were assessed in consensus meetings, eligibility of the studies was dis-
cussed by two of the authors (GvM, JH), and concerns of the methodo-
logical quality were discussed by two of the authors (GvM, MP). 
The quality of the economic evaluations was assessed using the Consen-
sus Health Economic Criteria list (CHEC-list), including 19 items 
(Donaldson C, 2002). Two items, concerning 'future costs' and 'ethical 
and distributional issues' do not apply to these studies and were omitted. 
Items scored as 'yes' received 1 point. Items scored as 'unclear' or 'no' 
received no points. A total score was calculated by summing up the 
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score of the 17 items (range, 0-17). Uncertainties about quality of the 
economic evaluations were assessed in a consensus meeting (GvM, HS). 
Statistics 
When median and range were reported for continuous outcomes, the 
mean and standard deviation were estimated by assuming that the 
mean was equivalent to the median and the standard deviation was 
one quarter of the range (O'Rourke, 2002). 
To evaluate the relation between length of stay at the ICU and the type 
of treatment, a regression analysis was performed. ICU stay was the de-
pendent and anesthetic treatment (low, unknown or high dose; coding: 
-1,0,1), temperature management (normothermia, unknown or hypo-
thermia, coding: -1,0,1) and extubation protocol (<8 hrs, unknown or >8 
hrs, coding: -1,0,1) were the independent variables. The number of pa-
tients in the study divided by squared standard deviation is used as a re-
gression weight in the model. Separated models were analyzed for stud-
ies categorized with or without major difference in anesthetic dose 
and/or extubation protocol between both studies arms. To correct for 
year of publication and the methodological quality variables (score of 1, 
if the score was adequate or yes and 0 if the score was unclear or no) 
were as co-variables included in the regression models. In two Forrest 
plots, the effects of the different studies with a major difference in anes-
thetic dose or extubation protocol on the ICU stay were presented. The 
CHEC-list score was not included in the models. 
Results 
Study inclusion 
Figure 1 summarizes the process of inclusion of the studies for review. Of 
the 643 studies that were selected by the performed search, we ex-
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eluded 367 studies as they did not evaluated fast-track treatments. An-
other 117 studies were excluded because the study population con-
tained a majority of non-CABG patients (n=106), or consisted of high-risk 
patients (n=2), children (n=6), or animals (n=3). A total of 83 studies were 
excluded due to study-related characteristics: no randomised clinical 
study (n=77), abstract (n=l), reviews (n=2), Japanese language (n=1), 
not traceable (n=2). The remaining 76 studies were randomised, con-
trolled trials reporting fast-track treatment in low-risk CABG patients. Thirty 
of them also reported IC stay and fulfilled all inclusion criteria. However, 
two studies, one performed by Cheng et al. (Cheng, 1996a) and the 
other performed by Howie et al. (Howie, 2001) were published in three 
additional reports (Cheng, 1996b; Cheng, 2001; Cheng, 2003). The data 
of these three additional reports were only used once for analysis. 
Figure 1: Process of inclusion of studies for review and analysis 
Rolrieved reports 
n=M3 
Reasons exclusion 
Intervenlion n=367 
Patient characteristics n= l 17 
Typo ol sludy n=83 
30 reports on 27 studies 
Eligible for Inclusion 
n=76 
Inlonslve care stay not reported as 
outcome n=<16 
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Study characteristics and study quality 
The 27 included studies contained a total of 2.821 patients; most of them 
were published after the year 2000. Due to classification of the interven-
tion as described in 'Materials and Methods', 12 studies (Berry, 1998; 
Cheng, 1996a; Engoren, 2001; Hall, 1991; Kadoi, 2003; Michalopoulos, 
1998; Myles, 2002; Quasha, 1980; Reyes, 1997; Royse, 2003; Sherry, 1996; 
Shroff, 1997) showed a contrast between both study arms (table 1). Nine 
of these studies (Berry, 1998; Cheng, 1996a; Engoren, 2001; Hall, 1991; 
Kadoi, 2003; Myles, 2002; Royse, 2003; Sherry, 1996; Shroff, 1997) were 
categorized as with as having a major difference in anesthetic dose. In 
two of them (Berry, 1998; Cheng, 1996a) the extubation protocol was 
also categorized as different. In three studies (Michalopoulos, 1998; 
Quasha, 1980; Reyes, 1997) the extubation protocol was the only con-
trast. The other 15 studies (Bowler, 2002; Engoren, 1998; Fillinger, 2002; 
Howie, 2001; Latham, 2000; Mangano, 1992; Mollhoff, 2001; Mora, 1995; 
Myles, 1997; Fetter, 2003; Samuelson, 1986; Simeone, 2002; Sulzer, 2001; 
Tritapepe, 2002; Zarate, 2000) did not show any differences between ei-
ther trial arms when using our categorization criteria (table 2). Only one 
study fulfilled the three methodological quality criteria we evaluated. Ten 
of the 27 studies did not adequately fulfill any of these criteria. In table 3, 
a summary of the pooled data of all reviewed studies is given. The CHEC-
list score of the seven studies that included data on costs varied be-
tween 5 to 12 (table 4). In five of the studies (Engoren, 2001; Engoren, 
1998; Mora, 1995; Myles, 2002; Sherry, 1996), the economic study design 
was not appropriate to the stated objective. Furthermore, in most of the 
studies not all relevant costs were identified and the identified costs were 
not measured (Engoren, 2001; Engoren, 1998; Fillinger, 2002; Mora, 1995; 
Sherry, 1996) and valued appropriately (Engoren, 2001; Engoren, 1998; 
Fillinger, 2002; Mora, 1995; Myles, 2002). None of the studies performed a 
sensitivity analysis. No statements on potential conflicts of interest were 
presented (scoring on separate items not shown). 
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Intensive care stay and hospital stay 
Table 5 shows the results of the six regression models, in the first three 
models ICU stay was the dependent variable, and in the last three mod-
els, hospital stay was the dependent variable. In all models, anesthetic 
dose, temperature management, and extubation protocol are the in-
dependent variables. Models 1 and 4 show the results of the studies with 
a major difference in anesthetic dose and/or extubation protocol, mod-
els 2 and 5 the results of the studies without a major difference in anes-
thetic dose and/or extubation protocol, models 3 and 6 show the results 
of all 27 studies. Due to coding (1, 0, -1), the height of the B is not corre-
spond with the number of hours or days reduction in ICU or hospital stay. 
All models except model 2 showed that extubation time has a significant 
effect on the ICU and hospital stay. If the quality variables and the year 
of publication are included in the models, the explained variance of all 
models improved. However, if these variables were eliminated the vari-
able 'extubation protocol' stayed the important predictor of ICU and 
hospital stay. The Forrest plot (figure 2) with the studies (n-7) reporting a 
major difference in anesthetic dose shows that the type of anesthetic 
dose (low vs. high) has no effect on ICU stay. For the studies (n=5) who 
were categorized reporting a major difference in extubation protocol, a 
small but significant difference in ICU stay between extubation within or 
after 8 hours after surgery was found (figure 3). 
The significance of the other variables in some of the models (for in-
stance temperature management in model 5 and anesthetic dose in 
model 3) may be the result of multiple testing. 
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Table 1: Summary of studies with a major difference in anesthetic dose and/or extubatlon protocol 
Intervention Study quality 
ICU stay 
Hrs 
Hospital 
stay, 
days Ml Death 
. lL. no. of Author, year ., . patients 
anesthetic 
dose 
Temp. 
Manage. 
Extub. 
Prot. 
Hrs in 
allocation 
concealment blinding N mean N mean N n N n 
Studies (n=7) with a major difference in anesthetic dose 
Kadoi, 2003 
180 
low 
high 
normo 
normo 
-
unclear unclear unclear 
90 
90 
120 
144 
- - : : : -
Royse, 2003 
76 
low 
high 
normo 
normo 
<8 
< 8 
no unclear unclear 
37 
39 
45.6 
48.1 
37 
39 
6.9 
7.2 
• - 37 
- 39 
0 
1 
Myles, 2002 low - <8 24 23 24 7.8 24 3 - -
77 high - <8 no adequate adequate 24 22 24 5 24 0 - -
low - <8 29 23 29 5.9 29 0 - -
Engoren, 2001 low normo < 8 30 18.8 30 5 - - 30 1 
90 high normo < 8 unclear unclear uncleqr 30 19.8 30 5 - - 30 0 
low normo < 8 30 21.5 30 5 - - 30 0 
Shroff, 1997 
21 
low 
high 
- < 8 
< 8 
yes adequate adequate 
12 
9 
55 
65 ; ; ; ; ; -
Sherry, 1996 
70 
low 
high 
normo 
normo ; no unclear unclear 37 33 
22.4 
23.6 
- - - - -
Hall, 1991 
47 
low 
high 
hypo 
hypo 
-
yes unclear adequate 
24 
23 
50 
59.8 
- - 24 
23 
1 24 
1 23 
0 
0 
Studies (n= 2) with a major difference in anesthetic dose and extubatlon protocol 
Berry, 1998 
85 
low 
high 
normo 
normo 
> 8 
< 8 
yes unclear unclear 
43 
42 
48 
48 
43 
42 
8 
8 
43 
42 
2 43 
2 42 
2 
0 
Cheng, 1996a* 
102 
low 
high 
normo 
normo 
<8 
> 8 
no unclear adequate 
51 
51 
29.2 
30.9 
51 
51 
7 
8.2 
60 
60 
0 60 
4 60 
1 
3 
Studies (n= 3) with a major difference in extubatlon protocol 
Michalopoulos, 
1998 1 4 4 
high 
high 
- < 8 
> 8 
unclear unclear adequate 
72 
72 
16 
23 
72 
72 
7.3 
8.4 
72 
72 
0 72 
0 72 
0 
0 
Reyes, 1997 
404 
high 
high 
normo 
normo 
<8 
> 8 
yes unclear unclear 
201 
203 
27 
44 
- - 121 
151 
4 201 
5 203 
15 
18 
Quasha, 1980 
36 ; - > 8 < 8 no unclear adequate 20 16 57 46 ; - 20 18 3 -0 - -
- = not reported, IC = Intensive Care Unit, Ml = myocardial infarction. Temp. Manage. = temperature management, 
Extub. Prot., = extubalion protocol, ITT= Intention-to-treat analysis, Normo = normothermla, Hypo = Hypothermia, 
•also Cheng 2003 and Cheng 1996b 
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Table 2: Summary of studies without a major difference in anesthetic dose and/or extubation protocol 
Intervention Study quality 
ICUstay Hospital stay M | D e Q ) h 
Hrs Days 
Author, year 
Extub. 
no. of anesthetic Temp. Prot. allocation 
patients dose Manage. Hrs ITT concealment blinding N mean N mean N n N n 
Studies (n=l S) without a major difference In anesthetic dose or extubation protocol 
Petter, 2003 
34 
- hypo <8 no unclear unclear 18 23 - - - - - -
- hypo <8 16 23.2 - - - - - -
Simeone, 2002 low <8 24 29 - . - -
49 unclear unclear unclear 
low - <8 25 46.1 - - - - -
Bowler, 2002 low normo <8 12 12 12 7 _ „ 12 0 
24 unclear unclear adequate 
low normo <8 12 27 12 13 - - 12 0 
Tritapepe, 2002 low - <8 65 28 65 7.4 65 2 65 4 
195 low - <8 unclear unclear adequate 65 26 65 7.8 65 1 65 3 
low - <8 65 20 65 7.5 65 1 65 3 
Sulzer, 2001 low normo <8 16 21.5 _ _ - -
36 no unclear unclear 
low normo <8 20 21.2 - - - - - -
Howie, 2001* normo 
154 low <8 154 24 154 4.9 - - 2 
304 unclear unclear adequate 
low normo <8 150 26.4 150 5 - - 150 3 
Mollhoff, 2001 low <8 148 21.6 148 6.1 148 3 _ 
293 no adequate adequate 
low - <8 145 26.4 145 6.9 146 4 - -
Latham, 2000 low normo <8 20 31.2 20 5.6 20 0 - -
40 no unclear unclear 
low normo <8 20 26.4 20 5.2 20 1 - -
Zarate, 2000 low <8 20 31.2 20 5.6 _ _ _ 
40 yes unclear unclear 
low - < 8 20 26.4 20 5.2 - - - -
Engoren, 1998 low _ <8 35 23 35 6 35 0 
70 unclear unclear unclear 
low - <8 35 21 35 5.1 - - 35 0 
Myles, 1997 tow _ <8 66 41 _ 66 2 66 0 
124 yes unclear unclear 
low <8 58 39 - - 58 0 58 0 
Fllllnger, 2002 high f e r r o <8 30 30 _ _ _ 30 0 
60 no unclear unclear 
high normo < 8 30 31.7 - - - - 30 1 
Mora, 1995 high - - 24 82 - - - - 24 1 
high _ 22 66 _ _ _ _ 22 1 
90 unclear unclear adequate 
high - - 23 66 - - - - 23 0 
high - - 21 71 - - - - 21 0 
Mangano, 1992 high hypo > 8 54 84 54 11.2 54 1 54 2 
106 unclear unclear adequate 
high hypo > 8 52 103.2 52 13.2 52 2 52 0 
Samuelson, 1986 high normo 10 29.9 _ _ . . _ 
24 yes unclear unclear 
high normo - 14 28.1 - - - - - -
see lable 1 for abbrevations, 'also Cheng 2001. 
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Table 3: Pooled data of all studies categorized by type of intervention 
IC stay, Hospital stay, 
Intervention .. _ ' M l Death 
Studies (n=12) with a major difference in anesthetic dose and/or extubation protocol 
Overall anesthetic dose N Mean N Mean N n N n 
high 8 89 44.38 330 7.38 565 16 742 37 
low 407 
36 
51.98 
52.11 
244 6.62 180 
38 
6 224 4 
3 - -
Overall temperature management 
hypothermia 47 54.80 _ _ 47 2 47 0 
normolhermia 1007 51.87 383 6.37 477 17 805 41 
- 278 27.61 221 7.28 259 6 144 0 
Overall extubation protocol 
! hrs 389 39.51 166 8.23 47 2 378 23 
! hrs 676 
297 
28.37 
94.08 
438 6.47 390 
47 
9 571 18 
2 47 0 
Studies (n=15) without a major difference In anesthetic dose and/or extubation protocol 
Overall anesthetic dose N Mean N Mean N n N n 
high 280 67.41 106 12.18 106 3 717 15 
low 1175 
34 
26.71 
23.09 
966 6.15 653 14 256 5 
Overall temperature management 
hypothermia 861 32.26 598 6.66 613 13 479 12 
normothermia 488 25.79 368 5.33 40 1 388 6 
- 140 76.34 106 12.18 106 3 106 2 
Overall extubalion protocol 
> f 3 hrs 106 93.42 106 12.18 106 3 106 2 
< i 3 hrs 1269 
114 
26.81 
26.81 
966 6.15 653 14 777 16 
- 90 2 
All studies (n=27) 
Overall anesthetic dose N Mean N Mean N n N n 
high 1169 49.90 436 B.55 671 19 1459 52 
low 1582 33.21 1210 6.24 833 20 480 9 
- 70 38.01 - - 38 3 - -
Overall temperature management 
hypothermia 908 33.43 598 6.66 660 15 526 12 
normothermia 1495 43.36 751 5.86 517 18 1193 47 
- 418 43.93 327 8.87 365 9 250 2 
Overall extubation protocol 
> 1 3 hrs 495 51.05 272 9.77 153 5 484 25 
<1 3 hrs 1945 27.35 1404 6.25 1043 23 1348 34 
- 411 75.42 - - 47 2 137 2 
36 
__ Systematic review 
Table 4: Data of studies reporting costs 
Conclusion 
Author, CHEC- Time Cost Identified Cost Valua- Concerning 
year list Design Perspective Year Currency Horizon (categories) tion Total Costs 
Studies (n=3) with a major difference In anesthetic dose 
Myles, 
2002 11 CMA hospital 1999 AUS $ 
operating 
theater 
ICU stay 
healthcare 
(surgery, anes-
thetic, 
ICU) 
unclear 
no significant 
difference 
belween the 
Iwo groups 
Engoren, 
2001 
8 CMA hospital unclear US $ hospital 
stay 
healthcare 
(anesthetic, 
hospital) 
unclear 
no significant 
difference 
between the 
two groups 
Sherry, 
1996 
l IK 
8 CMA hospital 1993 
pounds 
until ICU 
discharge 
heallhcare 
(nursing, drug) 
salary scales 
and acquisi-
tion cosl 
no significant 
difference 
belween the 
two groups 
Studies (n=l) with a major difference In anesthetic dose and extubatlon protocol 
Cheng, 
1996a* 
12 CMA insurer unclear CAN $ 
until 12 
months 
heallhcare 
(hospital, 
rehabilitation 
days, physi-
cian visils, 
cardiac drugs 
fees, expen-
ditures 
significant 
reduction of 
costs in low 
dose fentanyl 
and early 
extubation 
group 
Studies (n=3) without a major difference in anesthetic dose 
Engoren, 
1998 
cnO-
9 , . - unclear US $ 
analysis 
unclear 
heallhcare 
(drugs) 
acquisition 
cosl 
significant 
lower in one 
group 
Fillinger, 
2002 
9 CMA hospital unclear US $ 
hospital 
stay 
healthcare 
(unclear) 
charges 
no significant 
difference 
belween the 
two groups 
Mora, 
1995 5
 C O f t " . - unclear US $ analysis 
unclear 
healthcare 
(drugs) 
acquisition 
cost 
unclear 
- = not reported, CHEC-list = Consensus Health Economic Criteria list, CMA= Cost minimization analysis, ICU= Intensive Care Unit, 
•also Cheng 2003 and Cheng 1996a 
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F igure 2: For rest p lo t of s tud ies (n=9) w i t h a m a j o r d i f f e r e n c e in anes the t ic d o s e 
Kadoi 2003 
Royse 2003 
Myles 2002 
Engoren 2001 
Shroff 1997 
Sherry 1996 
Hall 1991 
Berry 1998 
Cheng 1996 
Overall (95% CI) 
1.14574 
Standardised Mean 
Difference (95% CI) 
-0.27 (-0.57,0.02) 
-0.17 (-0.62,0.28) 
0.11 (-0.37,0.60) 
0.06 (-0.38,0.49) 
-0.28 (-1.15,0.59) 
-0.01 (-0.48,0.46) 
-0.25 (-0.83,0.32) 
0.00 (-0.43,0.43) 
-0.14 (-0.53,0.25) 
-0.11 (-0.26,0.03) 
.14574 
% Weight 
24.6 
10.5 
9.1 
11.1 
2.8 
9.6 
6.4 
11.7 
14.1 
Standardised Mean difference 
F igure 3: For rest p lo t of s tud ies ( n = 5 ) w i t h a m a j o r d i f f e r e n c e in e x t u b a t i o n p r o t o c o l 
Berry 1998 
Cheng 1996 
Michalopoulos 1998 
Reyes 1997 
Quasha 1980 
Overall (95% CI) 
r 
-6.32368 
i! 
Standardised Mean 
Difference (95% CI) 
0.00 (-0.43,0.43) 
-0.14 (-0.53,0.25) 
-5.60 (-6.32,-4.87) 
-0.04 (-0.24,0.15) 
-0.48 (-1.14,0.19) 
-0.32 (-0.48,-0.17) 
6.32368 
; Weight 
13.0 
15.6 
4.4 
61.7 
5.3 
Standardised Mean difference 
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Table S: Regression models (1 -4) of the different studies with or without a major difference in 
anesthetic dose and/or extubation protocol 
Model 1 dependent ICU ° stay: Studies (n=12) with a major difference In anesthetic dose 
and/or extubation protocol 
R-Square = .714 B P-value 
B„ 2019.328 .320 
Aneslhetic dose -2.552 .394 
Temperature management -5.143 .552 
Extubation protocol -3.497 .000 
Intention-to-treat 13.524 .294 
Allocation Concealment 6.932 .448 
Blinding -4.329 .678 
Year of publication -.998 .325 
Model 2 dependent ICU stay: Studies (n=15) without a major difference In anesthetic dose 
and/or extubation protocol 
R-Square = .514 B P-value 
Bq -408.534 .802 
Anesthetic dose 1.757 .781 
Temperature management 6.857 .013 
Extubation protocol -16.979 .282 
Intention-to-treat -10.358 .201 
Allocation Concealment -13.997 .064 
Blinding 3.310 .059 
Year of publication .228 .781 
Model 3 dependent ICU stay: All studies (n=27) 
R-Square = .619 B P-value 
B„ 681.038 .453 
Anesthetic dose -4.826 .001 
Temperature management -.180 .938 
Extubation protocol -3.423 .000 
lnlention-to-lreat 5.020 .431 
Allocalion Concealment 2.180 .628 
Blinding .155 .926 
Year of publication -.329 .469 
Model 4 dependent hospital stay: Studies (n=A) with a major difference In anesthetic dose 
and/or extubation protocol 
R-Square = .933 B P-value 
B„ -1947.845 .010 
Anesthetic dose .160 .446 
Temperature management -1.878 .073 
Extubation protocol -.459 .019 
Intention-to-treat 5.185 .003 
Allocalion Concealment -4.568 .013 
Blinding 6,923 .006 
Year of publication .975 .010 
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T a b l e 5: (con t inued) r e g r e s s i o n m o d e l s (5-6) of t h e d i f fe ren t s tud ies w i t h or w i t h o u t a m a j o r 
d i f fe rence in anes the t ic d o s e a n d / o r e x t u b a t i o n p r o t o c o l 
Model 5 dependent hospital stay: Studies (n=8) without a major difference in anesthetic dose 
and/or extubation protocol 
R-Square = .550 B P-value 
Bo -1500.374 .011 
Temperature management 1.377 .005 
Extubation protocol -5.091 .001 
Intention-to-treat -1.455 .024 
Allocation Concealment -4.479X102 .946 
Blinding -.739 .395 
Year of publication .756 .011 
Model A dependent hospital stay: All studies (n=27) 
R-Square = .708 B P-value 
B„ -108.354 .613 
Anesthetic dose .274 .156 
Temperature management -3.287 X 10-2 .943 
Extubation protocol -.617 .002 
Intention-to-treat 1.325 .019 
Allocation Concealment -.586 .477 
Blinding 1.450 .016 
Year of publication 5.735X10' .593 
u ICU= Intensive Care Unit 
Myocardial infarction and death 
In six additional regression models, the influence of the different aspects 
of fast-track treatment on the percentage Ml and death was evaluated. 
Due to a limited number of studies reporting Ml and death, the three 
quality variables and the year of publication could not be taken into ac-
count. In none of the models were the anesthetic dose, temperature 
management or extubation protocol significant predictors for the per-
centage Ml and death (data not shown). 
Quality of life and cost-effectiveness 
Ten of the 27 reviewed studies reported QoL as study outcome (table 6). 
Most of these studies reported pain (Bowler, 2002; Engoren, 2001; Fillinger, 
2002; Howie, 2001; Mollhoff, 2001; Royse, 2003; Shroff, 1997; Zarate, 2000) 
and/ or cognitive function (Cheng, 1996a; Howie, 2001;Kadoi, 2003). 
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As the instruments used and the time point measured varied across stud-
ies, it was impossible to pool the data. 
Only one of the studies reporting pain categorized in the group -with a 
major difference in anesthetic dose or/and extubation protocol- was 
able to reduce the pain in the low-dose group significantly more com-
pared with the high-dose group (Royse, 2003). The two studies in this cat-
egory of studies reporting cognitive function did not find a difference 
between both treatment groups. 
Seven studies reported data on costs (table 4). Five included studies 
(Cheng, 1996a; Engoren, 2001; Fillinger, 2002; Myles, 2002; Sherry, 1996) 
refer to cost-minimization analysis and two studies (Engoren, 1998; Mora, 
1995) to cost analysis. All cost-minimization analyses were from a hospital 
perspective except the study performed by Cheng et al. (Cheng, 
1996a), which used an insurer perspective. Because the costs categories 
used and the time horizon of the measured costs varied, it was impossi-
ble to pool the cost data. Although the conclusions of the majority of 
economic evaluations do not report a decrease of costs, the study 
(Cheng, 1996b) with the highest CHEC-list score reports a significant de-
crease in costs. 
Discussion 
This meta-analysis evaluated the effect of three aspects of fast-track 
treatment (anesthetic dose, extubation protocol and temperature man-
agement). Results indicate that use of a protocol, directed toward early 
extubation (within 8 hrs after surgery) results in a substantial shortening of 
the total ICU and hospital stay of low-risk CABG patients. This effect was 
observed not only in studies that were categorized into different extuba-
tion protocols but also in all other studies and persisted when quality pa-
rameters were included in the analysis. An influence of the type of fast-
track treatment on mortality or the prevalence of postoperative Ml was 
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not observed. In general, the methodological quality of the included 
studies was moderate, and only one study fulfilled the three evaluated 
criteria. Similarly, only one of the seven studies that reported data on 
costs had an acceptable score on the CHEC-list (Donaldson C, 2002). 
However, the highest-quality study demonstrated a cost reduction. 
Fast-track treatment 
For decades, the most common anesthetic technique for CABG was 
anesthesia with a high qose of opioids, such as fentanyl in the range of 
50-100 pg/kg. High-dose-opioids anesthesia provides excellent intra -
operative hemodynamic stability and absence of adverse events; how-
ever, prolonged ventilatory support was needed (Stanley & Webster, 
1978). A shift from high- to low-dose opioids (e.g., <15pg/kg fentanyl) was 
made in the late 1990s. The use of low-dose opioids theoretically results in 
extubation within a few hours postoperatively. Recently, Remifentanyl 
(Rosow, 1993), an anesthetic with a half-life time of about 5-8 mins, was 
introduced to practice, it would permit an even more prompt tracheal 
extubation compared to low dose fentanyl. 
Temperature management is the second important aspect of fast-track 
treatment. Patients need to be normothermic (>35°C) before weaning 
can be started. As hypothermic patients (<35°C) need extra time before 
adequately warmed, hypothermia interferes with early recovery after 
surgery (Karski, 1995). 
Early extubation is also essential for fast-track treatment and is mostly de-
fined as extubation within 1 to 8 hours after surgery (Karski, 1998). These 
early extubation protocols are mainly use the following criteria: patient 
alert, hemodynamically stable, temperature 35.5-36.5°C, chest tube 
drainage of <100 ml for 2 hours, no intraaortic balloon pump, and ab-
sence of new or uncontrolled arrhythmias (Cheng, 1996a; Cheng, 1996b; 
Cheng, 2003; Michalopoulos, 1998; Mollhoff, 2001; Petter, 2003; Quasha, 
1980; Sulzer, 2001) 
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Intensive care stay and hospital stay 
Numerous non-randomised studies showed that early extubation or fast-
track treatments (Arom, 1995; Chong, 1993; Chong, 1992; Engelman, 
1996; Engelman, 1994; Foster, 1984; Klineberg, 1977; Konstantakos & Lee, 
2000; Lazar, 2001; Prakash, 1977) resulted in a decrease of ICU and hospi-
tal stay. As stated correctly by others, the above-described improve-
ments in the perioperative and postoperative treatments do not auto-
matically reduce ICU and hospital stay (Bowler, 2002). However, to ac-
complish a reduction in hospital and ICU stay, it is important to identify 
the important predictors. Our review shows that a protocol directed on 
early extubation could be regarded as a crucial step to reduce ICU and 
hospital stay. Although normothermic temperature management and 
fast-track anesthesia facilitate early extubation, it seems that extubation 
based on systematic application of criteria for stability is an essential 
step. Indeed, only extubated patients can be transferred to lower care 
facilities. Interestingly, the anesthetic dose was not an important predic-
tor of ICU stay. On one hand, this may be related to the categorization 
of the different types of anesthesia, in only two categories in our study. 
On the other hand, many of the studies were directed on the evaluation 
of safety and did not adapt ICU discharge policies (Myles, 1997; Myles, 
2002; Tritapepe, 2002). Indeed, only four studies reported their IC dis-
charge criteria (Cheng, 1996a; Howie, 2001; Myles, 2002; Tritapepe, 
2002). It is also possible that, as stated by others, the anesthetic dose is 
not the rate-limiting step in the fast-track process but the patient's pre-
operative physical status (age, sex) and postoperative complications 
(atrial arrhythmias and bleeding) (Arom, 1995; Bando, 1997; Doering, 
1998; Habib, 1996). 
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Table 6: Data of studies reporting quality of life 
Dimension of Measurement 
author, year QoL Instrument moments Conclusion 
Studies (n=4) with a major difference in anesthetic dose 
Kadoi, 2003 Cognitive Mini-Mental State Test preop, 6 months no significant difference 
function Rey auditory Verbal learning postop between the two groups 
test 
Trail-Making Test 
(part A and B) 
Digit span forward and 
grooved pegboard 
Royse, 2003 Pain visual analogue scale (0 to 10) 1-3 days postop significant lower pain 
(1-2 days) 
Posttraumatic subscales for posttraumatic 2,6 weeks postop less posttraumatic stress 
stress stress and depression of Min- and depression in low dose 
nesota group compared to high 
Depression preop, 3 days after 
dose group 
Multiphasic Personality inven- cessation of anal-
tory 2 gesia 
Somatic (MMPI 2) 
sensalion no significant difference 
von Frey hairs between the two groups 
Engoren, 2001 Pain 101-point rating scale 30 mins postop and no significant difference 
(Oto 100) 6:30 AM between Ihe Iwo groups 
Shroff, 1997 Pain pain score (0 to 10) 1 -24 hrs after sur- no significant difference 
gery between Ihe two groups 
Studies (n=l) with a major difference in anesthefic dose and extubatlon protocol 
f h o ^ n 1QQAn* Cognitive Mini-Mental State Test 4 and 48 hrs after no significant difference i^neng, 1770a function surgery between the two groups 
Studies (n=5) without a major difference In anesthetic dose 
Bowler, 2002 Pain visual analogue scale 1-6, 12 and 24 hrs significant lower in one 
(0 to 100) after extubation group until 2 hrs after extu-
bation 
Howie, 2001 " Pain pain score (0 to 10) baseline, 1-3 days significant more muscle 
postop ache (pain) in one group 
Cognitive Mini-Mental Slate Test No significant difference 
function between the two groups 
Mollhoff, 2001 Pain self-rated scale (0 to 4) every 10 min during significant more postopera-
down titration tive ache(s) in one group 
opioids 
15-30-60-90-120 min 
after discontinua-
tion of opioids 
Zarate, 2000 Pain visual analogue scale 1-2-4-8-12-24-48 hrs significant more postopera-
(Oto 100) after extubation tive pain in one group in all 
points In time 
Fillinger, 2002 Pain visual analogue scale first day postop no significant difference 
(Oto 100) between the two groups 
QoL= quality of life, preop= preoperative, postop= postoperative, mins= minutes, hrs= hours, *also Cheng 2003 
and Cheng, 1996b, ** also Cheng 2001 
44 
__ Systematic review 
The factor temperature management was also not significantly related 
to ICU and hospital stay. The explanation for this can be that in none of 
the 27 studies we evaluated was the intervention itself directed toward 
temperature management. Furthermore, only two of the studies reported 
hypothermia treatment, so the effect of this variable in the regression 
analysis is very limited (Hall, 1991; Petter, 2003). 
ICU and hospital stay are not exclusively dependent of the clinical readi-
ness for discharge. Few studies tried to overcome this problem by report-
ing besides the actual ICU discharge time, also the eligibility for ICU dis-
charge time (Cheng, 1996a; Cheng, 1996b; Cheng, 2003; Mollhoff, 2001). 
However, from a cost perspective, it is not important to know when a pa-
tient is clinical stable enough to be transferred from the ICU to a lower-
care facility but when she/he actually is transferred. The eligibility data 
however, give an indication for further reduction of stay if all other cir-
cumstances are optimal. 
Quality of life and cost-effectiveness 
The instruments and measurement moments used for the evaluation of 
QoL varied over the reviewed trials. When future research is planned in 
this field its advisable to standardize this; in this way, comparability of 
study outcomes is possible, and it enables reviewers to pool data. There-
fore, we recommend the use the visual analogue scale, (range from 0-
100) at 12 and 24 hours after surgery and at hospital discharge. The visual 
analogue scale was found to be methodologically sound, conceptually 
simple, and easy to administer (Coll, 2004). Furthermore, we recommend 
to measure different domains of QoL with instruments with established 
reproducibility, validity and responsiveness (Guyatt, 1989). Ideally, a ge-
neric instrument (like, EuroQoL) and disease-specific (for instance, an-
gina questionnaire) or domain-specific questionnaire (e.g., Beck Depres-
sion Inventory) should be used. These questionnaires should be filled out 
preoperatively and 1 month postoperatively. An additional follow-up as-
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sessment can be added, depending on the purpose of the study. Fur-
thermore, guidelines for reporting the QoL results should be used (Sta-
quet, 1996). 
Although it seems obvious that fast-track treatments reduce the total 
costs of the treatment of CABG patients, the evidence is mainly based 
on non-randomised studies (Chong, 1993; Engelman, 1994). Only one 
study (Cheng, 1996a) with a acceptable CHEC-list score (Donaldson C, 
2002) concluded that fast-track treatment is a cost saving approach. In 
the other studies (cost-effectiveness was not the main study outcome 
subject) that did not find a significant decrease in costs had poor quality. 
In our opinion for future research in this field, the quality economic 
evaluations need to be improved. This can be achieved by incorpora-
tion of the following aspects: 
1. Appropriate design should be used. A cost-minimization analysis is only 
suitable if the effects in both treatment arms of the trials are equal. How-
ever, more appropriate would be, even if effects are not significantly dif-
ferent, to use a cost-effectiveness design (Briggs & O'Brien, 2001). 
2. More detailed costing should be applied and reported. This means, 
identifying and reporting all relevant cost-items. Furthermore, measure 
and value all resources changes that can occur as a certain healthcare 
interventions are performed, not only reporting and calculating drug 
costs, but also these of all other relevant cost categories (such as blood 
samples, personnel and hospital stay). In addition, the real costs instead 
of fees or charges should be used to value the resources. The time hori-
zon should be until no influence of the intervention on the outcome can 
be expected. For instance, for anesthetic interventions the time frame 
should be until 1 month after surgery instead of until ICU or hospital dis-
charge. 
3. Up-to-date analysis techniques and presentation of cost-effectiveness 
data should be used -for instance, reporting uncertainty around esti-
mated mean outcome variables (e.g., in percentiles of standard devia-
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tions), reporting confidence intervals of cost differences, and performing 
sensitivity analysis of key variables. 
For further reading, see the two handbooks (Drummond, 1996; Gold, 
1996). 
Methodological aspects of this review 
1. Although the included studies were randomised trials, a meta-
regression across trials does not have the benefit of randomisation to un-
derpin a causal interpretation (Thompson & Higgins, 2002). Therefore, the 
interpretation of the results found incidentally most taken with precau-
tion. However, the main finding of this review, that the use of early extu-
bation was the important predictor of ICU and hospital stay, was a con-
stant outcome. 
2. The use of ICU and hospital stay as outcome. On one hand, ICU and 
hospital stay are not only dependent on the patient's clinical situation 
but also other factors such as availability of beds in step-down units, 
common practice at ICU, and preferences of medical personnel 
(Hwang, 1999; Velasco, 1995). Furthermore, transfer of patients during 
nighttime may not be warranted because it may result in sleep distur-
bances that can lead to psychosis and delirium (Gelling, 1999). On the 
other hand, not all studies reported the ICU and hospital stay as mean 
and standard deviation values as needed for analysis but in mean or 
median and (interquartile) range or percentiles (O'Rourke, 2002). The real 
variance of the study outcomes may therefore be different. 
3. The moderate methodological quality of the included studies. How-
ever, the results of this meta-regression were constant. 
4. As we focused on studies that evaluated fast-track treatments and 
reported ICU stay, we excluded studies that only reported safety in terms 
of morbidity and mortality. However, reviews which focused on safety 
also found no difference on Ml and death between different treatments 
(Hawkes, 2003; Meade, 2001; Myles, 2003). 
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Implications for further research and conclusion 
Although fast-track anesthetics and normothermic temperature man-
agement facilitate early extubation, the introduction of an early extuba-
tion protocol seems essential to accomplish a decrease of ICU and hos-
pital stay in low-risk CABG patients. Further trials should evaluate the ef-
fect of adding up ICU discharge criteria to fast-track protocols. Further-
more, randomised clinical trials of a good methodological quality are to 
be preferred. Ideally, cost-effectiveness evaluations should be up to the 
current standard (Drummond, 1996; Gold, 1996) 
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Appendix 1: Search strategy 
((random* in AB) or (random* in Tl) or (((singl* or double* or trebl* or tripl*) 
near (blind* or (mask* in Tl))) or ((singl* or double* or trebl* or tripl*) near 
(blind* or (mask* in AB)))) or ((singl* or double* or trebl* or tripl*) near 
(blind* or mask*)) or (explode CLINICAL-TRIALS/ all subheadings) or ((clin* 
near trial*) in AB) or ((RANDOMIZED-CONTROLLED-TRIALS) or (CON-
TROLLED-CLINICAL-TRIAL in PT) or (RANDOMIZED-CONTROLLED-TRIAL in PT) 
or (CLINICAL-TRIAL in PT) or (SINGLE-BLIND-METHOD) or (DOUBLE-BLIND-
METHOD) or (RANDOM-ALLOCATION)) or ((clin* near trial*) in Tl)) and 
((conventional near extubation) or (early near extubation) or (fast-track 
cardiac anesthesia) or (fast-track anesthesia) or (fast near track) or (re-
covery) or ("Anesthesia-Recovery-Period" in MIME,MJME) or (removal 
near endotracheal) or (fast extubation) or (mechanical near ventilation) 
or (late near extubation) or (routine near extubation) or (remifentanyl or 
remifentanil) or (sufentanil or sufentanyl) or (alfentanil or alfentanyl) or 
(fentanyl or fentanil or fentanyl*)) and ((Myocardial Revascularization) or 
(cardiac surgery) or (heart surgery) or ("Thoracic-Surgery"/ all subhead-
ings) or (explode "Cardiac-Surgical-Procedures"/ all subheadings) or (ex-
plode "Coronary-Artery-Bypass"/ all subheadings) or (Myocardial Revas-
cularisation)) and (intensive care or intensive or intensive care units or 
intensive care unit or IC or IC or recovery or length of stay) and 
(((AGE:MEDS = ADOLESCENT) or (AGE:MEDS = ADULT) or (AGE:MEDS = 
AGED) or (AGE:MEDS = MIDDLE-AGED)) and (TG:MEDS = HUMAN)) 
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Abstract 
Objective: To evaluate the safety and cost-effectiveness of short-stay 
intensive care treatment for low-risk coronary artery bypass patients. 
Design: Randomised clinical equivalence trial. 
Setting: University Hospital Maastricht, the Netherlands. 
Patients: low-risk coronary artery bypass patients. 
Interventions: A total of 600 patients were randomly assigned to undergo 
either short-stay intensive care treatment (8 hrs intensive care treatment) 
or control treatment (care as usual, overnight intensive care treatment). 
Measurements: The primary outcome measures were intensive care re-
admissions and total hospital stay. The secondary outcome measures 
were total hospital costs, quality of life, postoperative morbidity and mor-
tality. Hospital costs consisted of the cost of hospital admission or admis-
sions and outpatient costs. 
Main results: The difference in intensive care readmission between the 
two groups of 1.13% was very small and not significantly different (P-
value =.241; 95% confidence interval: -0.9% to 2.9%). The total hospital 
stay (P-value=.807; 95% confidence interval: 1.2 to -0.4) and postopera-
tive morbidity were comparable between both groups. The SSIC group's 
quality of life improved more compared to the control group (P-value 
.0238, 95% confidence interval: .0012 to .0464). The total hospital costs for 
SSIC were significantly lower (95% confidence interval: €-1,581 to €-174) 
compared to those for the control group (€4,625 and €5,441, respec-
tively). The estimated incremental cost-effectiveness ratio (cost/ delta 
quality adjusted life months) thus showed the dominance of SSIC. Boot-
strap and sensitivity analyses confirm the robustness of the study findings. 
Conclusions: Compared with usual care, SSIC is a safe and cost-effective 
approach. SSIC can be a considered as an alternative for conventional 
postoperative intensive care treatment for low-risk coronary artery by-
pass patients. 
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Introduction 
The réintroduction of off-pump coronary artery bypass grafting (CABG) 
has resulted in important changes in on-pump CABG as well. Improved 
extra corporal circulation technology for on-pump CABG and the use of 
low-dose opioid-based anesthetic techniques enabling early extubation 
have freed postoperative care from conventions that had held up for 
decades. Fast-track treatment after cardiac surgery is becoming very 
popular (Berry, 1998; Cheng, 1996a; Dumas, 1999; Engoren, 1998; 
Michalopoulos, 1998; Quasha, 1980; Reyes, 1997; Silbert, 1998; Sirio & 
Martich, 1999), although evidence-based research on safety and cost-
effectiveness is limited. For that reason, not all cardiac centers apply this 
treatment. 
A number of trials that evaluated early vs. late extubation suffered from 
methodological flaws in conducting intention-to-treat analyses (Meade, 
2001). Furthermore, they did not focus on the safety of early intensive 
care (IC) discharge. To the best of our knowledge, only one trial with a 
reasonable quality (n=100) has been performed to evaluate the cost-
effectiveness of early vs. late extubation (Cheng, 1996b). Although fast-
track treatments offer the possibility of discharging CABG patients from 
IC within a few hours, more quantitative evidence on safety and cost-
effectiveness is needed on whether or not to take the risk of early IC dis-
charge. 
The focus of this randomised clinical equivalence trial was to evaluate 
the safety and cost-effectiveness of early discharge -within 8 hours- of 
post-surgical CABG patients from IC to medium care (MC). 
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Materials and methods 
This single blinded, randomised, clinical equivalence trial was designed 
to evaluate the safety of patients who received short-stay intensive care 
(SSIC < 8 hrs) and its cost-effectiveness compared with control group pa-
tients who stayed overnight in IC (care as usual) (box, figure and table 1 
provide details on patient management). 
To investigate this, the following two hypotheses were formulated to 
evaluate the primary outcomes: 1) SSIC patients have a comparable 
number of IC readmissions in the first postoperative month compared 
with patients in the control group and 2) there is no difference between 
either group's total hospital stay. 
Another three hypotheses were formulated to assess the secondary out-
comes: 1) postoperative morbidity and mortality is comparable in both 
groups, 2) total hospital costs in the SSIC group are lower compared with 
costs in the control group as a consequence of lower IC costs and 3) 
quality of life, measured by means of EQ-5D, is not different between the 
two groups. 
Randomization and blinding 
Before starting the study, a random list of permutated blocks (with a 
length of 10) was generated for either control (n=300) or SSIC (n=300) by 
a computer, and the results were entered sequentially into numbered, 
opaque envelopes, sealed with tape. Research nurses not involved in 
the treatment assigned consecutive patients once written consent and 
baseline measurement had been obtained. The envelopes were 
opened by the IC nurses in IC immediately postoperatively. Patients and 
the surgical team were blinded for the group assignments. It was impos-
sible to blind IC-unit physicians who were responsible for discharge and 
readmission. However, the decision for readmission was made on the 
basis of objective criteria. Furthermore, the physicians were not aware 
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that IC readmission was one of the two primary endpoints of the study. 
Whenever possible, data entry and analysis were performed without 
knowledge of treatment allocation. The local ethical and research 
council approved the study. 
Patient recruitment and eligibility criteria 
All CABG patients who were admitted to the University Hospital of Maas-
tricht in the period between February 2001 and March 2003 were con-
sidered for inclusion. High-risk CABG patients were separated from the 
low-risk patients by means of a risk stratification system, based on the cri-
teria of Parsonnet et al. (Parsonnet, 1989) and Society of Thoracic Sur-
geons (STS, 2003) (box). 
Clinical effectiveness 
The medical data, obtained from different databases, case record 
forms, medical records, and discharge letters from both university (n=l) 
and district hospitals (n=5), were registered in a standardized manner. To 
include adverse events (morbidity and mortality), the follow-up time was 
<30 days after surgery. The power calculation was based on the primary 
outcome probability of IC readmission. The data on IC readmission rate 
was obtained from the University Hospital of Maastricht Cardio Thoracic 
Surgery department data registration system (SUMMIT). The expected 
probability of readmission for both groups was 5%. With a power of 80%, 
an alpha of 5% (one-sided), and an accepted IC readmission difference 
of 5% between SSIC and control groups, 300 patients were needed in 
each group. Mortality was defined as any death occurring within 30 days 
after surgery. The definitions of the Society of Thoracic Surgeons were 
used to describe postoperative morbidity (STS, 2003). 
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Costs 
The cost analysis was performed from a hospital perspective with a time 
horizon from admission to IC until 30 days postoperative. Costs were ex-
pressed in euros (2001) and identified for all patients, including the cost 
of clinical and outpatient procedures and the cost of inpatient hospital 
days. 
The resource use of clinical and outpatient procedures (e.g., electrocar-
diography, chest radiography, cardiologist visit) in the university hospital 
was measured by means of the hospital billing system. Data on outpa-
tient procedures in district hospitals were obtained by questionnaires. The 
number of hours or days of inpatient hospital stay in the different de-
partments (IC, MC, Low Care (LC)) in the university hospital were ob-
tained from medical records, and data on LC inpatient stays in the dis-
trict hospitals were obtained from discharge letters. 
The calculation of unit costs of inpatient days was performed according 
to the Dutch guidelines for costing (Oostenbrink, 2003; Oostenbrink, 
2000). Guideline prices were used for the cost categories: nutrition, laun-
dry, accommodation, cleaning, overheads and equipment. As these 
prices were not available for inpatient stay on the MC department, the 
mean of IC and LC prices was applied. Guideline prices were converted 
into euros and price-indexed (CBS, 2003). Hospital-specific cost prices 
were calculated to estimate other cost categories (nursing, specialists 
and residents, material and medication) (Oostenbrink, 2003). Nursing 
costs were calculated on the basis of actual salary and occupation fig-
ures for the different departments. As specialists and residents have vari-
ous tasks it was unachievable to calculate cost prices, so guideline prices 
were used (Oostenbrink, 2000). The cost of material and laundry was 
based on average use by a CABG patient. Medication costs were 
based on the cost calculation of a random sample of 50 patients in 
each group. The unit costs for one day's inpatient hospital stay were 
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€1,082, €502, €249, and €246, respectively, for IC, MC and LC in the uni-
versity hospital and for LC in a district hospital. 
All cost calculations were based on the actual situation, except for the 
SSIC patients who received their first hours of MC treatment in the IC de-
partment. The valuation of these hours of MC stay was based on a sha-
dow price. Due to logistics, it was not possible to transfer these patients 
immediately from the IC department to MC (box). Therefore, because 
MC was provided, the unit prices of MC in the MC department were 
used as a shadow price for these hours of MC treatment in IC. 
BOX 1: Patient management 
Exclusion criteria 
Exclusion criteria were: age > 78 yrs, ejection fraction < 30%, stage 3 obesity (body mass 
index >40 kg/m2), hemodialysis (kidney-replacing therapy), pulmonary hypertension (sys-
tolic pressure of < 40 mm Hg), recent cardiovascular accident (<1 month), recent myocar-
dial infarction (<24 hrs), cardiogenic shock (systolic blood pressure of < 80 mm Hg, central 
filling pressure of > 20 mm Hg, cardiac index of <1,8 Lmin-'nr2), need for inotropic therapy 
(>Smgpg-'min 1 dopamine or dobutamine), ongoing infarction (a significant increase of 
myocardial muscle creatine kinase isoenzyme within 4 hrs before surgery), or the need for 
intraaortic balloon pump. Other reasons for exclusion were, for instance, inability to give 
informed consent, inability to speak/read/understand the Dutch language, emergency 
surgery. For details on reasons of refusal and exclusion criteria, see figure 1. 
Preoperative and Perioperative treatment 
The preoperative and perioperative treatment protocol was the same for all CABG pa-
tients. The day before surgery, patients underwent a general screening (e.g., physical ex-
amination, electrocardiography, chest radiography, laboratory testing). During surgery, all 
patients were anesthetized with total intravenous infusions of propofol and a short acting 
opioid. 
Postoperative treatment 
Postoperative treatment for control group and SSIC group was different according to the 
study design. The flow chart shows the time lines for both groups (figure). 
Intensive Care treatment protocol 
Both control and SSIC group patients received standard IC monitoring, which consisted of: 
a five-lead electrocardiograph, a pulmonary artery catheter for continuous blood pressure 
management, and temperature probes for central and peripheral temperatures. Continu-
ous cardiac output and mixed venous oxygen saturation were measured (Vigilance). At 
arrival in intensive care, electrocardiography and chest radiography were performed. 
Blood sampling was done at arrival, 2, 4, 8, 12 and 16 hrs after admission. Heart rate, blood 
pressure, pulmonary artery pressure, central venous pressure, occlusion pressure, oxygen 
saturation, and temperature were checked every 15 mins during the first 4 hrs. After 4 hrs, 
the checks were performed once every 30 mins. Chest tube drainage and urine produc-
tion were checked every 30 mins. After extubation, measurements were performed every 
hour unless the postoperative course necessitated more frequent checks. 
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Intensive care discharge policy 
To allow the transfer of SSIC patients from intensive care to medium care within 8 hrs, the 
discharge criteria described in table 1 had to be fulfilled. The SSIC patients who did not fulfill 
the discharge criteria within 8 hrs and all control group patients were treated according to 
the usual care. 
Protocol adjustments 
The discharge criteria were adapted at two points in time. First, the following criterion: Pao2 
of > 10 kPa and P a c o 2 of < 6.5 kPa" was adapted to " P a o 2 of > 10 kPa and the P a c o 2 < 6.0 
kPa, depending on observation of the patient's clinical situation". This protocol adjustment 
was made on February 7, 2001. 
The other protocol adjustment was done as follows to the criterion: " the blood gas sam-
pling is done". To this criterion, the following part is added: "but the results do not need to 
have come back". This adjustment was made November 27, 2001. 
Medium care treatment protocol 
For logistical reasons, it was not possible to transfer SSIC patients who fulfilled the criteria for 
early discharge from intensive care to the medium care situated on another floor in the 
hospital. Consequently, the nurse/patient ratio of one nurse to one patient was maintained. 
However, the care provided by the nurse was adapted to the medium care guidelines. 
Thus, these patients received medium care treatment in the intensive care unit according 
to the following protocol: 
1. One full blood sample was taken on arrival to medium care, and one arterial and venous 
blood sample were taken in the morning. 
2. Heart rate, blood pressure, mixed venous oxygen saturation, temperature, respiratory 
rate, chest tube drainage, urine production, blood and fluid balance were measured 
every hour. 
3. If stable for 4 hrs, checks were carried out after every 2 hrs. 
4. If emergencies occurred, adherence to the protocol was abandoned, and all measures 
necessary for the safety of the patient were taken. 
5. The pulmonary artery catheter stayed in situ for safety reasons because of the investiga-
tional conditions, after a patient was transferred to the medium care, but the monitor for 
the registration of the cardiac index was switched off. 
6. The arterial catheter was left in situ, which is common use in our medium care. 
Transfer of patients one day postoperatively 
The morning after surgery, all patients were transferred to a medium care ward connected 
to the general ward. The nurse/patient ratio in this medium care was one nurse to two pa-
tients. Patients stayed there for another 24 hrs. The treatment protocol consisted of the fol-
lowing: 
1. One full blood sample was taken on arrival to medium care. 
2. Heart rate, blood pressure, mixed venous oxygen saturation, temperature, respiratory 
rate, chest tube drainage, urine production, blood and fluid balance were measured 
every hour. 
3. If stable for 4 hrs, checks were carried out after every 2 hrs. 
4. If emergencies occurred, adherence to the protocol was abandoned, and all measures 
necessary for the safety of the patient were taken. 
On the second postoperative day patients were admitted to the general ward (low care), 
where they stayed until discharge or transfer to the district hospital. 
58 
Short-stay intens ive care trial and cost-effect iveness 
Table 1: Description of criteria for discharge from ICU for SSIC and control group 
Pulmonary 
Patient needs to be exlubated for at least 30 mins before he or she can be transferred to the medium care unit 
Last blood gas sampling is done, but the results do not need to have come back 
Palient doesn't need > 5 L oxygen nasally 
Breathing frequency > 10 to < 25 breaths/min 
Pao2 of > 10 kPa and P a c 0 2 < 6.0 kPa, depending on clinical observation, can be deviated from this value (in 
consultation with ward doctor) 
In case of chronic obstructive pulmonary disease or with pulmonary-challenged patients, the arterial blood gas 
may not deviate > 20-25% from preoperative blood gas (in consultation with ward doctor) 
Cardiac 
Patient has no ongoing infarction 
Patient has no ischemic changes on the electrocardiogram 
Patienl has no arrhythmia with hemodynamic consequences 
Fluid balance 
Patient has < 100 mL chest tube drainage per hour 
Patient has diuresis > 0.5 mL/kg-'/hr1 
Neurologic 
Patient has no signs/symptoms of neurologic complications 
Hemodynamic and supporting therapy 
Pa lie n! doesn't need inolropic support or sodium niproprusside (nitroglycerin and dopamine (2Mg/kg-'/min-1) are 
allowed) 
Patienl does not have an intraaortic balloon pump 
Patient with pulmonary artery catheter: the last measured cardiac index of > 2 L/min-' /m-J mixed venous salura-
tion (55-60%) 
Figure: Flow chart of the treatment for the two study groups 
'coronary artery bypass grafting; ""intensive care; ***medium care 
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Quality of life 
Quality of life (QoL) was measured 1 day before and 1 month postopera-
tively using EQ-5D (EuroQoL-Group, 1990). The EQ-5D includes five 3-level 
dimensions: morbidity, self care, usual activities, pain, and anxi-
ety/depression. The patient's answers to the five EQ-5D-items were used 
to express a single utility value, ranging from 0 to 1. In the absence of a 
set of Dutch population-based utility weights, we used the most robust 
valuation set (Dolan, 1997). 
The utility values were used to calculate the delta quality adjusted life 
month (A QALM) for follow-up. This is calculated by subtracting the utility 
measured at the end of follow-up from the baseline utility score divided 
by two. By dividing the delta by two, the average gain or loss in utility is 
estimated over the course of the month, assuming that the change was 
linear over that time period. 
Statistical analyses 
All analyses were conducted according to the intention-to-treat princi-
ple. A P-value <.05 was considered to be statistically significant. All data 
were analyzed with SPSS, version 10.1 (SPSS, Chicago, IL). Missing values 
were imputed by the mean group scores. 
The differences in clinical outcome measures between the two groups 
were analyzed by means of Chi-square or Mann Whitney test, depend-
ing on level and type of variables. 
As cost and QoL data are not normally distributed and skewed, a non-
parametric bootstrap sampling method with 1,000 replications was used 
to assess the statistical significance of cost or QoL differences between 
the SSIC and the control group (Briggs, 1997). The mean costs (total hos-
pital costs) and effects (A QALM) of the control group were subtracted 
from the mean costs and effects of the SSIC group, resulting in an incre-
mental cost-effectiveness ratio (ICER). The non parametric bootstrap 
sampling method was used to estimate the probability that the esti-
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mated ICERs dominate. Figure 3 shows the cost-effectiveness plane, 
which simultaneously represents the difference in mean costs (on the Y-
axis) and differences in A QALM (on the X-axis) between the SSIC and 
the control group. 
Sensitivity analysis 
In six 1-way analyses, the unit costs of hospital inpatient days were varied 
with a minimum and maximum cost estimate. The estimates of IC stay 
were based on the results of a study performed by Oostenbrink (Oosten-
brink, 2003). The same proportion of the costs is used to determine the 
range for MC and LC costs (table 6). In an additional sensitivity analysis, 
the shadow price of MC stay for SSIC patients who received their first 
hours of MC treatment in the IC department, was replaced by the IC 
price. 
The worst-case scenario for the SSIC group was shown in a multivariate 
analysis. The lowest cost estimate for IC (€36.18), the highest estimate for 
MC (€16.74) and the lowest for LC (€11.83) were used to calculate the 
costs of inpatient stay. 
Results 
Study population 
Between February 2001 and March 2003, 1062 patients were admitted to 
the University Hospital Maastricht for CABG surgery. Of these, 380 (35.1%) 
patients were excluded and 181 were identified as high-risk patients. A 
total of 199 patients were excluded for logistical reasons and research-
related factors (figure 1). A total of 702 of the patients (66.1%) were eligi-
ble for inclusion and were asked to give informed consent. Of these eli-
gible patients, 102 patients (14.6%) refused to participate in this study 
(figure 1). A total of 600 patients (55.5%) gave informed consent. Three of 
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the patients included initially were excluded from the study before 
treatment allocation was revealed (figure 2). The preoperative and intra-
operative patient characteristics are described in table 2. The study 
population consisted of a group of CABG patients with a mean age of 
62 years; 80% of the patients were men. All measured data -
demographic, previous cardiac, medical, and operative history- were 
comparable between the two groups. 
T a b l e 2: C o m p a r i s o n of d e m o g r a p h i c data , p r e v i o u s m e d i c a l a n d c a r d i a c h is tory a n d o p e -
ra t ive d a t a b e t w e e n con t ro l a n d SS IC pat ien t s 
Control SSIC 
N n % N n % 
Demographic data 
Age (Years)" 297 62.6 9.42 296 62.7 9.30 
Body Mass Index (Kg/M2) ° 276 27.4 3.92 274 28.1 3.70 
Male (sex) 299 240 80.3 298 236 79.2 
Previous cardiac and medical history data 
Ventricle ejection fraction 276 281 
> 3 5 % 174 58.2 180 60.4 
35 - 40 % 37 12.4 39 13.1 
40 - 50% 65 21.7 62 20.8 
NYHA classification angina 278 281 
1 9 3.0 7 2.3 
II 58 19.4 46 15.4 
III 129 43.1 143 48.0 
IV 82 27.4 85 28.5 
Hypertension 299 132 44.1 298 130 43.6 
Hypercholesterolemia 299 190 63.5 298 194 65.1 
Smoking 299 101 33.8 298 98 32.9 
Family history 299 188 62.9 298 174 58.4 
Diabetes mellitus 299 53 17.7 298 52 17.4 
Operative data 
Number of grafts" 291 3.2 1.2 296 3.1 1.2 
Cardiopulmonary Bypass time in mins° 299 78.4 32.9 298 77.9 32.5 
Aorta cross-clamp time in mlnsa 299 50.4 23.3 298 48.6 24.5 
Without aorta cross-clamping 299 66 22.1 298 56 18.8 
Re-do CABG 299 18 6.0 298 16 5.4 
a In Mean (standard deviation] 
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Figure 1: Flow chart of patient inclusion 
1062 (100%) patients were admitted lo Ihe University Hospital 
for CABG surgery in the period from March 2001 until February 
2003 
702 (66.l%| patients lulfilled Ihe Inclusion criteria 
102 (14.5%) refused 
Reasons for non-Informed consenl. 
Categories 
l'allant related —32— 
Was anxious, emotional or nervous 18 
Was loo tired. Ill 5 
Thought to be too old lor study 2 
Has gone through too much during last period 3 
Has loo much to think of 11 
Previous experiences 12 
Previous surgery 6 
Previous research 5 
Displeasure ghoul walling list ] _ 
Research related 27 
Family didn't want the patient lo participate In Ihe study 9 
Assurance Appendix 5 
Not willing lo fill In the questionnaires 13 
No spacillc reason 2*1 
_ U l n l _ in? 
600 |85.5%| Informed consent 
- W 360133.9%) patient; were excluded 
% 38,2 
181 (50.3%) risk slralificallon 
Reasons and number of excluded palienls based on 
risk- stralltication criteria. 
Catenaries n % 
Older than 78 years 77 42.5 
Having inlra aortic balloon pump 50 27.6 
Ejeclion fraction of less than 30 % 36 19.8 
Stage 3 obesily (BMI > « K g / f t 6 3.3 
Haemodlalysls 4 3.3 
Recent myocardial Inrarctlon 3 1.7 
Pulmonary hypertension 2 I . I 
Need for Inotropic therapy 1 0.6 
Recenf CVA 0 0 
Cardiac shock 0 0 
Onaolna Inlarction 0 0 
Total 181 100 
179 (47.7%) other criteria 
Number ol excluded palienls for loglsllcal reasons and 
rosoarch related factors. 
Categories n % 
Parllclpallon In other research project 62 31.2 
tafe surgery schedule change 59 29,4 
or urgonl surgery 
Not able lo speak / read / Dulch 22 I I . 1 
Not able lo give informed consent 15 7.5 
Second CABG surgery In study period 7 3.5 
Other le.n. missed polienl) 14 7.0 
Tolal -179" 100 
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Figure 2: Trial Profile 
c 
O 
0 
u 
0 
< 
Allocated to control group fN=300/ 
Received allocated control intervention (N=297J 
Did not receive allocated control interventionfn=3J 
Reasons 
- Exclusion (n=l) 
1 patient appeared to have < 30% left ventricle 
ejection fraction intra operatively 
- Not treated according to protocol (n=2)* 
treated as SSIC pal ieni (n=2J 
*100 of the 300 control group patients checked 
Missing data 
Maximum number of missing medical data 
Preoperative (n=23) (table 2) 
Postoperative (n=3) (table 3-<t) 
Cost data 
Clinical postoperative (n=0) (table 5) 
Outpatient postoperative (n=3 l ) 
Quality o l Life data 
Preoperative (n= l ) 
Postoperative (n=28) 
Analyzed (N=299) 
Excluded from analysis (n=IJ 
Reason 
1 patient appeared to have < 30% left ventricle 
ejection fraction perioperatively 
Allocated to SSIC group (N=300j 
Received allocated SSIC intervention /N=283J 
Did not receive allocated SSIC intervention (n=(9J 
Reasons 
- Exclusion (n=2) 
1 patient underwent CABG and additional surgery 
1 patient died during surgery 
- Not treated according to protocol (n=17) 
9 patients were treated as control patient 
2 patients received additional blood gas measures 
after 8 hours 
3 patients had their clinical situation wrongly interpreted 
1 patient was extubated after 8 hours without reason 
2 patients reason unknown 
Missing data 
Maximum number of missing medical data 
Preoperative (n=24) (table 2) 
Postoperative fn=0) (table 3-4} 
Cost data 
Clinical postoperative (rt=0) (table 5) 
Outpal ient postoperative (n= 19) 
Quality of Life data 
Preoperative (n= l ) 
Postoperative (n=ló) 
Analysed (N=298) 
Excluded from analysis (n=2) 
Reasons 
I patient underwent CABG and additional surgery 
I patient died during surgery 
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Missing data and protocol deviations 
Mean imputation was used because the number of missing data were 
very limited (details provided in figure 2). As the analysis before and after 
mean imputation showed the same results, the method of imputation of 
the missing data had no influence on the outcomes. 
The protocol deviations in both groups were minimal (SSIC group, n=17 
and, control group, n=2 (figure 2). Data were obtained from all SSIC pa-
tients and a random sample of control patients (n= 100) on actual MC 
and IC treatment by evaluating bed lists. This was performed by check-
ing the registration of actual extubation time, the registration of pulmo-
nary artery occlusion pressures and the number of laboratory tests per-
formed. 
Clinical effectiveness 
The primary study outcome revealed that IC readmission was lower in 
both groups than the expected 5%. IC readmission was 1.34% (n=4) and 
2.68% (n=8) in the control group and the SSIC group, respectively. The 
difference of 1.13% was not significantly different (P-value = .241 95% 
confidence interval (95% CI): -.9% to 2.9%). In other words, if patients 
were treated according to the SSIC protocol, a maximum of 3 out of 100 
patients needed IC readmission. 
The reasons for the four readmissions in the control group were infection, 
respiratory insufficiency, reexploration for bleeding, and lack of beds in 
MC. In the SSIC group, readmission was necessary eight times for the fol-
lowing reasons: cardiologie, hemodynamic (three times), re-exploration 
for bleeding (twice), respiratory insufficiency, and order of physician. 
No statistically significant differences were found between the two 
groups with respect to postoperative morbidity and 30 day-mortality (ta-
ble 3). The patients in the SSIC group stayed in the IC unit for significantly 
fewer hours compared to control group patients (P-value = .000, 95% CI: 
13.1 to 9.5) (table 4). In the SSIC group, 161 patients (55%) were trans-
65 
Chapter 2 
ferred from IC to MC within 8 hours. The different reasons for not transfer-
ring the 137 patients in the SS1C group were: surgical (n=18), anesthetic 
(n=25), respiratory (n=19), hemodynamic (n=18), patient-dependent 
(n=27), cardiologic (n=30), protocol (n=30), and other (n=8) (patients 
could be grouped in more then one category). The mean postoperative 
total hospital stay was comparable between the two groups (P-value of 
.807, 95% CI: 1.2 to -0.4). 
T a b l e 3: C o m p a r i s o n of p o s t o p e r a t i v e m o r b i d i t y a n d mor ta l i ty b e t w e e n c o n t r o l g r o u p a n d 
SS IC pat ients , d a t a p r e s e n t e d in n u m b e r (%) 
Control SSIC Relative Risk 95% CI ° P-value 0 
N n % N n % 
Postoperative morbidity 
Re-exploration for bleeding 299 14 4.7 298 11 3.7 0.78 .36 to 1.71 .546 
Re-exploration for occlusion graft 299 3 1.0 298 1 0.3 0.33 .03 to 3.19 .317 
Tamponade 299 1 0.3 298 2 0.7 2.00 .03 to 5.26 .561 
Postoperative Mlc 299 16 5.4 298 17 5.7 1.06 
.18 to 
21.94 .850 
Atrial arrhythmias 299 84 28.1 298 85 28.5 1.01 .52 to 1.96 .979 
Pleura / Pericard effusion 296 3 1.0 298 3 1.0 1.00 .77 to 1.28 .997 
Sternum superficial wound infect." 298 4 1.3 298 3 1.0 0.75 16 to 3.32 .479 
Sternum deep-wound infect. 298 1 0.3 298 0 0.0 0.99 e .318 
Other infections 298 19 6.4 298 19 6.4 1.18 .61 to 2.25 .997 
Stroke permanent 299 2 0.7 298 2 0.7 1.00 .14 to 7.07 .997 
Increased creatinine 299 7 2.3 298 7 2.3 0.99 .35 to 2.8 .995 
Dialysis 297 2 0.7 298 0 0.0 0.05 0 .157 
30 day-mortalily 299 3 1.0 298 1 0.3 0.33 .03 to 3.20 .317 
° 95% CI- 95% confidence interval, 6 Chi-square tesl,c Mb myocardial infarclion, d infect.= infection,0 not appli-
cable 
Quality of life 
The 1-month utility score was equal in both groups (mean (standard er-
ror), 0.71 (0.01)). However, the mean and standard error for baseline util-
ity score were 0.71 (0.01) and 0.66 (0.01) for the control group and SSIC 
group, respectively. This was significantly different between the two 
groups (mean 95% CI: -0.05 (-0.01 to -0.09). Thus, the A QALM difference 
between both groups was small (.0238) but significantly different (95% CI: 
.0012 to .0464) between the two groups. Assuming that A QALMs are 
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equal on the other days of the month, patients in the SSIC group would 
be in full health for 1.4 days compared to 0 days in the control group. The 
A QALM was .0015 ± .1388 and .0253 ± .1424 for the control group and 
SSIC group respectively, indicating that the control group improved less 
in overall quality of life compared with the SSIC group. 
T a b l e 4: C o m p a r i s o n o f e x t u b a t i o n a n d h o s p i t a l s t a y d a t a b e t w e e n cont ro l a n d SS IC pat ien t s 
Control SSIC 
N Mean Median 2.5° 97.5 b N Mean Median 2.5 97.5 95% CI P-valuec 
Extubation 
time in (hrs) 
299 9.4 7.0 .0 39.9 298 7.7 6.5 2.0 19.8 3.5 to .1 .514 
Total IC stay 
in UH « (hrs) 
299 31.0 22.3 16.5 117.0 298 19.7 8.0 5.0 89.6 13.1 to 9.5 .000 
Total MC stay 
in UH (hrs) 
299 24.8 20.5 .0 66.8 298 36.9 32.7 16.0 84.3 16.5 to 7.7 .000 
Total LC stay 
in UH (days) 
299 4.7 4.0 1.5 15.5 298 4.5 4.0 1.0 11.0 4.6 to 4.2 .984 
LC Slay 
in DH » (days) 
299 1.4 0.0 .0 13.5 298 1,2 0 .0 11.5 .7 to .3 ,598 
Total hospital 
stay (days) 
299 8.5 6.7 4.6 24.6 298 8.1 6.7 4.5 26.7 1.2 10 .4 .807 
"2.5 »> Percenlile, "97.5 »' Percentile, Mann-Whitney U tesl, «University Hospital (n=i),t-'District Hospilal (n=5) 
Costs 
The mean total costs were €5,441 in the control group and €4,625 in the 
SSIC group. The mean difference was €-816. The costs were significantly 
lower (95% CI: €-1,581 to €-174) in the intervention group, due to lower 
costs for clinical procedures and for IC stay at the university hospital (ta-
ble 5). 
However, costs of the MC stay were higher in the SSIC group, indicating 
that part of the cost savings from the IC stay were compensated by 
higher costs of the MC stay. However, overall, it turned out that SSIC 
would lead to substantial cost savings per patient for the hospital. The 
costs of LC, outpatient procedures, and costs in district hospitals were 
comparable in both groups. 
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Table 5: Summary of the total clinical costs of the SSIC patients and the control patients 
Summary Information bootstrapped 
Control SSIC cost-differences 
% o f % o f 
total total 
Cost Category Mean costs Mean costs Mean Median 2.5 a 97.5 b 
Procedures 
Total Clinical proce-
dures CTC IC c 1,073.89 19.74 
845.74 18.29 -260 235 -507 -50 
Total Clinical proce-
dures MC and LC 
540.16 9.93 464.60 10.04 -74 -73 -177 26 
Total Clinical proce-
dures other deparl- 306.55 5.63 185.94 4.02 -118 -104 -432 126 
ments 
Total outpatient pro-
cedures UH d 75.95 1.40 73.93 1.60 -2 -2 -20 14 
and DH e 
Total procedures' 1,996.55 36.70 1,540.93 33.32 -454 -444 -945 -21 
Hospital admission days 
Total IC stay UH 1,397.07 25.68 890.45 19.25 -506 -509 -703 -308 
Total MC slay UH 518.77 9.54 771.74 16.69 250 246 167 349 
Total LC stay UH 1,177.28 21.64 1,128.56 24,40 -50 -48 -178 72 
Total Care stay UH' 3,093.12 56.85 2,790.75 60.34 -294 -294 -561 -44 
Total LC stay DH 350.98 6.45 294.42 6.37 -60 -63 -180 75 
Total inpatient Stay' 3,444.10 63.30 3,085.18 66.70 -358 -357 -671 -56 
Tolal costs ' 5,440.64 100.00 4,625.29 100.00 -823 -816 -1,581 -174 
° 2.5 111 Percentile, » 97.5 1,1 Percentile,c These figures also include medium care procedures for SSIC patients who 
were discharged from IC to MC within 8 hrs,d University Hospital (n=l), « District Hospilal (n=5), 'Costs do not add 
up correctly due to rounding errors 
Cost-effectiveness 
Figure 3 shows the bootstrap results of the ICERs (cost/ A QALM). The 
ICERs were situated in the Southeast quadrant, indicating that the SSIC 
group is dominant over the control group. Ninety-eight percent of the 
bootstrapped ICERs showed that SSIC patients' QoL improved more and 
their costs were lower compared to control patients. Only 0.016% of the 
bootstrapped ICERs was situated in the Southwest and 0.004% in the 
Northeast quadrant. 
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Figure 3: Cost-effectiveness plane showing the results of difference between cost and effect 
between both treatments arms in 1,000 bootstrap replications 
500 
-0,0200 -O.OlflO 0,0 ',0500 0,0600 0,0700 
T> •o < - 1 . 0 ® 
-1.500 ' 
. • i A « 8 
Southeast 
-2.000 
Additional effects 
Sensitivity analyses 
The results of the one-way sensitivity analyses on the minimum and 
maximum estimate of the unit cost of inpatient hospital days showed 
that these results were very robust. At least 97% of the bootstrapped 
ICERs lay in the same quadrant as in the base case analyses. Zero per-
cent of the bootstrapped ICERs are situated in the Northwest quadrant, 
where the SSIC group would be inferior (less effective and more costly). 
As explained previously, the hypothetical cost for first hours of MC stay 
were calculated for SSIC patients. The unit price for these hours of MC 
treatment was replaced by the IC treatment unit price. This sensitivity 
analysis showed that calculation of the actual costs did not influence the 
base case findings. Even in a worst-case scenario, when the costs of IC 
and LC were set at the lowest cost estimate (SSIC patients stay less time 
in IC and LC compared with the control group) and the MC costs were 
set at the highest cost estimate (SSIC patients stay longer in MC com-
pared with the control group), the results of the primary analyses still held 
up (table 6). 
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Table 6: Results of the different univariate and one multivariate sensitivity analyses (percen-
tage of bootstrap ICERs). 
Costs NE ° NW b SE i 
Base case 0 0 2 98 
Hospital admission days: univariate 
LC Costs (minimum) 8.30 per hr 0 0 2 98 
LC Costs (maximum) 11.83 per hr 0 0 2 98 
MC Costs (minimum) 16.74 per hr 0 0 2 98 
MC Costs (maximum) 23.85 per hr 1 0 1 98 
IC Costs (minimum) 36.18 per hr 1 0 2 97 
IC Costs (maximum) 51.51 perhr 0 0 3 97 
Replacing MC unit cost by IC unit cost in 5 0 1 94 
SSIC patients who received MC treatment on IC 
Hospital admission days: multivariate worst-case scenario 
IC Costs (minimum) 
MC Costs (maximum) 
LC Costs (minimum) 
36.18 perhr 
23.85 per hr 
8.30 per hr 
1 0 2 97 
NE= Northeast quadrant: SSIC more effective and more costly compared to control group, ^ NW= Northwest 
quadrant: SSIC less effective and more costly compared to control group (inferior), ^SW= Southwest quadrant: 
SSIC less effective and less costly compared to control group, d SE= Southeasl quadrant: SSIC more effective and 
less costly compared to control group (dominant) 
Discussion 
Summary of the results 
SSIC discharge for low-risk CABG patients from IC to MC after 8 hours is 
safe and feasible. There is no increase in IC readmissions compared to 
postoperative overnight IC stay. An influence of SSIC treatment on the 
total hospital stay, 30 day-mortality and postoperative morbidity was not 
observed. Furthermore, SSIC is a cost-effective approach as it lowers the 
total hospital costs and has a positive effect on QoL. However, it is ques-
tionable whether this QoL improvement is clinically relevant. 
Clinical effectiveness 
Several trials have examined strategies to reduce the duration of me-
chanical ventilation in patients after CABG surgery. Methodologic prob-
lems occurred in these trials: for instance a lack of information concern-
ing concealment, a lack of intention-to-treat analyses, and flaws in 
power calculations, dealing with missing data and loss to follow up 
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(Berry, 1998; Michalopoulos, 1998; Quasha, 1980; Reyes, 1997; Silbert, 
1998). As stated before by Meade et al, a trial of thousands of patients -
or at least many hundreds of patients with a combined endpoint- would 
be required to study the safety of early extubation due to low adverse 
event rates (Meade, 2001 ). Our study, with safety as its primary endpoint, 
defined as the probability of being readmitted to IC, has tried to over-
come this problem. Our trial and three other studies (Arom, 1995; 
Michalopoulos, 1998; Reyes, 1997) reporting the number of IC readmis-
sions found no significant difference between the two study groups. Al-
though the true IC admission rate of 1.13% was lower than the expected 
5%, the results were clinically acceptable. In the power calculation of our 
study, it was presumed that a maximum of 8% of the patients treated in 
SSIC needed IC readmission. The results of this trial showed that a maxi-
mum of 3% of these patients had to be readmitted on the IC. The most 
plausible reason in our opinion for the discrepancy between real and 
expected readmission rate is the fact that the power calculation was 
performed in 1999 and the study started two years later. In addition to 
this, the power calculation was based on retrospective data, whereas 
the trial was based on prospective data. 
Successful discharge of the majority of patients in the SSIC group to MC 
resulted in a decrease of 11 hours IC stay. This is more than the weighted 
mean difference of -7.02 (95% CI: -7.42 to -6.61) reported in an recently 
published review (Hawkes, 2003). In contrast to two previous studies 
(Michalopoulos, 1998; Silbert, 1998) we did not notice a decrease in the 
number of hospital admission days. Our design meant that we deliber-
ately focused on IC discharge only. After IC discharge, both SSIC and 
control patients received routine conventional care, including one over-
night stay in MC. If the MC stay had been restricted to 24 hours instead of 
an overnight stay, it might have been possible to decrease MC treat-
ment to only 24 hours. A reduction of 1 day's hospital admission stay is 
feasible, as demonstrated by the pooled results of five studies (relative 
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ratio: -1.06, 95% CI: -1.32 to -0.08) (Meade, 2001). The ability to transfer a 
patient may be affected by various factors unrelated to the patient's 
clinical situation. These factors include the availability of beds and nurs-
ing staff and, perhaps more importantly, the reluctance of medical per-
sonal to transfer patients in the middle of the night (Velasco, 1995). 
Cost-effectiveness 
Besides evaluating medical effects, it is also important to evaluate 
whether SSIC influences the QoL. To our knowledge, to date, no study 
has investigated the differences in overall QoL for low-risk CABG patients 
after fast-track treatment. The SSIC group improved significantly more in 
QoL compared with the control group. However, the effect is very small, 
indicating that its clinical relevance is doubtful. 
The conventional effect measure in cost-effectiveness analyses is the 
quality adjusted life year (QALY). We chose to use QALM instead of 
QALY, as the follow-up in this study was 1 month. Besides this, it is difficult 
to interpret a 1-month follow-up QALY (maximum QALY in one month is 
0.083). The area under the curve is estimated in such a calculation, in 
other words the sum of the utility score for both measurement moments 
(at baseline and 1 month) divided by 2 and multiplied by 1/12 (Gold, 
1996). We used a A QALM (Guthrie, 1999), because baseline differences 
in the utility score for the QALM calculation were not suitable. Only the 
increment of baseline utility score and utility score at 1 month divided by 
2 was used for the A QALM calculation. 
Gold et al. recommended employing cost-effectiveness analyses from a 
societal perspective (Gold, 1996). However, we chose to perform the 
study from a hospital perspective as we assumed that, given the rela-
tively short time horizon, there would be no difference in costs outside 
the hospital between both groups. Furthermore, as the recovery of both 
groups was comparable, other medical costs like costs of primary care 
were not expected to be different between both groups. 
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It is interesting to see that the driving force of fast-track recovery is cost 
containment (Higgins, 1992), but as stated by Velasco, current literature 
has produced inconsistent evidence that only early extubation reduces 
the costs of cardiac surgery (Velasco, 1995), not transferring the patients 
to MC. Grade-1 evidence has only been produced by one randomised 
clinical trial (Cheng, 1996b). Other studies (Arom, 1995; Engelman, 1994; 
Lee, 1996; Westaby, 1993) that claimed to study cost reductions or even 
cost-effectiveness gave incomplete or no information concerning cost 
calculation, uncertainty of outcomes and unit prices, which are essential 
for interpreting the results of an economic evaluation. Furthermore, most 
cost studies were not randomised clinical trials, and thus, evidence of 
causal relations cannot be supported. 
The decrease of total hospital costs in our study of the SSIC group was 
due to fewer laboratory blood tests being performed in IC and by a 
shorter stay in the high-cost IC setting. A reduction in laboratory blood 
tests was also reported by others (Cheng, 1996b; Foster, 1984; Lee, 1996). 
As in our study, the early transfer to a lower level of care resulted in cost-
savings (Cheng, 1996b), as 1 hr of IC stay is twice as expensive as 1 hr of 
MC stay (IC, €45; MC,€21). 
Limitations of the study 
The SSIC intervention was restricted to the first 24 hours of postoperative 
care (8 hrs IC treatment, IC discharge and 16 hrs MC treatment). The 
conventional overnight MC treatment was maintained for both patient 
groups in accordance with local protocol. From a financial point of view, 
a reduction of up to 24 hours of MC treatment would have resulted in 
additional cost-savings, but for purity of study findings, it was necessary 
to separate these factors. 
We chose only one decision moment to transfer SSIC patients from IC to 
MC to minimize protocol deviations. This moment was after 8 hours of IC 
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treatment. It might have been more effective if the decision to transfer 
the SSIC patients had also been taken 10 or 12 hours after IC admission. 
It is not possible to extrapolate our findings to more high-risk CABG pa-
tients. 
We used data obtained from an English population for the valuation of 
the EQ-5D items. One may argue that these valuations may differ from 
the Dutch population; however, no Dutch value set is currently available, 
and we used the one that was recommended as being the most robust 
(Books & de Charro, 2003). 
The general applicability of the results may be limited because not all 
patients who fulfilled the inclusion criteria were included. Patients who 
refused to participate in the study were on average older, a higher pro-
portion of them were women, and generally had a lower ventricle ejec-
tion fraction. Furthermore, the ability to generalize may be limited due to 
the fact that this study was a single-center study. Other hospitals may use 
other treatment protocols and have different patient/nurse ratios in IC 
and MC, which may influence the actual cost savings. 
Conclusions 
This is the first randomised clinical trial that shows that short-stay in IC is 
safe for low-risk CABG patients. The IC readmission rate was very low in 
SSIC patients, and postoperative complications and 30 day-mortality in 
SSIC patients were comparable with patients who stayed overnight on 
the IC. SSIC is also a cost-effective approach. It lowers the total hospital 
costs, and it has a positive effect on QoL. SSIC can be a considered as 
an alternative for conventional postoperative IC treatment for low-risk 
CABG patients. 
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Abstract 
Purpose: This randomised clinical equivalence trial was designed to 
evaluate health-related quality of life (QoL) after a fast-track treatment 
for low-risk coronary artery bypass patients (CABG). 
Methods: Four hundred and ten CABG patients were randomly assigned 
to undergo either short-stay intensive care treatment (SSIC, 8 hrs of inten-
sive care stay) or control treatment (care as usual, overnight intensive 
care stay). QoL was measured until one year postoperatively by means 
of the Multidimensional Index of Life Quality (MILQ), the EQ-5D, the Beck 
Depression Inventory and the State-Trait Anxiety Inventory. 
Results: At one month after surgery no statistically significant differences 
in the summary scores were measured (MILQ-score P-value=.508, Overall 
MILQ-index P-value=.543, EQ-5D VAS P-value=.593). The domains, physi-
cal and social functioning of the MILQ, were significantly higher at one 
month postoperatively in the SSIC group compared with care as usual 
(respectively, P-value= .049; 95% CI: 0.01 to 2.50 and P-value = .014; 95% 
CI: 0.24 to 2.06). However, these differences were no longer observed at 
one-year follow-up. 
Conclusions: According to our definition of clinical equivalence, the QoL 
of SSIC patients is similar to patients receiving care as usual. As safety and 
cost-effectiveness of this intervention was demonstrated in a previously 
reported analysis, SSIC can be considered as an adequate fast-track in-
tensive care treatment option for low-risk CABG patients. 
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Introduction 
Rapid technological advancements changed the practice of intensive 
care medicine in the last few decades. These improvements facilitated 
the introduction of fast-track protocols for the treatment of cardiac sur-
gical patients, which are very popular as they contribute to a more effi-
cient utilization of the existing care facilities. Various reviews, based on 
randomised controlled studies, focused on the evaluation of the clinical 
effectiveness of different types of fast-track treatments (Hawkes, 2003; 
Meade, 2001; Myles, 2003). However, for the evaluation of these intensive 
care interventions it is essential to also assess its impact on QoL(Suter, 
1994). These patient-reported outcomes contain valuable information for 
intensive care physicians, other healthcare providers, policymakers, pa-
tients and their relatives. 
Several 'fast-track' trials incorporated QoL as an outcome measure in 
their evaluations, but mostly only one specific domain with a short follow-
up time has been assessed (Bowler, 2002; Cheng, 1996a; Cheng, 1996b; 
Cheng, 2001; Cheng, 2003; Engoren, 2001; Fillinger, 2002; Howie, 2001; 
Kadoi, 2003; Mollhoff, 2001; Royse, 2003; Shroff, 1997; Zarate, 2000). These 
limited assessments are helpful in describing the domains of patient out-
come in a specific area of QoL. However, they are not designed to 
evaluate either the overall health state (Heyland, 1998) or the specific 
domains of QoL which may contain important aspects of health. For a 
comprehensive evaluation of QoL it is important to asses both overall or 
generic QoL and disease specific QoL (Mayou & Bryant, 1993). We chose 
to use the EQ-5D as a generic measure, because it's brief, simple and 
easy to administer. The reliability and validity of the EQ-5D has been stud-
ied successfully for cardiac patients (Nowels, 2005; Schweikert, 2006) and 
critical care patients (Badia, 2001). In a previous paper we also reported 
generic QoL at one month after surgery as an outcome measure in an 
eco.nomic evaluation of the short-stay intensive care treatment (van 
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Mastrigt, 2006). The patient's answers to the five EQ-5D items were used 
to calculate an utility value (a score of 0 to 1), based on population 
weights (Dolan, 1997). In the current study this outcome was not reported 
because the aim of this paper was to report data from a patient point of 
view and not from a societal perspective. 
As disease specific measure, the Multidimensional Index of Life Quality 
was chosen. Although this questionnaire is not frequently used its reliabil-
ity and validity has been tested by Avis et al. for cardio vascular patients 
(Avis, 1996). In addition, we assessed the impact of the fast-track treat-
ment on anxiety and depression, as these two psychological aspects of 
QoL may be affected after cardiac surgery (Duits, 1997). 
As several studies after intensive care admission have demonstrated the 
importance of long-term follow-up (Badia, 2001; Cuthbertson, 2005; Hurel, 
1997; Konopad, 1995), we assessed QoL at one year after surgery. 
The focus of this randomised clinical equivalence trial is to evaluate the 
impact of a fast-track protocol, i.e. early discharge -within 8 hours- of 
post-surgical coronary artery bypass patients from intensive to medium 
care on disease specific, generic and domain specific (anxious and de-
pressive feelings) QoL up to one year postoperatively. 
Materials and methods 
Study design and hypotheses 
This single blinded randomised clinical equivalence trial was designed to 
evaluate the QoL of low-risk CABG patients at one year postoperatively 
who were randomised for either short-stay intensive care (SSIC < 8 hrs) or 
overnight intensive care stay (control group patients). 
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To investigate this, the following hypothesis was formulated to evaluate 
the primary outcome: 1 ) up till one year postoperatively the disease spe-
cific QoL (measured by means of MILQ) will be similar in both groups. 
Two additional hypotheses were formulated to assess the secondary out-
come measures: 1 ) in the first year after surgery both generic (measured 
by means of EQ-5D) and domain specific QoL (measured by means of 
Beck Depression Inventory and State-Trait Anxiety Inventory) will be com-
parable in both groups, 2) at one month postoperatively disease specific, 
generic and domain specific QoL will also be comparable in both 
groups. 
For details on patient recruitment, eligibility criteria, treatment, randomi-
zation and blinding, see chapter 3. 
Procedures quality of life measurement 
After obtaining informed consent, QoL questionnaires were self-
administered by the patients the day before surgery at the hospital, 
one month and one year postoperatively at home. If a patient was un-
able to complete the questionnaire individually, the research nurse per-
formed an interviewed administration. The application of the four QoL 
instruments took almost 20 minutes and was done in a fixed order: first the 
EQ-5D, secondly the MILQ, followed by State-Trait Anxiety Inventory and 
Beck Depression Inventory. 
Patients who did not respond to the follow-up questionnaires received a 
written reminder. If they still did not respond, they were contacted by 
telephone to find out the reasons for non-response. 
Quality of life questionnaires 
The Multidimensional Index of Life Quality (MILQ), a QoL measure spe-
cially developed for cardiovascular disease, was used to measure dis-
ease specific QoL (Avis, 1996). In the first item (which is referred to as the 
'MILQ-score') the respondent is asked to rate his/her QoL on a seven 
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point-Likert scale (from 1= worst to 7= best possible QoL score). In the 
other 35 items the respondent's degree of satisfaction with various as-
pects of QoL is scored on a seven point-Likert scale (from 1= very dissatis-
fied to 7= very satisfied). These items cover the following nine domains: 
mental health, physical health, physical functioning, cognitive function-
ing, social functioning, intimacy, financial status, relationship with health-
care professionals and productivity. As each domain contains 4 items, 
the total theoretical domain score ranges from 4 to 28 (except for the 
domain of productivity which contains 3 items, the total score ranges 
from 3 to 21). The Dutch translation of the MILQ has been used to assess 
the QoL of CABG patients (Falger, 2000). An unweighted index was cal-
culated by adding up overall nine-domain scores, theoretically ranging 
from 35 to 245 (which is referred to as the 'overall MILQ-index'). 
Furthermore, generic QoL was measured by the EQ-5D (EuroQoL-Group, 
1990). The EQ-5D consists of two components: an EQ-5D descriptive sys-
tem and an EQ-5D Visual Analogue Scale (EQ-5D VAS). In the descriptive 
system the respondent is asked to rate his or her health by checking one 
of three levels of severity - 'no problems' (coded as 1), 'some or moder-
ate problems' (coded as 2), 'severe problems or unable to perform' 
(coded as 3)- in each of the following five EQ-5D dimensions; mobility, 
self care and pain/discomfort, usual activities and anxiety/ depression. 
For the EQ VAS, participants draw a line from a box to the point on the 
thermometer-like scale corresponding to their health state (with a range 
from 0 'the worst imaginable health state' to 100 'the best imaginable 
health state'). 
Depression was evaluated by means of the Beck Depression Inventory 
(BDI) (Beck & Steer, 1987). The State-Trait Anxiety Inventory (STAI-S) was 
used to measure temporal and transient aspects of anxiety (van der 
Ploeg, 1986). Both STAI-S (20 items) and BDI (21 items) contain items ex-
pressed on a four point-Likert scales. Both BDI and STAI-S have been used 
in studies with CABG patients (Boudrez & De Backer, 2001; Eisenberg, 
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2001; Langeluddecke, 1989), and are considered as valid and reliable 
instruments (Beck & Steer, 1987; van der Ploeg, 1986). 
One year quality of life equivalence and power analysis 
Equivalence in QoL was defined a priori. It was expected that the dis-
ease specific QoL (MILQ) measure would be the most sensitive to detect 
differences between the two groups. The overall MILQ-index varies be-
tween 1 (worst of health) and 7 (best of health). Equivalence on the 
overall MILQ-index at one year was assumed if the SSIC group and the 
control group would not differ within a tolerance range of 5%, i.e. within 
0.4 on a 7 points scale. It was assumed that the standard deviation of this 
difference would be 1.15, so with a two-sided test, alpha of 0.05, a power 
of 90% and an expected drop-out percentage of 10% the number of pa-
tients needed amounted to 194 for each study group. For the MILQ-score 
and EQ-5D VAS the power calculations resulted in a lower number of pa-
tients needed to be included in each trial arm. In the line with the as-
sumptions of the power analysis, a difference of approximately one third 
of the standard deviations of the one-year QoL differences with baseline 
score between SSIC group and control group was defined as a clinical 
meaningful difference. 
Statistical analysis 
The reasons for non-response were categorized as follows: 'Informative 
censoring' (if the reason was non-random e.g. related to the health 
status) (Staquet, 1996), 'non-informative censoring' (if the reason was 
random) (Staquet, 1996) and 'unclear' (if the reason was unknown). 
All analyses were conducted following the intention-to-treat principle. 
Missing values were imputed by the separate mean group scores of non-
missing patients for the SSIC and the control group, This way, chances of 
the alternative hypothesis that possible differences in QoL are statistically 
significant were enhanced to the detriment of our equivalence hypothe-
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sis of no clinically relevant differences. QoL scores at baseline were re-
ported in means and standard deviations and at follow-up as mean 
change scores (baseline minus one month or one year minus one month) 
with a 95% confidence interval for both groups. The Kolmogorov-Smirnov 
test was used to test for normality of the differences between postopera-
tive one month and one year scores on QoL scales at one hand and 
preoperative scores at the other. Student t-tests were performed to ex-
amine the mean differences in QoL change between both treatment 
groups at one month after surgery. 
Repeated measures ANCOVA analysis using the preoperative scores as a 
covariate was performed to test equivalence of QoL scores at one year. 
Interaction effects between preoperative QoL and treatment modality 
group on one-year differences in QoL were also tested for statistical sig-
nificance. Next, in regression analyses with the MILQ-score, the overall 
MILQ-index and the EQ-VAS as 'dependent' variables the relation with 
other factors was tested. Selection of the potential predictors in the re-
gression models was based on results of previous research (see appen-
dix). Regression modeling was done with list wise deletion of missing 
cases using both forward selection and backward elimination tech-
niques. Predictors statistically significant in both techniques were selected 
in the model, except for treatment modality group, which was always 
kept within the model, irrespective of its statistical significance. Finally, 
eventual regression model results are presented in table 4 with unstan-
dardized effects, P-values and variance explained (R-square) by each 
eventual model. 
A P-value of less than 0.05 was assumed to be statistically significant. All 
data were analyzed with SPSS, version 12.0.1 (SPSS, Chicago, IL). 
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Results 
Study population 
Between February 2001 and March 2003, out of the 1062 available CABG 
patients, 702 were eligible for inclusion for the clinical part of the study 
(figure 1). They were asked to give informed consent. A total of 600 pa-
tients gave informed consent and participated in the SSIC-trial. For this 
QoL-study only the first 410 of the included CABG patients were needed. 
The study population consisted of a group of low-risk CABG patients with 
a mean age of 62 years, 80% of them were men (table 1). 
The non-response rates were low and appear to be similar for control 
and SSIC group in all three categories (informative, non-informative and 
unclear) and at the three measurement moments (table 2). Four patients 
died (control n=l and SSIC n=3) and one patient was readmitted to the 
hospital. These events were unrelated to the IC treatment received. 39 
follow-up questionnaires (4.8% of the total) were not returned for reasons 
that were unclear, however, mortality as reason was ruled out. 
Figure 1: Flow chart of patient inclusion 
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The non-responders were more often females with no partner, had slightly 
longer surgery times and hospital stay compared to the responders. 
However, there was no difference in patient characteristics between the 
non-responders in the control and the non-responders in the SSIC group 
(data not shown). Baseline QoL outcomes appeared to be not signifi-
cantly different between SSIC group and control group (P-values not 
shown). 
Disease specific quality of life 
At one month after surgery, the change scores (one month postopera-
tive minus baseline) of both the MILQ-score and overall MILQ-index were 
not significantly different between the two treatment groups (MILQ-score 
P-value=.270; 95% CI: -0.11 to 0.40, overall MILQ-index P-value=.154; 95% 
CI: -1.49 to 9.41) (table 3). However, the domains physical and social 
functioning of the MILQ were significantly better in the SSIC group com-
pared to the control group (respectively, P-value = .049; 95% CI: 0.01 to 
2.50 and P-value = .014; 95% CI: 0.24 to 2.06) (table 3). 
Results of the repeated measures ANCOVA analysis with the baseline 
QoL scores as covariates show no statistically significant differences be-
tween the SSIC group and the control group in the linear trend in the 
year after surgery on the MILQ-score (P-value= .508), nor on the overall 
MILQ-index (P-value = .543) (table 3). 
In the regression models the linear trend of the MILQ-score and the linear 
trend of the overall MILQ-index were used as "dependent" variables. 
Controlled for potential confounding factors, the type of intensive care 
treatment received was again no significant predictor of QoL (MILQ-
score, P-value= .736; 95% CI: -.115 to .162, nor for the overall MILQ-index 
P-value = .934; 95% CI: -3.64 to 3.35) (table 4). Apart from this, the base-
line scores of the corresponding QoL measures were significant predictors 
of linear trend of QoL. All tests for first-order interactions and all tests on 
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the other predictors like gender, age and disease severity (appendix) 
were not statistically significant (table 4). 
Table 1: Comparison of demographic data, previous medical, cardiac history and operati-
ve data between control and SSIC patients 
Control SSIC 
N n % N n % 
Demographic data 
Age (Years) ° 206 62.6 13.7 201 61.8 10.67 
Body Mass Index (Kg/M') " 193 27,4 3.84 185 27.8 3.55 
Male (sex) 207 169 81.6 201 161 80.1 
Civil state 201 198 
Married 150 72.5 158 78.6 
Unmarried no partner 40 19.3 31 15.4 
Unmarried with partner 14 6.8 9 4.5 
Education 195 196 
Primary school not finished 2 1.0 5 2.5 
Primary school 53 25,6 40 19.9 
Lower education 47 22.7 57 28.4 
Intermediate education 63 30.4 64 31.8 
High education 30 14.5 30 14.9 
Previous cardiac and medical history data 
Ventricle ejection fraclion 193 189 
> 3 5 % 115 55.6 120 59.7 
35 - 40 % 30 14.5 27 13.4 
40 - 50% 48 23.2 42 20.9 
NYHA classification angina1' 195 191 
1 8 3.9 5 2.5 
II 41 19.8 26 12.9 
III 82 39.6 96 47.8 
IV 64 30.9 64 31.8 
Hypertension 204 88 42.5 201 86 42.8 
Hypercholesterolemia 196 124 59.9 194 136 67.7 
Smoking 199 69 33.3 198 73 36.3 
Family hislory 195 126 60.9 191 117 58.2 
Diabetes mellilus 205 38 18.4 201 33 16.4 
Operative data 
Number of grafts" 204 3.2 1.3 200 3.1 1.2 
Cardiopulmonary Bypass time in mins" 207 81.6 35.3 201 77.4 34.1 
Aorta cross-clamp time in mins" 207 52.5 25.9 201 47.8 27.3 
Without aorta cross-clamping 207 56 27.1 201 47 23.4 
Re-do CABG 207 14 6.8 201 10 5.0 
" in Mean (Standard deviation),b NYHA= New York Heart Association 
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Table 2: Reasons of missing data in baseline, one month and one year questionnaire 
Reason Control SSIC 
N % N % 
Baseline questionnaire 
Informative censoring 
Psychological problems 1 0.3 0 0.0 
Non-intormative censoring 
Lost questionnaire 0 0.0 1 0.3 
Total 1 0.3 1 0.3 
One month questionnaire 
Informative censoring 
Deceased 1 0.5° 0 0.0 
Admitted to a hospital 1 0.5 0 0.0 
Non-informative censoring 
Not willing to fill in 3 1.4 2 1.0 
Private or family circumstances 1 0.5 0 0.0 
No telephone number / address available 2 1.0 1 0.5 
Reason censoring unclear 
Admitted to a nursing home 2 1.0 0 0.0 
Not reported 3 1.4 7 3.5 
Total 13 6.3 10 5.0 
One year questionnaire 
Informative censoring 
Deceased 1 0.5° 3 1.5 
Non-informative censoring 
Not willing to fill in 2 1.0 4 2.0 
Private or family circumstances 1 0.5 0 0.0 
No telephone number / address available 3 1.4 3 1.5 
Reason censoring unclear 
Admitted to a nursing home 1 0.5 0 0.0 
Not reported 18 8.7 11 5.5 
Total 26 12.6 21 10.5 
°Same patient 
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Table 3: The short term and long term results of the quality of life for both the control group and the short-stay intensive care group 
Baseline One month post-operative Twelve months post-operative ANCOVA? 
Control SSIC Control SSIC T-Test Control SSIC 
Mean 
Mean Mean change Mean Mean Time Group X 
worse- change® change0 difference P- change0 change0 P- Time 
best Mean SD° Mean SD SD SD m groups 95% Cl= Value SD SD Value P- Value 
Disease specific: MILQ 
Mental health 0-28 20.4 4.29 20.6 4.21 1.09 4.62 1.10 4.30 0.01 -0.86 - 0.87 .985 -0.26 3.79 -0.02 3.63 <.001 .620 
Physical health 0-28 17.3 5.42 17.2 4.96 2.08 5.50 2.54 5.07 0.46 -0.58 -1.48 .388 1.49 4.32 1.00 4.63 <.001 .445 
Physical 0-28 16.3 6.63 15.5 6.03 -0.33 6.73 0.93 6.03 1.26 0.01 - 2.50 .049 4.25 5.52 3.69 5.57 <.001 .295 
Social 
functioning 0-28 21.4 4.43 20.9 4.18 -1.15 4.75 0.00 4.61 1.15 0.24 - 2.06 .014 1.96 4.29 1.43 3.80 <.001 .070 
Intimacy f 0-28 20.9 4.29 23.1 4.55 -0.19 4.45 0.66 4.35 0.85 -0.02-1.71 .054 0.27 3.78 -0.14 3.78 <.001 .527 
Cognitive 
functioning 0-28 22.9 4.17 23.0 3.59 -0.06 3.79 -0.16 3.69 -0.10 -0.83 - 0.62 .775 0.06 3.24 0.22 3.20 <.001 .841 
Financial status 0-28 23.6 4.27 23.4 4.17 -0.13 4.47 -0.40 3.69 -0.27 -1.07-0.53 .508 -0.52 4.03 -0.22 3.80 <.001 .558 
Healthcare 0-28 24.1 2.78 24.2 2.80 -0.74 3.70 -0.99 3.77 -0.25 -0.98 - 0.47 .491 -0.42 3.88 -0.14 4.26 <.001 .725 
Productivity 0-21 12.9 5.08 12.2 4.82 -0.65 5.11 0.28 5.43 0.93 -0.10- 1.95 .077 2.54 4.72 2.21 4.36 <.001 .579 
Overall MILQ-
Index s 35-245 180.2 28.8 177.8 26.9 -.10 28.1 3.86 27.3 3.96 -1.49-9.41 .154 9.50 24.99 7.98 25.19 <.001 .543 
MILQ score 1-7 4.5 1.2 4.4 1.1 0.35 1.33 0.50 1.33 0.15 -0.11 -0.40 .270 0.39 1.12 0.36 1.15 <.001 .508 
Generic: EQ-5D 
VAS h 0-100 60.4 18.2 58.04 18.9 7.00 19.0 9.99 21.8 2.99 -0.98 - 6.96 .140 6.45 16.19 5.20 17.23 <.001 .593 
Mobility' 3-0 1.5 .53 1.5 .51 -0.23 .56 -0.18 .59 0.05 -0.07-0.16 .433 0.08 0.48 0.00 0.55 <001 .217 
Self care' 3-0 1.1 .31 1.1 .29 0.04 .39 0.07 .40 0.03 -0.04-0.11 .386 -0.05 0.34 -0.10 0.37 <.001 .325 
Usual activities1 3-0 1.6 .62 1.7 .65 0.16 .79 0.06 .80 -0.10 -0.25 - 0.06 .248 -0.37 0.64 -0.36 0.64 <.001 .924 
Pain/discomfort' 3-0 1.5 .55 1.6 .57 0.14 .70 0.11 .64 -0.03 -0.16-0.10 .669 -0.21 0.70 -0.28 0.56 <.001 .311 
Anxiety/ 
Depression' 3-0 1.5 .64 1.5 .62 -0.22 .64 -0.30 .64 -0.08 -0.21 -0.04 .175 -0.46 0.53 -0.04 0.49 <.001 .569 
Domain specific: BDI/ and STAI-S " 
Total BDI 21-0 8.0 5.55 8.4 5.27 -0.J8 4.75 •0.52 5.46 -0.34 -0.13 -0 .65 .496 -0.14 5.23 -0.44 5.53 <.001 .621 
Total STAI-S 80-20 44.3 12.0 45.0 12.1 -7.19 12.1 -8.58 12.8 -1.39 -3.8 - 1.03 .259 -0.38 10.13 0.14 8.87 <.001 .653 
=SD= Standard Deviation,- one month - baseline score, = CI= Confidence Interval, - one year - one month score,e ANCOVA= Analysis of covariance,' n=164 control and n=167 SSIC group, 
3 Overall MiLQ-index= Multidimensional Index of Life Quality; clinically meaningful defined as difference of 0.4 points between SSIC and control group at one year is, " VAS= Visual Analogue 
Scale, difference of 8 points at one year, • difference of 0.3 points at one year, < BDI= Beck Depression Inventory, * STAI-S= State-Trait Anxiety Inventory 
Chapter 8 
T a b l e 4: Resul ts o f l inear r e g r e s s i o n a n a l y s e s fo r f h e p r e d i c t i o n m o d e l s o f qua l i f y o f l i fe a t 
o n e y e a r af ter s u r g e r y 
B P-value 
Model 1: Linear trend of the MILQ-score 0 
R-square =.334 
Bo 2.43 <.001 
Group .024 .736 
MILQ-score at baseline -.435 <.001 
Model 2: Linear trend of the Overall MILQ-lndex» 
R-square = .208 
Bo 77.29 <.001 
Group -.148 .934 
Depression at baseline -.406 .050 
Overall MILQ-index at baseline -.368 <.001 
Model 3: Linear trend of fhe EQ-5D VAS = 
R-square = .357 
Bo 30.33 <.001 
Group -.648 .556 
Gender -5.00 <.001 
Anxiety at baseline .106 .026 
EQ-5D VAS at baseline -.424 <•001 
° Cl= Confidence Interval." MILQ= Multidimensional Index of Life Quality, = VAS= Visual Analogue Scale 
Generic quality of life 
The linear change score of the EQ-5D VAS was not significantly different 
for both groups at one month (P-value= .140; 95% CI: -0.98 to 6.96) (table 
3). The same accounts for the change scores of the five EQ-5D domains. 
QoL increased similarly in both groups in the first year after surgery on EQ-
5D VAS (P-value=.593) and on all five EQ-5D domains (table 3). 
In the regression models, the type of intensive care treatment had no 
statistically significant effect on the linear trend of the EQ-5D VAS (P-
value=.556; 95% CI: -2.81 to 1.51; table 4). The baseline score of the EQ-
5D VAS, the baseline anxiety score and gender were significant predic-
tors of the linear trend of the EQ-5D VAS. All tests for first-order interac-
tions and all tests on the other predictors (appendix) were not statistically 
significant (table 4). 
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Domain specific quality of life 
The change score of the BDI and STAI-S did not differ in both groups at 
one month offer surgery (P-value= .496; 95% CI: -0.13 to 0.65, P-value= 
.259; 95% CI: -3.8 to 1.03) (table 3). 
The results of the repeated measures ANCOVA analysis show no statisti-
cally significant differences in the linear trend at one year after surgery 
for both groups on BDI (P-value=.621) or STAI-S (P-value=.653) (table 3). 
Discussion 
Summary of study findings 
This large randomised controlled equivalence trial is to our knowledge 
the first study that evaluates the impact of a short-stay intensive care 
treatment (a type of fast-track treatment) on disease specific, generic 
and domain specific QoL in the year after surgery, in low-risk CABG pa-
tients. 
After controlling for baseline differences and potential confounding fac-
tors like gender and age, the changes of disease specific, generic and 
domain specific QoL in the first year after surgery appear to be similar for 
patients who received the short-stay intensive care treatment (discharge 
within 8 hrs after surgery), and those who stayed overnight on the inten-
sive care. The scores on the domains physical and social functioning of 
the MILQ were significantly higher in the SSIC group compared to the 
control group at one month after surgery. However, these differences 
were no longer observed at one-year follow-up. 
Fast-track treatments and quality of life 
The desirability of decreasing post-cardiac surgery intensive care utiliza-
tion was recognized two decades ago (Johnson, 2006) with as main driv-
ing force, cost containment (Higgins, 1992). Examples of fast-track treat-
91 
Chapter 4 
ments which make IC discharge within a few hours after surgery possible 
are for instance: the use of fast-track anesthesia, normothermic tem-
perature management and early extubation at the intensive care. Due 
to the heterogeneity of the interventions, differences in case-mix, various 
quality of life questionnaires used and variable measurement moments 
used, a proper comparison between study findings is difficult. Neverthe-
less, our results confirm the findings of others that fast-track treatments do 
not have an impact on cognitive function (Cheng, 1996a; Howie, 2001; 
Kadoi, 2003). Royse et al. found less posttraumatic stress and depression 
at two and six weeks postoperative in the fast-track group receiving low-
dose anesthetics compared to the group that received a high dose 
(Royse, 2003). We did not find any evidence of a difference in the num-
ber of depressive and anxious feelings between the two groups in the 
first postoperative year. No comparison with other studies on the dimen-
sion pain can be made as these trials only reported on pain in the first 
days after the IC-treatment (Bowler, 2002; Engoren, 2001; Fillinger, 2002; 
Howie, 2001; Kadoi, 2003; Mollhoff, 2001; Shroff, 1997; Zarate, 2000). 
Clinical relevance of study findings 
A strong point of our study is its sample size. In the current study we were 
able to detect the possibility of a clinically meaningful QoL difference at 
one year (of 0.4 points on the MILQ, of 0.3 points on the EQ-5D domains 
and of 8 points on the EQ-5D VAS) between the SSIC and the control 
group. As none of these three scales at one year showed a statistically 
significant difference between the two groups, the reported differences 
between both groups cannot be defined as clinically meaningful. This 
indicates that the short-stay intensive care intervention does not have a 
relevant adverse impact on quality of life at one year after surgery. In 
another study (chapter 5) we investigated the validity of both the MILQ 
and the EQ-5D. One of the findings was that the baseline ceiling effects 
(a high percentage of patients with a maximum score) in all EQ-5D di-
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mensions were substantial, but these were not found on the MILQ-score 
and EQ-5D VAS. For the current study this indicates that there is a possibil-
ity that not all relevant changes in QoL measured by means of the EQ-5D 
domains were identified, however as outcomes reported by means of 
the EQ-5D domains are consistent with those of the EQ-5D VAS and the 
MILQ, the impact of this on the study conclusions is probably negligible. 
The differences at one month postoperative on the physical and social 
functioning of the MILQ were statistically significant different between 
the two groups, however these differences were no longer observed at 
one year follow-up. As the power calculation was based on one-year 
differences of QoL between the two groups it is not possible to make a 
proper judgment whether the reported small positive effects in the SSIC 
group at short term are of clinical relevance. 
In a previous paper we also reported generic QoL at one month after 
surgery as an outcome measure in the EE of the short-stay intensive care 
treatment. The patient's answers to the five EQ-5D items were used to 
calculate an utility value based on population weights (Dolan, 1997) 
(ranging from 0 to 1) and subsequently the A Quality Adjusted Life 
Months (A QALM's) was calculated. The generic QoL significantly im-
proved more in the SSIC group compared to the control group. In the 
current study this outcome was not reported because the aim of this pa-
per was to report data from a patient point of view and not from a socie-
tal point of view. The observed difference measured at one month was 
very small (0.0238) and lower than the score of 0.03 which in the current 
study is considered as being clinically relevant (Marra, 2005). 
If we compare the change scores of the EQ-5D at 12 months after sur-
gery in our study with the results in patients receiving planned surgery re-
ported by Badia et al. (Badia, 2001), the results of the domains self care, 
usual activities, pain/discomfort of the EQ-5D and the EQ VAS are very 
similar, but the scores on the other domains, mobility and anxi-
ety/depression, are different. The mean score on mobility improved clini-
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cally meaningful were as in our study no such an improvement was ob-
served. In contrast, patients in the SSIC study reported a decrease on the 
psychological dimension of the EQ-5D whereas patients planned for 
various types of surgeries this score did not change. An explanation for 
these discrepancies between the two studies can be related to differ-
ences in the patient characteristics. For instance, the mean age was 
lower in the study performed by Badia et al. compared to the mean age 
of our patients. Furthermore, not only CABG patients but also liver trans-
plant patients and other types of cardio surgical patients were included 
in the Spanish study. Another explanation can be related to the differ-
ences in measuring the baseline quality of life. The retrospective rating of 
the baseline QoL in the Spanish study can have resulted in an under- or 
overestimating of the scores and hence, in an under- or overestimation 
of the QoL change scores. 
Study limitations 
This study has the following limitations. Ideally, preoperative administra-
tion of the QoL questionnaires should be done before emotional re-
sponses could confound the QoL measures, but this was not possible due 
to logistic reasons. However, as this study was comparative this cannot 
have influenced study findings much. 
A measurement of pain within a few days after intensive care treatment 
was not performed, as it was practically impossible to perform this. 
The generalizability of this study may be somewhat limited because in 
the group of the primary non-responders, older patients and females 
were over represented compared with the group of the responders. 
However, as all baseline characteristics for the responders and the non-
responders of the two treatment modalities were comparable this can-
not have had a large impact on our study results. 
Finally, fatigue of the responders may have biased the study findings. 
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The limitations concerning the study design and patient eligibility are de-
scribed elsewhere (van Mastrigt, 2006). 
Conclusions and recommendations 
This randomised controlled equivalence trial evaluated thoroughly the 
impact of a short-stay intensive care protocol on quality of life in low-risk 
CABG patients. The short-stay intensive care treatment appears to have 
no effect on disease and generic QoL in the first year after surgery. As 
none of the observed QoL differences between the two groups can be 
defined as clinically meaningful, and safety and cost savings of the SSIC 
intervention already have been demonstrated (van Mastrigt, 2006), 
short-stay intensive care can also from a patient perspective be consid-
ered as a good alternative for postoperative IC treatment in low-risk 
CABG patients. 
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Appendix: Potential predictors of qualify of life used in the regression models 
Independent Source Coding Description 
Group Case Record 
Form 
care as usual=0 
SSIC=1 
Demographic data 
Age (Years) database continuous high age 
(Chocron, 1996; Herlitz, 2005; Welke, 2003) 
Sex (female) idem female=l 
male=0 
female 
(Chocron, 1996; Herlitz, 2005; Herlitz, 1999; 
Phillips Bute, 2003; Simchen, 2001; Yun, 1999) 
Civil state 
self reported with partner=l no partner 
without partner=0 (Phillips Bute, 2003) 
idem primary school not low education 
Education finished 
yes=l, no =0 
(Duits, 1997) 
Previous cardiac and medical history 
Left ventricular ejection 
fraction database <50%= 1 (Caine, 1999; Chocron, 1996) 
>50%, <50% >50% =0 
NYHA classification idem NYHA classification lll-IV 
angina ° 
1- II, lll-IV 
lll-IV= 1,1-11=0 (Chocron, 1996; Simchen, 2001) 
Hypertension 
idem yes=l history of hypertension 
no =0 (Herlilz, 2005; Herlitz, 1999; Yun, 1999) 
COPD b 
idem yes=l history of COPD 
no =0 (Herlitz, 2005; Herlitz, 1999; Welke, 2003) 
CVAc 
idem yes=l 
no =0 
history of CVA 
(Al-Ruzzeh, 2005; Herlitz, 2005; Herlitz, 1999) 
Smoking 
idem yes=l 
no =0 
history of smoking 
(Schräder, 2004) 
Diabetes mellites 
idem yes=l 
no =0 
diabetes 
(Herlilz, 2005; Herlitz, 1999; Yun, 1999) 
Quality of life data 
Baseline depression 
self reported depressive feelings at baseline 
(Duils, 1997; Schräder, 2004) 
Baseline anxiety 
idem continuous anxious feelings at baseline 
(Duits, 1997; Schräder, 2004) 
Baseline EQ-5D-VAS 
idem continuous baseline QoL 
(Herlitz, 2005; Herlitz, 1999; Rumsfeld, 2001) 
Baseline MILQ Index 
idem continuous baseline QoL 
(Herlilz, 2005; Herlitz, 1999; Rumsfeld, 2001) 
Other data 
Postoperative (life) idem yes=l 'stressful life event' 
events no =0 (Chocron, 1996; Pirraglia, 1999) 
° NYHA=New York Heart Association, " COPD= chronic obstructive pulmonary disease, c CVA= cardiovascular 
accident, 
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Abstract 
Objective: To assess the validity and the reliability of the EuroQoL (EQ-5D) 
and the Multidimensional Index of Life Quality (MILQ) in coronary artery 
bypass surgery patients. 
Study design: Prospective comparative study. 
Setting: University Hospital. 
Patients: 410 CABG patients completed both EQ-5D and MILQ preopera-
tively, and at one and twelve months postoperatively. 
Results: At baseline all five EQ-5D dimensions (35.7% to 90.0%) showed 
substantial ceiling effects, which were also observed in the MILQ dimen-
sions financial status and healthcare professionals. The effect sizes (or the 
predictive validity) at one month of the EQ-5D domain anxi-
ety/depression, EQ-5D Visual Analogue Scale (EQ-5D VAS), the MILQ 
domain physical health and the MILQ-score were moderate (effect sizes: 
-5.0 to .67). At 12 months postoperatively, the EQ-5D VAS, the MILQ-score 
and the two physical dimensions of the MILQ had a good predictive abil-
ity (effect sizes: .89 to 1.0). Only the EQ-5D domain usual activities and 
the EQ-5D VAS distinguished patients who were classified in different 
New York Heart Association functional classification categories. The test-
retest reliability of both questionnaires can be defined as not adequate. 
Conclusions: The discriminative validity of the EQ-5D domains and the 
external criterion, the predictive validity and reliability of both the EQ-5D 
and the MILQ were limited. Therefore, these two questionnaires are not 
the first choice when evaluating quality of life in CABG patients. 
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Introduction 
Quality of life (QoL) is an important outcome measure in randomised 
controlled clinical trials. To measure this outcome it is recommended to 
use two types of instruments (Dempster & Donnelly, 2000). Firstly, disease 
specific QoL questionnaires are mostly developed from a patient per-
spective, for a specific disease and are in general more responsive 
compared to generic ones (Wiebe, 2003). Secondly, generic instruments, 
as they are developed from community perspective, measuring general 
health and therefore make comparisons between various populations 
possible. As policy decisions regarding the reimbursement of healthcare 
interventions are based on general health outcomes, generic QoL in-
struments are essentially from a 'decisional perspective' (Dowie, 2002). 
On the other hand, patients, healthcare professionals and policy makers 
value a deep understanding of the benefits and harms an intervention 
produces (Guyatt, 2002). Therefore, from a 'knowledge perspective' dis-
ease specific QoL measures render important outcomes. 
When selecting a QoL instrument, it is important to know how well it will 
perform in providing the most appropriate and required information 
(Thompson, 1998). Therefore, both the reliability and validity of a ques-
tionnaire should be explored. These are not one-time-only attributes: they 
need to be re-established when the instrument is used in different popu-
lations or cultures (Thompson & Yu, 2003). Various investigators investi-
gated the psychometric proportions of both generic and disease spe-
cific measures used in cardiac patients, like for instance Short Form-36, 
Quality of Life after Myocardial Infarction (QLMI) and Seattle Angina 
Questionnaire (SAQ) (Dempster & Donnelly, 2000; Smith, 2000). They con-
clude that the available instruments have a lack of sensitivity to change 
and further research is needed on this topic. In this study the psychomet-
ric proportions of the EQ-5D and the Multidimensional Index of Life Qual-
ity (MILQ) are examined. The EQ-5D (EuroQoL-Group, 1990) developed 
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by a consortium of investigators in Western Europe is nowadays a well-
accepted and broadly used generic QoL measure. This questionnaire 
can be used in two different ways, firstly as a generic utility measure 
(based on the health state valuations it is suitable for economic evalua-
tions), and secondly as a measure to generate health profiles of patients. 
The psychometric proportions of the EQ-5D were previously assessed af-
ter myocardial infarction and cardiac rehabilitation (Nowels, 2005; 
Schweikert, 2006), however the validity and the reliability of this question-
naire in coronary artery bypass surgery patients was never assessed. The 
MILQ was developed by Avis et al. for the measurement of QoL in car-
diovascular patients (Avis, 1996). Although the MILQ seems to be a valid 
and a reliable instrument for the measurement of QoL, this questionnaire 
has rarely been used in studies (Falger, 2000; Sleeper, 2005; Smith, 1999; 
Smith & Larson, 2003). The objective of this study was the evaluation of 
the psychometric proportions of both the EQ-5D and the MILQ in CABG 
patients regarding the response and the item completion rate, the dis-
criminative, the predictive and the external criterion validity, and the 
test-retest reliability. 
Materials and methods 
Design 
For this prospective comparative study data were used of CABG patients 
who were included in the short-stay intensive care trial between February 
2001 and March 2003 at the University Hospital in Maastricht. In this study 
a stay of 8 hours intensive care was compared with the usual treatment 
of overnight intensive care stay. A detailed description of exclusion crite-
ria, short-stay intensive care protocol, clinical effectiveness, cost-
effectiveness and QoL data is available elsewhere (chapter 3 and 4). 
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The ethical and research council of the University Hospital Maastricht 
approved the study. 
Procedures 
After obtaining informed consent from the patients the QoL question-
naires were self-administered at three times: the first time at the day be-
fore surgery at the hospital, then twice at home, at one and twelve 
months after surgery. If a patient was unable to complete the baseline 
questionnaire by him-/her self, a research nurse assisted by filling in the 
form. At follow-up the patients were asked to respond without help from 
another person (s), but if this was not possible, to ask a relative or friend to 
assist. Patients who did not respond to the follow-up questionnaires re-
ceived a reminder letter together with a new copy of the questionnaire. 
If again they did not return the questionnaire, they were contacted by 
telephone to find out the reasons of non-response. 
Quality of life questionnaires 
Generic QoL was measured by the EQ-5D (Brooks, 1996). The EQ-5D con-
sists of two components: the EQ-5D descriptive system and the EQ Visual 
Analogue Scale (EQ-5D VAS). In the descriptive system the respondent is 
asked to rate his or her health by checking one of three levels of severity 
- 'no problems' (coded as 1), 'some or moderate problems' (coded as 
2), 'severe problems or unable to perform' (coded as 3)- in each of the 
following five EQ-5D dimensions: mobility, self care and pain/discomfort, 
usual activities and anxiety/depression. For the EQ-5D VAS, participants 
draw a line from a box to the point on the thermometer-like scale (with a 
range from 0 'the worst imaginable health state' to 100 'the best imag-
inable health state') corresponding to their health state. At follow-up, 
patients were asked whether their general health had been improved, 
deteriorated or stayed the same, compared to the previous situation. 
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The MILQ is a QoL measure especially developed for patients with car-
diovascular disease (Avis, 1996). In the first item (referred to as 'MILQ-
score') the respondent is asked to value his/her general QoL on a seven 
point-Likert scale (from 1= worst to 7= best possible QoL). In the other 35 
items the respondent's degree of satisfaction with various aspects of QoL 
on a seven point-Likert scale (from 1= very dissatisfied to 7= very satisfied) 
is scored. These items cover the following nine domains: mental health, 
physical health, physical functioning, cognitive functioning, social func-
tioning, intimacy, financial status, relationship with healthcare profes-
sionals and productivity. The domains contain each 4 items, so the addi-
tive domain score can range from 4 to 28 (except for the domain pro-
ductivity which contains 3 items, for which the maximum score lies theo-
retically between 3 and 21). The Dutch translation of the MILQ already 
has been successfully used to assess the QoL of CABG patients (Falger, 
2000). An unweighted index was calculated by summarizing overall nine 
domain scores. The total overall score range from 35 to 245 is referred to 
as the 'overall MILQ-index'. 
On the average, answering the EQ-5D takes five minutes, while answer-
ing the MILQ takes fifteen minutes. 
Psychometric analysis methods 
Firstly, the response and the item completion rates are assessed. These 
rates are investigated by calculating the proportion of the missing ques-
tionnaires and the proportion of missing items of the respondents within 
both questionnaires. It is assumed that both questionnaires achieve an 
acceptable response and item completion rate. 
Secondly, the discriminative validity of both questionnaires is assessed. 
Discriminative validity is defined as the instrument's ability to detect 
changes in the observed variable without provoking 'floor' or 'ceiling' ef-
fects. For each domain the proportion of the respondents with a mini-
mum score (referred to as 'floor effects') or a maximum score (referred 
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to as 'ceiling effects') is calculated. Floor and ceiling effects over 15% 
are considered critical (McHorney & Tarlov, 1995). At forehand it is ex-
pected that floor effects will be rarely (less than 10%) and ceiling effects 
will more frequently be observed in both questionnaires. Kolmogorov-
Smirnov tests (K-S) for assessing normality are performed. 
Thirdly, the predictive validity (or responsiveness) is tested. It is assumed 
that this type of validity is reflected by its ability to detect small but impor-
tant changes in QoL. Only patients who reported a change (improve-
ment or deterioration) in their health state were included for these analy-
ses. Two statistics were calculated to assess the predictive validity: the 
Standardized Response Mean and the Standardized Effect Size. The 
Standardized Response Mean (Cohen, 1988) is calculated: (SRM= (Ml-
M2)/(SD1-SD2)), where as Ml is the mean pre-assessment and M2 is the 
mean post assessment and SD1 is the standard deviation of the pre-
assessment and SD2 is the standard deviation of the post assessment. The 
Standardized Effect Size (SES) is calculated: ((M1-M2)/(SD1)). An SES or 
SRM of less than 0.2 can be described as a 'minimal' effect; an SES or 
SRM of 0.2 to 0.5 can be defined as a 'small' effect, 0.5-0.8 as a 'moder-
ate' effect and an SES or SRM above 0.8 as a 'large' effect (Cohen, 
1988). It is expected that the predictive validity of the MILQ will be better 
compared to the predictive validity of the EQ-5D. 
Fourthly, external criterion validity is assessed for both questionnaires. It is 
assumed that this type of validity is reflected by its ability to discriminate 
at baseline between patients with mild and severe disease by showing 
higher QoL scores in mild compared to lower QoL scores in more severely 
diseased patients. The New York Heart Association functional classifica-
tion (NYHA) classes (1—11, III and IV) are used as a criterion for cardiovascu-
lar disease severity (NYHA, 1994). To test the discriminative ability, the in-
dependent sample f-test was performed for the overall MILQ-index while 
all other scores were analyzed using Mann-Whitney U tests. It is expected 
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that the MILQ and the EQ-5D are able to discriminate between the dif-
ferent NYHA classes. 
Finally, the one-month test-retest reliability of QoL of the consecutive 
measurements (before surgery and at one month postoperatively) of 
both questionnaires is assessed for the sub sample of patients who indi-
cated that their QoL remained the same. The proportion of agreement 
and a kappa statistic (k) is calculated for both the five EQ-5D domains 
and the MILQ-score. For continuous data of the MILQ domains and the 
EQ-5D VAS the Intraclass Correlation Coefficients (ICC's) are calculated 
(Jenkinson & McGee, 1998). This is done by reliability analyses (two-way 
random effects model based on consistency agreement). The following 
four categories were used: k or ICC of >.20 indicating poor agreement-
scores from .21 to .40 suggest a fair degree of agreement, values from 
.41 to .60 represent moderate and >.60 good or adequate agreement 
(Altman, 1999). It will be expected that both questionnaires have at least 
a kappa or ICC score of .60 (McDowell & Newell, 1996). 
A P-value of less than 0.05 was assumed to be statistically significant. All 
data were analyzed with SPSS, version 12.0.1 (SPSS, Chicago, IL). 
Results 
Study population 
Six hundred patients gave informed consent and participated in the 
short-stay intensive care trial performed at the University Hospital Maas-
tricht. The data of this study are based on the first 410 patients. Two of the 
included patients had to be excluded from the study before treatment 
allocation was revealed. 
At randomization, the mean age of the patients was 62 years. Only 
twenty percent of the patients were females. Eighty patients were cate-
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gorized in NYHA class l-ll (20.7%), 178(46.1%) in NYHA class III and 128 
(33.2%) in NYHA class IV. 
Response rate and item completion rate 
The response rates were very high at baseline; only two (0.6%) question-
naires were missing. At one and twelve months postoperative, the non-
response rates were respectively 23 (11.3%) and 47 (23.1%). The percent-
age of missing items in the EQ-5D was less then 1 %. For the MILQ it 
ranged from 2 to 5%. Patients living alone (n=71) did not complete the 
four questions of the MILQ dimension intimacy (data not shown). 
Table 1: Discriminative validity, preoperative data of the EQ-5D and the MILQ 
Floor 
effects (%) 
Ceiling 
effects 
(%) Mean S D " Median 
Quartlle 
ranges Skewness 
EQ-5D 
Mobility 0.9 44.3 1.53 0.52 2 1-2 0.09 
Self Care 0.9 90.0 1.09 0.30 1 1-1 3.52 
Usual activities 10.9 35.7 1.65 0.44 2 1-2 0.44 
Pain/discomfort 4.8 39.6 1.60 0.56 2 1-2 0.25 
Anxiely/depression 7.8 53.4 1.50 0.63 1 1-2 .848 
EQ-5D VAS 0.0 0.4 59.22 18.56 60 50-75 -0.23 
MILQ 
Mental health 0.0 3.5 20.51 4.25 21 18-24 -0.73 
Physical health 0.0 0.9 17.22 5.19 17 13-21 -0.19 
Physical functioning 0.0 1.3 15.92 6.35 16 11-22 0.03 
Social functioning 0.0 6.1 21.13 4.31 22 19-24 -0.83 
Intimacy 0.0 2.6 21.05 4.33 22 18-24 -0.87 
Cognitive functioning 0.0 7.4 22,93 3.89 23 22-25 -1.80 
Financial status 0.0 21.3 23,48 4.21 24 22-27 -1.69 
Healthcare professionals 0.0 15.2 24.17 2.79 24 23-26 -1.12 
Productivity 0.0 2.2 12.55 4.96 13 9-17 -0.23 
Overall MILQ-index 0.0 0.0 179.00 27.88 180 160-200 -0.27 
MILQ-score 0.9 1.7 4.46 1.16 5 4-5 -0.16 
" SD = standard deviation 
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Discriminative validity 
At baseline ceiling effects on the EQ-5D dimensions were substantial, 
varying from the lowest in the dimension usual activities (35.7%) to the 
highest percentage in the dimension self care (90.0%) (table 1). Ceiling 
effects in the MILQ were observed in only two dimensions: financial status 
(21.3%) and healthcare professionals (15.2%). Floor effects were not ob-
served in the EQ-5D and MILQ. Only the overall MILQ-index showed a 
normal distribution (K-S test, P-value =.189). 
Table 2: Predictive validity of the EQ-5D and the MILQ of patients who reported a change in 
their health state (n=259) 
One month postoperative Twelve months postoperative 
SES» SRM" SES° SRM b 
EQ-5D 
Mobility -.47 -.40 -.38 -.34 
Self care .13 .10 -.10 -.09 
Usual activities .05 .04 -.51 -.44 
Pain/Discomfort .16 .12 -.30 -.24 
Anxiely/Depression -.50 -.51 -.54 -.54 
EQ-5D VAS £L ,54 1.0 .83 
MILQ 
Mental health .35 .34 .29 .29 
Physical health M =61 .90 .77 
Physical functioning .26 .25 .89 .74 
Social functioning -.11 -.09 .33 .28 
Intimacy .13 .12 .14 .13 
Cognitive funclioning -.03 .03 .10 .09 
Financial status -.01 -.02 -.14 -.15 
Healthcare professionals -.26 -.20 -.31 -.24 
Productivity -.16 -.15 M <51 
Overall MILQ-index -.25 .25 .22 
MILQ-score j59 .49 .92 .81 
Moderate effects are underlined, Large effects are indicated in bold, ° SES= Standardized Effect Size, " SRM= 
Standardized Response Mean 
Predictive validity 
The data in table 2 give an indication of the predictive validity of the EQ-
5D and MILQ questionnaire of the 259 patients who reported a change in 
their health state. A moderate effect size was observed for the following 
'one-month' change scores: the EQ-5D dimension anxiety/depression, 
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the EQ-5D VAS, the MILQ dimension physical health and the MILQ-score. 
For the EQ-5D dimension mobility, the MILQ dimensions mental health, 
physical functioning, healthcare professionals and the overall MILQ-index 
small effects were observed. In all other dimensions the SES's and SRM's 
at one month can be categorized as minimal. 
Large SES's and SRM's were observed for the 'one year' change scores 
of the EQ-5D VAS, the MILQ dimensions physical functioning and physical 
health, and the MILQ-score. Moderate effects were observed for the EQ-
5D dimensions usual activities and anxiety/depression, the MILQ dimen-
sion productivity and the overall MILQ-index. The effects of all other 
scores can be categorized as minimal or small. 
Table 3: External criterion validity, distribution of the MILQ and the EQ-5D over the New York 
Heart Association functional classification classes in median (quartile range) 
New York Heart Association functional classification 
Ml III IV 
N=80 N=178 N=128 
EQ-5D 
Mobility 1 (1-2) 2(1-2) 2(1-2) 
Self care 1 (1-1) 1 (1-1) 1 (1-1) 
Usual activities 1(1-2)* 2(1-2) 2 (1-21" 
Pain/Discomfort 1 (1-2) 2(1-2) 2(1-2) 
Anxiety/Depression 1 (1-2) 1 (1-2) K l - 2 ) 
EQ-5D VAS 70 (50-80) 40 (50-70) 58 140-75) 
MILQ 
Mental health 22 (19-24) 21 (18-24) 20 (17-24) 
Physical health 19 (14-22) 17 (12-21) 18(13-22) 
Physical functioning 18(11-23) 15 (11-20) 15 (10-22) 
Social functioning 22 (19-24) 21 (18-24) 23(19-24) 
Intimacy 22 (18-24) 21 (18-24) 23(19-24) 
Cognitive functioning 23 (20-25) 23 (22-25) 24 (22-26) 
Financial status 24 (22-27) 24 (22-26) 24 (22-27) 
Healthcare professionals 24 (23-26) 24 (23-25)"* 24 (24-261 
Produclivity 15(9-18) 12(3-15) 13 (8-18) 
Overall MILQ-index 188 (159-204) 172 (160-196) 180 (159-203) 
MILQ-score 5 (4-5) 4 (4-5) 4 (3-5) 
•Indicated in Bold signilicant difference (P-value<.005) between NYHA classes l-ll and III; usual aclivities (P-
value=.002], pain/discomfort (P-value=.003), EQ-5D VAS (P-value=.003], "Underlined significant difference be-
tween NYHA classes l-ll and IV; usual activities (P-value=.009), EQ-5D VAS (P-value=.003), " ' indicated in Italic 
significant difference between NYHA classes III and IV; relalionshlp with healthcare professionals (P-value=.022) 
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External criterion validity 
Table 3 presents the median and quartile range of the scores on both 
questionnaires of patients classified into the different New York Heart As-
sociation functional classification categories. The EQ-5D dimension usual 
activities and the EQ-5D VAS discriminate between patients in the NYHA 
category l-ll versus III as well as in the category l-ll versus IV. Furthermore, 
the EQ-5D dimension pain/discomfort discriminated between NYHA 
categories l-ll versus III. The MILQ dimension healthcare professionals was 
able to differentiate between NYHA category III and IV. 
Table 4: Test-retest reliability, agreement of the MILQ and the EQ-5D, of the patients who 
reported a stable health state (n =149) 
Proportion of agreement N (%) Kappa » 
EQ-5D 
Mobility 106 (72.1) .413 
Self care 129 (86.6) .222 
Usual activities 72 (48.2) .115 
Pain/Discomfort 89 (59.7) .219 
Anxiety/Depression 101 (67.8) .297 
MILQ 
MILQ-score 37.5 (54.0) .147 
Mean difference 
(standard deviation) 
Test-retest ICC 
EQ-5D 
EQ-5D VAS 4.58 (18.1) .433 
MILQ 
Mental health .399 (4.7) .395 
Physical health .980 (5.1) .404 
Physical functioning -1.57 (6.0) .414 
Social functioning -.87 (4.4) .550 
Intimacy -.130 (4.1) .550 
Cognitive functioning -.618 (3.6) .550 
Financial status -.622 (4.8) .465 
Healthcare professionals -1.20 (3.9) .229 
Productivity -1.57 (5.1) .400 
Overall MILQ-index 4.58 (27.6) .520 
" Moderate kappa and ICC scores are indicated In bold 
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Test-retest reliability 
Table 4 shows the results among those CABG patients who reported no 
change in QoL in the first postoperative month compared with the base-
line score. The agreement measured by means of the kappa for the EQ-
5D dimensions can be classified as poor for usual activities, moderate for 
mobility and fair for the domains: self care, pain/discomfort and anxi-
ety/depression. In the EQ-5D VAS, the MILQ dimensions mental health 
and physical health QoL improved, in all other MILQ dimensions a dete-
rioration of QoL was observed. The EQ-5D VAS and six out of nine dimen-
sions of the MILQ the ICC can be classified as moderate. 
Discussion 
The purpose of this study was to evaluate the psychometric proportions 
of a generic QoL measure (EQ-5D) and a disease specific measure (Mul-
tidimensional Index of Life Quality (MILQ)) in patients with coronary heart 
disease. The methods used to examine this will be discussed below. 
Response rate and item completion rate 
In terms of practicality, it was expected that the MILQ would be a more 
difficult instrument to complete than the EQ-5D. This appears to be sup-
ported by the higher proportion of missing items in the MILQ compared 
to the EQ-5D. However, the number of missing data in both question-
naires was lower compared to other studies (Holland, 2004; Schweikert, 
2006). Although the questionnaires were applied in a trial setting and it is 
expected that the percentage item response would be lower in a real 
world setting, these findings indicate that the two questionnaires are well 
understood by CABG patients. It should be noted that the EQ-5D was 
completed prior to the MILQ at baseline, and there is a theoretical possi-
bility that filling in the former will be influenced by filling in the latter. 
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Discriminative and predictive validity 
At one month after surgery in both questionnaires no large effects were 
observed for those patients who reported a change in their health state. 
This indicates that at short term after surgery it can be difficult to measure 
change (improvement and deterioration) in QoL with both question-
naires. 
A responsiveness of the EQ-5D was reported in a study in which the EQ-
5D was administered at 12 months after intensive care unit discharge by 
patients who were received a planned liver transplant or cardiac surgery 
(Badia, 2001). These findings could not be confirmed in our study, be-
cause at 12 months after surgery only for the EQ-5D VAS large effects 
were found. 
For the MILQ domains mental health, social functioning, intimacy, cogni-
tive functioning, financial status and healthcare professionals, the re-
sponsiveness was lower compared to the more 'physical' MILQ domains 
physical health, physical functioning and productivity. An explanation for 
this finding can be that patients undergoing a CABG surgery experience 
the most benefit on the physical aspects of their quality of life. Another 
explanation can be that the MILQ questionnaire was not sensitive 
enough to detect a change in these 'non'-physical dimensions of quality 
of life. 
The predictive validity of the MILQ was better compared to EQ-5D. Dif-
ferences in the characteristics of both questionnaires can provide an ex-
planation of these findings. Firstly, the 7 point-Likert items of the MILQ are 
likely to be more sensitive to changes compared to the 3 point-Likert 
items of the EQ-5D. Secondly, the EQ-5D contains for every dimension 
only one item, while the different MILQ domains contain 4 items each. 
Furthermore, a high proportion of patients reporting 'no problems' (scor-
ing 1 on the different items) probably will influence the responsiveness of 
the EQ-5D. This phenomenon known as 'ceiling effect' was previously 
reported in EQ-5D in cardiac patients with acute coronary syndromes 
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and patients with acute myocardial infarction (Macran, 2003; Nowels, 
2005; Schweikert, 2006). The consequences of significant ceiling effects 
for individual scores can be that measurement of an improvement from 
the baseline score is not possible; in other words there is a possibility that 
the questionnaire is unable to detect clinically significant changes at the 
higher spectrum of QoL. 
External criterion validity 
It was assumed that both the MILQ and the EQ-5D were able to detect 
cross-sectional differences between individuals by an independently ex-
ternal measured criterion. The NYHA functional classification was used as 
such a criterion (NYHA, 1994). 
Dougherty et al. reported that the Seattle Angina Questionnaire (disease 
specific) was able to discriminate between coronary artery disease pa-
tients in the four Canadian Cardiovascular Society functional classes 
(comparable with the four NYHA classes) (Dougherty, 1998). Furthermore, 
they found that the Short Form-36, a generic QoL measure, could only 
distinguish for selected subscales between the Canadian Cardiovascular 
Society functional classes. This ability was also reported for the EQ-5D in 
patients with an acute myocardial infarction (Nowels, 2005). We were 
not able to confirm these findings. Only the EQ-VAS and the dimension 
usual activities of the EQ-5D were able to distinguish between different 
NYHA classes. As the dimension usual activities directly measures func-
tional status, which is represented in the different NYHA classes, this is not 
surprising. Contrary to this, the domains physical functioning and produc-
tivity of the MILQ and the dimensions self care and mobility of the EQ-5D, 
which are also related to physical aspects of QoL, were not able to dis-
tinguish between severe or milder cardiac disease states. 
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Test-retest reliability 
The good test-retest reliability scores of the MILQ reported by Avis et al. 
(Avis, 1996) could not be confirmed in our study. The reason for this can 
be the difference in test-retest period in both studies. We used a recall 
period of one month whereas they used a two-week interval period (10 
to 21 days). In addition, our data were collected by means of self-
administration, and their data were collected only by means of a tele-
phone interview. Our EQ-5D reliability scores were lower compared to 
the reliability observed for patients with acute coronary syndrome 
(Schweikert, 2006). However, in the study performed by Schweikert et al. 
the number of patients who were assessed (reporting no change in QoL) 
was limited (n=l 1). The recall period in that study was relatively long (3 
months) compared to the one-month period in our study. 
Study limitations 
A limitation of our study is that its not possible to extrapolate our findings 
to other patient groups like for instance high-risk CABG patients. Another 
drawback is the method of assessment of the reliability; a golden stan-
dard for the assessment of test-retest reliability of questionnaires is the 
assessment of QoL in a patient population whose health status is stable. 
However, there is some evidence that health transition questionnaires 
are also valid (Fitzpatrick, 1993). 
Conclusion 
The item completion rate of both the EQ-5D and the MILQ are accept-
able. Contrary to the EQ-5D, ceiling effects are rarely observed in the 
MILQ. Both questionnaires were not sensitive to change at short term. 
Only the EQ-5D VAS, the MILQ-score and the two physical dimensions of 
the MILQ had a good predictive ability at 12 months after surgery. In ad-
dition, the external criterion validity for disease severity and the test-retest 
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reliability of both the EQ-5D and the MILQ can be classified as less ade-
quate. Based on these findings, we conclude that for the assessment of 
QoL in low-risk CABG patients the MILQ and the EQ-5D are not to be the 
preferred questionnaires. Further research on the psychometric propor-
tions of generic and disease specific QoL measures suitable for the eval-
uation of QoL in cardiac patients is needed to identify the most valid 
and reliable instruments. 
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Abstract 
Background: To our knowledge, a comparison of different adjustment 
methods for imbalances in baseline utility between treatment groups in 
Quality Adjusted Life Year (QALY) calculations has not been performed. 
Methods: The data of a trial based cost-effectiveness analysis evaluating 
a short-stay intensive care treatment for coronary artery bypass patients 
was used as an example. In the current study five different methods 
suited for the analysis of quality of life data on a patient level were used 
for calculation of QALY differences: 1) Conventional QALY calculation 
method (no adjustment for imbalances in baseline utility); 2) Mean dif-
ference adjustment method: correction with the differences in the mean 
baseline utility of the treatment groups; 3) Delta adjustment: uses the 
change in utility over time; 4) Regression-based utility adjustment: adjust-
ing the follow-up utility with a regression model with the follow-up utility 
as dependent variable, and baseline utility as independent variable; 5) 
Regression-based QALY adjustment: adjusting the QALY with a regression 
model with the QALY as dependent variable, and baseline utility as in-
dependent variable. 
Results: The mean and standard error for baseline utility score for control 
and experimental group were respectively .71 (.01) and 0.66 (.01). The 
mean total hospital costs during follow-up were significantly lower in the 
experimental group: €-816 (95% CI: €-1,581 to €-174). Cost-effectiveness 
acceptability curves show that the different adjustment methods result in 
different study outcomes. 
Conclusion: As imbalances between treatment groups in baseline utilities 
can have an impact on the QALY as outcome, we recommend report-
ing the outcomes of the regression-based QALY adjustment in the base 
case analysis and the outcomes of the other proposed adjustment 
methods in additional sensitivity analyses. 
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Introduction 
Quality Adjusted Life Year (QALY) is a well established outcome in ran-
domised clinical trial based cost-effectiveness analyses (Drummond, 
2005). In trials, it is common to report the distributions of several baseline 
variables by treatment group and to identify any 'unlucky' imbalances 
between treatment groups that may have arisen by chance (Pocock, 
2002). The importance of the impact of baseline differences depends on 
the strength of the association of the variable with the outcome (Po-
cock, 2002). This certainly holds for studies analysing QALY, because 
baseline quality of life (EuroQoL-Group) or the baseline utility is incorpo-
rated in QALY calculations and can therefore directly impact the study 
findings. Furthermore, it is known that a patient's baseline utility is likely a 
strong predictor for follow-up QoL measurements (Manca, 2005). How-
ever, as Richardson et al. demonstrated, only five of the 23 published trial 
based cost-effectiveness studies performed adjustments for baseline util-
ity if baseline imbalances in utility occurred (Richardson & Manca, 2004). 
In literature two different methods are described to adjust for imbalances 
in baseline utility in QALY calculations. The first one, known as 'delta 
QALY method' (A QALY), corrects by using only the change over time in 
QoL (increase or decrease in utility), instead of calculating the area un-
der the curve, which is used in conventional QALY calculations. Several 
studies used the delta method to calculate the QALY as study outcome 
(Cheng, 2000; Guthrie, 1999; Hurskainen, 2001; Lee, 2002; Patterson, 
1995). Manca et al. proposed the use of a regression method in the cal-
culation of the QALY when baseline QoL imbalances do occur (Manca, 
2005). However, this regression-based method only corrects for baseline 
imbalances on a group level and not on an individual level. In our opin-
ion, the latter is preferred because patient data are needed for applying 
bootstrap analyses in order to identify the uncertainty around the esti-
mated incremental cost-effectiveness ratios (ICERs) and constructing 
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cost-effectiveness acceptability curves (CEACs) (Briggs, 1997; Fenwick, 
2004). 
The purpose of the present study is to compare the conventional QALY 
calculation method with different adjustment methods for baseline utility 
imbalances between treatment groups which allow analyses of data on 
a patient level, and which can be applied in QALY calculations. The re-
sults of the different QALY calculation methods will be illustrated by 
means of the data of a randomised controlled trial. Finally, recommen-
dations will be given regarding which adjustment method to apply when 
imbalances in baseline utility occur. 
Materials and methods 
The case study 
The data of the short-stay intensive care study, a randomised controlled 
clinical equivalence trial designed to evaluate the safety and cost-
effectiveness of two types of intensive care treatment, was used. Six 
hundred low-risk coronary artery bypass patients were randomised for 
either discharge from the intensive care within 8 hours after admission 
(experimental group, e), or overnight stay at the intensive care (control 
group, c). 
The utilities were measured at baseline, before randomization (patients 
were blinded for group assignments) and at one month postoperative, 
using the EQ-5D descriptive system (EuroQoL-Group, 1990) and valued 
by means of the British valuation set (Dolan, 1997). For a simplification of 
interpretation of the results of the present study, the utilities measured at 
one month in the trial are presumed to be the utility scores at one year in 
order to make it possible to calculate a reasonable QALY. 
The cost analyses were performed from a hospital perspective with a fol-
low-up of one month postoperative. The included costs were inpatient 
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hospital days, clinical procedures and outpatient procedures. A detailed 
description of the short-stay intensive care treatment protocol, study and 
results is available elsewhere (chapter 3). 
Different methods for calculating QALYs 
In the following section five different methods are described that can be 
used to calculate the QALYs. 
An overview of the different formulas is presented in table 1 to make 
comparison between the different QALY calculation methods. 
1 Conventional method (no baseline adjustment) 
The equations 1 and 2 give a description of the QALY calculation for the 
experimental or control group given one follow-up measurement. 
(1) Qe = '/2 (Ueo + Uei) 
(2) Qc = '/2 (Uco + Uci) 
Qe and Qc represent the QALY of the patient in the experimental and in 
the control group, Ueo and Uco the baseline utility of the patient in the 
experimental and in the control group, and Uei and Uci the follow-up 
utility of the patient in the experimental and in the control group. The in-
cremental QALY (IQ) between the experimental and the control treat-
ment is calculated by subtracting the mean QALY of the experimental 
group from the mean QALY of the control group (table 1). 
2 Mean difference adjustment 
In this method the incremental QALY is adjusted according to the differ-
ence of the mean baseline utility between the two groups. The adjust-
ment with the mean difference can be applied as follows: the baseline 
and follow-up utility in the group with the lowest mean baseline utility (in 
our case study the experimental group) is increased with half of the 
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mean baseline utility difference, and in the group with the highest mean 
baseline utility (in our case study the control group) the baseline and fol-
low-up utility is decreased with half of the mean baseline utility differ-
ence. For the calculation of the QALY at patient level this means for the 
experimental group subtracting a quarter of the difference between 
mean baseline utilities of the experimental and the control group (Mean 
difference adjustment A, table 1). One could also decrease with the 
mean baseline utility difference between the experimental and the con-
trol group in the group with the highest mean baseline utility score (in our 
case study the control group) (Mean difference adjustment B, table 1). 
Another way of applying the mean difference adjustment is adding the 
baseline difference in the group with the lowest utility score. At patient 
level this means that individual values of the QALY in the experimental 
group are increased with the difference in baseline utilities between the 
experimental and the control group (table 1, Mean difference adjust-
ment C). We only reported the first mean difference adjustment method 
(A), as the estimated QALY increments between the experimental and 
the control group of all the mean difference adjustment methods (2A-
2C) are identical (table 1). 
3 Delta adjustment 
In this adjustment method not the area under the curve but the change 
in utilities between baseline and follow-up measures is used for the calcu-
lation of the QALY. For each individual patient, this so-called delta-QALY 
is defined as the change in utility and calculated by multiplying the dif-
ference between baseline utility and follow-up utility by one half. To en-
able comparison between the different adjustment strategies, the mean 
utility at baseline of the complete group is added to this score to calcu-
late the individual QALY. The consequence for the QALY increment be-
tween the experimental and the control group using the delta adjust-
ment method is shown in table 1. 
124 
Adjustment methods for imbalances in baseline utility 
4 Regression-based utility adjustment 
The adjustment for baseline difference based on a regression model uses 
the follow-up utility as dependent variable (equation 3). 
(3) Regression Utility: Ui = au + (3uUa 
Where Ui = follow-up utility 
Uo = baseline utility 
au, |3u = regression coefficients 
The regression coefficient (|3u) (equation 3) is used as a correction factor 
for the follow-up utilities. The individual QALYs and the increment be-
tween groups are calculated from the equations described in table 1. 
5 Regression-based QALY adjustment 
In this method the individual QALY is the dependent variable and base-
line utility the independent variable. 
(4) Regression QALY: QALY = aQ + pQUo 
The QALYs are calculated using the beta (Pq) (equation 4) from the re-
gression as a correction factor. Equations for the QALY in the experimen-
tal and the control group as well as the increment are given in table 1. 
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T a b l e 1: O v e r v i e w o f t h e f o r m u l a s f o r t h e i n d i v i d u a l Q A L Y c a l c u l a t i o n s o f p a t i e n t s i n t h e e x -
p e r i m e n t a l a n d in t h e c o n t r o l g r o u p , a n d t h e d i f f e r e n c e in Q A L Y s b e t w e e n t h e t w o g r o u p s 
Method QALY of patient In QALY of patient in Difference in 
experimental group control group QALYs 
No baseline adjustment (conventional method) Q e Q c IQe-c 
Mean difference adjustment A Q s - 'A Ao Q c + '/< A0 I Q e c - 'A Ao 
Mean difference adjuslment B Q » Q c - 'A A0 I Q « - 'A Ao 
Mean difference adjustment C Q „ + 'A Ao Q c IQ0t - 14 Ao 
Delta adjustment Qe + Uo - Ueo Qc + Uo - Uco IQec - Ao 
Regression-based utility adjustment Q„ + 'A (Uo - Ueo) Qc + % Pu (Uo - Uc0) IQe-c - V4 Pu Ao 
Regression-based QALY adjustment Qe + po (Uo - UeQ) Qc + Pq (Uo - Uco) IQe-c - Pa Ao 
Qe and Qe = QALY in experimental and control group 
IQe-c = 'A (Ueo + Uei) - 'A (Uco + UCi) 
Uo = mean of baseline utility of complete group 
Oeo and U c o = mean of baseline utility of experimental and control group 
A o = O e o - O c o 
|Ju = regression coefficients with utility as outcome 
Pa = regression coefficienls with QALY as outcome 
Statistical analysis 
Firstly, the mean costs (total hospital costs) and mean effects (using dif-
ferent adjustment methods) of the control group are subtracted from the 
mean costs and effects of the experimental group, resulting in the in-
cremental cost-effectiveness ratios (ICERs). Secondly, to quantify uncer-
tainty in the estimated ICERs, bootstrap sampling was applied using both 
the individual cost values and the values of the individual QALY for the 
different correction methods (Briggs, 1997). Cost-effectiveness planes (CE 
planes) were constructed after performing 1000 bootstrap replications 
(figure 1). Cost-effectiveness acceptability curves (CEACs) (figure 2) 
were used to show the probability of ICER acceptability given the various 
maximum levels that decision makers may be willing to pay/accept to 
gain/lose an additional QALY (van Hout, 1994). 
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Results 
The mean and standard error for baseline utility score were .71 (.01) and 
.66 (.01) for respectively the control (n=299) and the experimental group 
(n=298). The difference was statistically significant 
(mean difference = -.05; 95% confidence interval: -.01 to -.09). The follow-
up utilities were equal in both groups (mean = .71; standard error = .01). 
The mean total hospital costs were €5,441 in the control group and 
€4,625 in the experimental group. The mean total hospital costs were sig-
nificantly lower € -816 (95% confidence interval: €-1,581 to €-174) in the 
experimental group. 
Table 2: The different ICERs calculated by the means of the different correction methods 
and percentages bootstrapped ICERs in the four quadrants of the cost-effectiveness planes 
Percentage bootstrapped 
ICERs 
ICER |CER qua-
ICER (Cost/effect) drant N E " NW" SWc SE " 
No baseline adjuslment 
(conventional method) 
€ 29,843 (€-815/ -.030) Southwest 0 5 85 10 
Mean difference adjustment A € 273,079 (€-815/-.000) Soulhwest 1 3 52 44 
Delta adjustment €-35,512 (€-815/ .020] Southeast 2 0 3 95 
Regression-based utility 
adjustment € 38,678 
(€-815/ -.002) Southwest 1 3 82 14 
Regression-based QALY 
adjustment € - 181,173 (€-815/. 000) Southeast 1 3 
33 63 
11 NE = Norlheasl quadrant: experimental group more effective and more costly compared lo conlrol group, >< 
NW = Norlhwesl quadrant: experimental group less effective and more costly compared to control group (infe-
rior), SW = Soulhwest quadrant: experimental group less effective and less costly compared to conlrol group,11 
SE = Southeast quadrant: experimental group more effective and less costly compared lo control group (domi-
nant) 
When the conventional QALY calculation method (no baseline adjust-
ment for imbalances of baseline utility) is applied, the point estimate of 
the ICER (€ 29,843 (€-815/-.030) and most of the bootstrapped ICERs 
(85%) are situated in the Southwest quadrant of the CE plane, indicating 
that the experimental intervention is less effective and less costly (table 2, 
figure 1). In the mean difference method (mean difference adjustment 
A, table 2, figure 1) approximately 50% of the bootstrapped ICERs is situ-
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ated in the Southwest quadrant. 82% of the bootstrapped ICERs of the 
regression-based utility method is situated in the Southwest quadrant 
(table 2, figure 1). However, the estimated ICERs of the delta adjustment 
and the regression-based QALY adjustment (table 2, figure 1) indicate 
dominance of the experimental treatment, which is confirmed by the 
bootstrap analyses. 
Figure 1: Cost-effectiveness planes with 1000 bootstrap replications of the incremental cost-
effectiveness of the experimental versus the control group for no baseline adjustment and 
the four different adjustment methods 
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Figure 1: continued 
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Figure 2 presents the results of the CEACs for the different applied QALY 
calculation methods. As expected based on the results from the CE 
planes, the conventional QALY method and the regression-based utility 
adjustment are represented by the two lowest curves. When choosing a 
specific ceiling ratio these two curves have a lower probability of accep-
tance compared to the other higher curves. The delta adjustment 
showed the highest curve, followed by the regression-based QALY 
adjustment and the curve of the mean difference adjustment A. All 
curves except for the highest one (delta adjustment) show a decline of 
the ICER with an increasing ceiling ratio, indicating that the probability of 
ICER acceptance is decreasing with an increase of the ICER limit. The 
CEA-curve of the delta adjustment is the only curve that is not influenced 
by increased ceiling ratios. 
Figure 2: Cost-effectiveness acceptability curves for the cost-effectiveness of the experi-
mental versus the control group with no baseline adjustment and the four adjustment me-
thods 
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Discussion 
Summary of study findings 
The results of this study show that not applying a correction method for 
the calculation of QALYs when baseline utility imbalances between 
treatment groups occur, resulted in different cost-effectiveness out-
comes compared to when various correction methods for the calcula-
tion of QALYs were applied. The magnitude of the impact of these cor-
rection methods on the study outcome are dependent on the type of 
correction method used. 
Impact of baseline differences 
If a randomization procedure in a randomised controlled trial is per-
formed according to the recommendations (is patient really randomly 
assigned to one of the treatment arms (Altman, 2001 j) there is still the 
possibility of imbalances of baseline characteristics between both treat-
ment arms. It is well accepted to correct for these baseline disparities in 
prognostic characteristics by means of a covariate-adjusted analysis 
(Pocock, 2002). In trial based cost-effectiveness studies baseline utility 
scores can be imbalanced between treatment groups as well. The im-
pact of these imbalances in baseline utility can be substantial as these 
utilities are directly incorporated in the calculation of the study outcome, 
the QALY. Corrections of imbalances in baseline utility in trial based cost-
effectiveness studies are rarely performed (Richardson & Manca, 2004). 
For the interpretation of cost-effectiveness studies it is important to report 
any measured variation of the study outcomes, because only when data 
at patient level are available, bootstrap analysis can be applied and 
presentation of results in CEA-curves can be done. 
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Mean difference adjustment 
Based on the theoretical advantages and disadvantages, the following 
considerations can be made for the different adjustment methods pro-
posed. The mean difference adjustment methods (A-C) are not pub-
lished in the literature. For the incremental effects it makes no difference 
which of the variants (A-C) are used. Apart from variation due to the 
bootstrap procedure, they all will result in the same CE planes and 
CEACs. These mean difference adjustment methods are the least pre-
ferred methods for correction as they have two important drawbacks. 
Firstly, they replace the individual baseline utility scores by group scores. 
Using this method the mean difference of utilities of the total group or a 
specific treatment arm at baseline is subtracted or added to the individ-
ual scores, which results in a higher percentage of patients that end up 
having a utility of one or higher (in our case study = 13.6%). As utilities are 
at a maximum 1, all values over 1 need to be adapted. The second 
drawback, of the mean difference adjustment method is that this 
method does not correct for the regression towards the mean phe-
nomenon, because, baseline values negatively correlate with change as 
patients with low scores at baseline generally improve more than those 
with high scores (Bland & Altman, 1994). 
Delta adjustment 
This last disadvantage also applies to the delta adjustment method. This 
method is a well accepted and commonly used method (Cheng, 2000; 
Guthrie, 1999; Hurskainen, 2001; Lee, 2002; Patterson, 1995). Another dis-
advantage of the delta adjustment is that the comparison of the study 
findings using delta adjustment with other QALY calculations is only pos-
sible if the mean baseline utility of the total group is added. Besides these 
two drawbacks, the advantages of this method are twofold: it is suitable 
for both small (less then 50 patients) and large study populations, and if 
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the correlation between baseline and follow-up is high (r > .8) the power 
is still acceptable (Vickers, 2001). 
Regression adjustment 
Manca et al. were the first to propose a regression based technique to 
correct for baseline imbalances in utilities when calculating of QALYs 
(Manca, 2005). However, this method is not suitable for the calculation of 
individual QALYs and therefore ICER uncertainty cannot be explored. 
The two regression based correction methods we propose make individ-
ual QALY calculation possible. Compared to the previous described cor-
rection methods, they have the highest statistical power and do correct 
for regression towards the mean. There are also disadvantages of these 
two correction methods. Firstly, the assumptions for applying regression 
analysis need to be fulfilled. The most important assumption is that the 
baseline utilities need to be normally distributed. In small studies this is 
rarely the case. In large studies it is difficult to transform the data be-
cause of the wide range of possible health states. The second disadvan-
tage of the regression-based utility adjustment is the possibility of over or 
under correction, as the 'uncorrected' baseline utility is used to calculate 
the adjusted QALY. 
Study limitations 
The generilisability of our findings is questionable. In the reported case 
study, there is only one follow-up moment. As a consequence, the im-
pact of the baseline difference is larger compared to other studies 
where there are more follow-up measurements. Besides this, the impact 
of the different correction methods can vary if the differences in costs 
between the two treatment groups are less robust than found in the pre-
sent case study. Therefore, exploring the impact of the different methods 
for correcting baseline utility imbalances should be repeated using the 
data of other trial based cost-effectiveness studies. 
133 
Chapter 8 
Recommendations 
Researchers should be aware of imbalances in baseline utility in trial 
based cost-effectiveness studies. If an imbalance is observed, the follow-
ing approach can be used: 
Firstly, be sure that baseline imbalances are the result of coincidences 
and not due to shortcomings in the performed randomization procedure. 
When it is expected that there is a problem with the applied randomiza-
tion procedure, propensity score matching can be used as a correction 
method (Joffe & Rosenbaum, 1999). 
Secondly, always report baseline and follow-up utilities of both groups in 
mean and variance (standard deviation orsfandord error). 
Thirdly, if baseline imbalances of utilities occur, we propose on theoreti-
cal grounds to use the regression-based QALY adjustment method in the 
base case analysis. Assuming that an adjustment is necessary, methods 
such as the mean difference and the delta adjustment methods men-
tioned in the present paper will not adjust for regression to the mean ef-
fects, and therefore will probably over adjust for baseline differences. 
They will also result in an unjustified strong influence of outliers in the 
baseline measurement. The regression-based QALY method takes into 
account the regression towards the mean phenomenon and will there-
fore be the most accurate adjustment method. As the QALY calculation 
uses the baseline value as such, solely adjusting the follow-up utility solves 
the problem only partly. Thus, using this regression-based QALY adjust-
ment method will not only correct the follow-up utility values but will also 
prevent that the original baseline utility values are again used to calcu-
late the QALY. 
Furthermore, the impact of the other baseline adjustment methods can 
be explored as an additional sensitivity analysis. When applying regres-
sion based correction methods, check if the assumptions for regression 
analysis are fulfilled (e.g., normality of baseline utility, n>50). If baseline 
utilities are not normally distributed, transform data to a log normal distri-
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bution. The choice to use one of the mean difference adjustment meth-
ods should be based on one of the three methods that lead to the mini-
mum number of unrealistic high utility values. For the interpretation of the 
results of the mean difference adjustment method and delta adjustment 
method, always be aware of regression towards the mean phenome-
non. 
Conclusion 
For cost-effectiveness studies with imbalances in the baseline utilities, 
only reporting study findings using the conventional QALY calculation is 
not sufficient. We suggest using the regression-based QALY adjustment 
for dealing with imbalances in baseline utility between treatment groups. 
Ignoring baseline utility imbalances in QALY calculations can lead to mis-
leading interpretation of cost-effectiveness analysis results. Researchers 
should always be aware of this problem. 
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This chapter contains six major parts, which will summarize and discuss 
the contents of this thesis. In the first part (1) a summary will be given of 
the different studies performed. The barriers for implementation of the 
short-stay intensive care intervention will be discussed in the second part 
(2). In the third part (3) aspects of framing future research will be dis-
cussed. In the fourth part (4) the use of different quality of life measures 
for future research will be discussed. In the fifth part (5) the impact of us-
ing adjustment methods to correct imbalances in baseline utility in QALY 
calculations on the SSIC study findings will be discussed. In the last two 
parts (6 and 7) a summary of recommendations for future research will 
be given. 
1 Summary 
1.1 State of the art of fast-track treatments for low-risk CABG patients 
(chapter 2) 
In the second chapter the results of a systematic review are described. 
None of the previous studies that evaluated fast-track treatments focus-
sed on IC discharge criteria. They investigated related topics as type and 
dose of anesthetics (high dose: fentanyl>15|jg/kg, low dose: fen-
tanyl<15|jg/kg) or extubation protocols used (the intention to extubate 
patients within or after 8 hours postoperative). 27 randomised controlled 
trials evaluating fast-track treatments were identified. The main finding of 
this review and meta-regression analysis is that the introduction of an 
early extubation protocol is an important predictor for the decrease of IC 
and total hospital stay in low-risk CABG patients. 
The epidemiological quality of the studies was moderate. Only one study 
fulfilled all three methodological criteria: the use of intention-to-treat 
analysis for the primary study outcome IC stay, allocation concealment 
(is patient really randomly assigned to one of the treatment arms) and 
blinding of person(s) deciding on the length of IC stay. 
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The quality of the economic evaluations (EEs) of the 7 studies reporting 
on costs was assessed by means of the Consensus Health Economics Cri-
teria list (CHEC-list). The CHEC-list scores on the 17 evaluated items of the 
various studies were low (on average 8 points). The drawbacks of these 
studies were mainly related to the choice of study design (not appropri-
ate to the stated objective) and costing methods (irrelevant costs were 
identified and not appropriately valuated). The findings of our review in-
dicate that there is a need for quality improvement of both the study de-
sign and the design of EEs. 
1.2 Clinical effectiveness and cost-effectiveness of the SSIC protocol 
(chapter 3) 
The short-stay intervention is evaluated in low-risk CABG patients by 
means of a randomised controlled clinical equivalence trial and an EE 
performed alongside it. We defined low-risk patients as patients who ful-
filled the following criteria: having a stable cardiological situation (not 
having a cardiogenic shock, no need for inotropic therapy, no need for 
intraaortic balloon pump, and no ongoing or recent myocardial infarc-
tion), age < 78 years, ejection fraction of > 30% and not requiring hemo-
dialysis or having pulmonary hypertension. Patients assigned to the SSIC 
group were transferred from IC to MC within 8 hours if they fulfilled the 
following discharge criteria: extubated for at least 30 minutes, normal 
breathing, arterial blood gas p02 > 10 Kpa and PCO2 < 6.0 Kpa, cardiac 
stable, fluid balance in control (< 100 ml chest tube drainage per hour 
and a diuresis > 0.5 ml/kg/hour), no signs/symptoms of neurological 
complications, no need for hemodynamic and supporting therapy. 
The primary study endpoints were IC readmission and total hospital stay. 
IC readmission was 1.34% (n=4) and 2.68% (n=8) in the control group and 
the SSIC group respectively. The difference of 1.13% was not significantly 
different (P-value = 95% CI: -.9% to 2.9%). No differences were found be-
tween the two groups with respect to 'total hospital stay' and the sec-
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ondary outcomes measures 'postoperative morbidity' and '30 day-
mortality'. The patients in the SS1C group spent significantly fewer hours at 
the IC compared to control group patients. In the intervention group the 
mean costs per patient were €4,625 versus €5,441 in the control group. 
The difference was €-816, mainly due to lower costs of clinical proce-
dures and IC stay. The generic quality of life was valuated by societal 
health values. The delta quality adjusted life months (A QALM) was sig-
nificantly different between the two groups, in favour of the SSIC group. 
The incremental cost-effectiveness ratio and 98% of the bootstrapped 
ICERs were situated in the Southeast quadrant, indicating that the SSIC 
group is dominant over the control group. The conclusion of this study is 
that SSIC is a safe and cost-effective approach compared to usual care. 
1.3 Health-relafed quality of life after fast-track treatment (chapter 4) 
The objective of this prospective randomised equivalence trial was to 
evaluate disease specific (Multidimensional Index of Life Quality), ge-
neric (EQ-5D) and domain specific (Beck Depression Inventory, State-Trait 
Anxiety Inventory) health-related quality of life (QoL) until one year after 
fast-track treatment for low-risk coronary artery bypass patients (CABG 
patients). Quality of life was measured at baseline, one and twelve 
months after treatment. The main findings were that in a multivariate 
analysis at one year after surgery no statistically significant differences in 
QoL between the two groups were shown. In addition, after controlling 
for potential confounders at one year no statistical significance between 
both groups was found. The conclusion of this study is that QoL of SSIC 
patients are similar to patients receiving care as usual, and that none of 
the observed QoL differences between the two groups can be defined 
as clinically meaningful. 
140 
Summary and general discussion 
1.4 Testing validity and reliability of the EuroQoL and Multidimensional 
Index of Life Quality (chapter 5) 
The objective of this prospective comparative study was to test the valid-
ity and reliability of the EuroQoL (EQ-5D) and the Multidimensional Index 
of Life Quality (MILQ, a disease specific instrument) in coronary artery 
bypass surgery patients. 
The main findings of this comparative study were that the discriminative 
validity was limited due to substantial ceiling effects in all five EQ-5D di-
mensions shown. These effects were also observed in the MILQ dimen-
sions financial status and healthcare professionals. The predictive validity 
at one month of the EQ-5D domain anxiety/depression, EQ-5D VAS, MILQ 
domain physical health and the MILQ-score was moderate. At 12 months 
after surgery the EQ-5D VAS, MILQ-score and the two physical dimen-
sions of the MILQ had a good predictive validity. Only the EQ-5D domain 
usual activities and the EQ-5D VAS distinguished between patients of dif-
ferent New York Heart Association functional classification categories 
(external criterion validity). The test-retest reliability of both questionnaires 
can be classified as not adequate. 
The conclusions of this study are that the discriminative validity of the EQ-
5D domains, the external criterion and the predictive validity of both the 
EQ-5D and the MILQ were limited. In addition the reliability of both ques-
tionnaires was not adequate. These questionnaires are not the first 
choice when evaluating QoL in CABG patients. 
1.5 Adjustment methods for imbalances in baseline utility between 
treatment groups in QALY calculations (chapter 6) 
The objective of this study was to evaluate different strategies, which cor-
rect imbalances in baseline utility in quality adjusted life year (QALY) cal-
culations and are suited for the analysis of data on a patient level. 
The data of a trial based cost-effectiveness study evaluating a short-stay 
intensive care treatment for coronary artery bypass patients was used as 
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a case study. Five different methods were used for calculation of QALY 
differences: 1) Conventional QALY calculation method (no adjustment 
for imbalances in baseline utility); 2) Mean difference adjustment 
method: correction with the differences in the mean baseline utility of 
the treatment groups; 3) Delta adjustment: uses the change in utility over 
time; 4) Regression-based utility adjustment: adjusting the follow-up utility 
with a regression model with the follow-up utility as dependent variable, 
and baseline utility as independent variable; 5) Regression-based QALY 
adjustment: adjusting the QALY with a regression model with the QALY as 
dependent variable, and baseline utility as independent variable. 
The results of this study show that not applying a correction method for 
the calculation of QALYs when imbalances in baseline utility occur, re-
sults in a different cost-effectiveness outcome compared to various sim-
ple or advanced correction methods for the calculation of QALYs having 
been applied. The magnitude of the impact of these correction methods 
on the study outcome is dependent on the type of correction method 
used. We recommend in case of imbalances in baseline utility to report 
the outcomes of the regression-based QALY adjustment in the base case 
analysis and to report the outcomes of the other proposed adjustment 
methods in additional sensitivity analyses. 
2 Possibilities for implementation of the current SSIC protocol 
The encouraging results of the SSIC study make it desirable to implement 
the SSIC protocol. We know that in the Netherlands hospitals use fast-
track protocols; at the moment, however, more than three years after 
publication of the main study findings, we did not get any information 
about hospitals currently using our protocol. 
One may ask if the findings of one randomised controlled trial and an EE 
performed alongside it are sufficient evidence to policy makers to actu-
ally decide to use the SSIC protocol in their hospitals? This study demon-
strates the second-best level of evidence (level IB): an individual ran-
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domised controlled trial with narrow confidence intervals. In other words 
an randomised controlled trial which excludes clinical harm from the 
new treatment (Straus, 2005). The best level of evidence is not available 
as this was the first study that evaluated this type of fast-track treatment 
(SSIC-protocol) and therefore no systematic review with homogeneity of 
randomised controlled trials could be performed (Level 1 A). 
Reliability and transferability of the study findings will be discussed below 
as they are also important to decision makers in making decisions on 
whether or not to implement a new treatment strategy (Drummond & 
Pang, 2001; Mason & Mason, 2006). Decision makers need to be con-
vinced of the reliability of the study findings, in other words; does the 
study give an accurate estimate of the study outcomes, which are free 
of biases? This may apply to the main effect measure of the EE, the 
QALY. Several surveys indicate that policymakers are less comfortable 
with the methods of QALY calculations. They find the concepts behind 
the measurements difficult to understand, they have concerns about the 
reliability of the estimation methods themselves, and finally, they have a 
general concern about the aggregation of healthcare benefits in a sin-
gle index (Barbieri, 2005). The transferability of a study means, to which 
extent study findings of a specific study are directly applicable to the 
decision maker's own setting. This is not always the case with cost-
effectiveness findings, as they can vary by settings, by levels of clinical 
experience, by disease severity, by co-morbidity, by resource use, by 
prices and by utilities (Manca, 2005; Mason & Mason, 2006; Sculpher, 
2006). This may be a reason for decision makers not to implement the 
SSIC protocol. However, not implementing the protocol for transferability 
reasons was minimized by thoroughly and accurately describing the 
study design, conduct, and analysis in the published articles. By doing so, 
policy makers were able to distillate which part of the findings do or do 
not apply to their own specific healthcare setting. 
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An important step in the implementation process is to determine various 
potential barriers that impede implementation (Grol & Wensing, 2001). In 
the following sections the potential barriers of implementation of the SSIC 
protocol related to the system (infrastructure and budgets (2.1.1-2.1.2)) 
and the social environment (healthcare professionals and patients) will 
be discussed (2.1.3-2.1.4). 
2.1.1 System: Infrastructure of the IC and MC 
Cardio Thoracic (CT) ICs in the Netherlands can have different structures: 
being a separated CT IC, the CT unit is situated on the general IC, and a 
combined CT-cardiology IC. An MC care facility is not always available 
and therefore patients sometimes need to be directly transferred to the 
nursing ward. If centers do not have a separated CT IC nor a MC directly 
attached to the IC, this may pose a barrier to the implementation of the 
SSIC protocol, and, subsequently, to patient logistics. 
2.1.2 System: Budgets 
From a health economic point of view the available resources as a result 
of the reduced IC hours and clinical procedures can be used for the 
treatment of more complex patients. Another possibility of a more effi-
cient use of IC and MC capacity can be that more surgeries can be per-
formed and fewer patients are being refused for IC admission. However, 
although decision makers will understand these abovementioned argu-
ments their main concern is the financial budget constraints. Currently 
the reimbursement per treated patient is not related to the total stay at 
the various departments, but to all aspects of a specific clinical pathway 
(DBC; Dutch for Diagnosis treatment Combination). Besides, another im-
portant aspect for not implementing the SSIC protocol will be the costs of 
the actual implementation of the intervention itself. These are for in-
stance the costs of rebuilding the IC and/or MC departments and the 
costs of education and organizing meetings for healthcare professionals. 
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2.1.3 Social environment: healthcare professionals 
Due to the fact that it is not possible to predict exactly at what time of 
the day which and how many SSIC patients will be ready to be trans-
ferred to medium care, the planning of personnel can be a barrier to 
healthcare professionals to implement the protocol. In our study 55% of 
the SSIC patients fulfilled the discharge criteria and were transferred from 
IC to MC within 8 hours. As the decision to transfer SSIC patients can be 
made not only at 8 hours but at any time a patient has a stable clinical 
situation (for instance at 6 or 12 hrs after surgery), these percentages will 
probably be higher in daily practice. Further research is needed to con-
firm these expectations. 
Another barrier related to healthcare professionals can be the type of 
profession of the general manager of the IC department. He or she can 
decide whether or not to implement the SSIC protocol. For example, the 
development of the SSIC protocol by a cardiac surgeon might affect the 
acceptability for implementation by other professions, like intensivists or 
anesthesiologists who can also be the general managers of the IC. 
Other potential barriers might be the attitude and resistance to change 
felt by IC and MC nursing staff. During the Maastricht trial e.g. nurses 
were very sceptical about the benefits of treating patients according to 
the SSIC protocol, as they feared that their workload would increase (for 
example, patients are not constantly asleep any more during their stay 
at the IC department). 
2.1.4 Social environment: patients 
The following data indicate that the motivation for implementing a SSIC 
protocol specially developed for low-risk CABG patients may have de-
creased in recent years due to changes in the CABG-patient population. 
From 2004 to 2006 a decline of the number of hospitalizations due to 
CABG and an increase of the number of hospital admissions for percu-
taneous coronary interventions (like stent placement) was observed in 
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the Netherlands (Prismant, 2008). A comparable trend was also observed 
in other western countries (Nallamothu, 2007). These results, together with 
ageing, resulted in a greater proportion of higher risk cardiac patients 
who were selected for elective surgery (Cheng & Barash, 2006; Flynn, 
2004; Goss, 2006). 
3 Framing a future study 
As discussed, implementation of the SSIC protocol is difficult for various 
reasons. Therefore it is important that future studies in this field must dimin-
ish the implementation barriers by taking them into account as much as 
possible in the design phase of the study. The development of a new EE 
in this field will be discussed by means of the concept of framing. Fram-
ing can be defined as a series of decisions that collectively define and 
describe the EE study to be undertaken (Gold MR, 1996). The main as-
pects of framing are; defining the study objective and audience (3.1), 
the type of analysis (3.2), the perspective of the analysis (3.3), the inter-
vention and the comparison treatment and the target population (3.4), 
and finally the boundaries and the time horizon (3.5). 
3.1 Objective and audience 
In our opinion the objective of a future study must be: performing a be-
fore-after multicenter trial with EE evaluating the entire clinical pathway 
of CABG patients. In the first 12 months before evaluating the clinical 
pathway, all relevant clinical outcomes, quality of life and cost data 
need to be gathered for the care as usual in various hospitals. In the 
second period of 12 months the same data will be collected when treat-
ing patients according to the clinical pathway. 
The primary audience of this new study is the general managers of the IC 
units and the board of directors of the hospitals. Therefore it is important 
to focus the analysis on topics that are relevant for these two groups of 
decision makers. For instance, a future study should focus more on an 
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intervention that can easily be implemented in different hospital settings. 
Besides the costs and consequences that are part of a conventional EE, 
other aspects that are important to decision making should be assessed 
as well. Issues that need to be included are for example: calculations of 
the implementation costs, and scenario analyses on the impact of the 
new treatment on changes in patient flow and waiting lists. 
3.2 Type of analysis 
As it is expected that the clinical pathway of CABG patients is more ef-
fective compared to the usual care, the preferred type of analysis of a 
future study is CEA (or CUA). However, given the idea described above 
that other aspects are relevant to decision makers, the framework of 
cost-outcome analysis, being a specific method of EE, might be consid-
ered for this purpose to cover the outcomes that cannot be expressed 
as either costs or patient outcome. 
3.3 Perspective of analysis 
For a future study we would advise to choose both the hospital and so-
cietal perspective for the EE. A hospital perspective should be used, be-
cause at this level the decisions about the use of the clinical pathway of 
CABG patients will be made. A societal perspective is also important for 
the foundation of arguments for implementation. Due to the proposed 
changes in treatment it is expected that treatment according to the 
clinical pathway will have a positive effect on recovery (like reduced 
overall hospital stay, higher scores on physical aspects of quality of life) 
compared to care as usual. Patients treated according to the clinical 
pathway for instance will be discharged earlier from hospital after sur-
gery. In addition, cost-savings will probably take place. The direct medi-
cal costs, like the hospital costs (costs of inpatient days and clinical pro-
cedures) will probably decrease, but some indirect medical costs will 
probably increase (for instance more informal care or paid help after 
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hospital discharge will be needed). The indirect non-medical costs, how-
ever, will be lower as it is expected that the intervention patients restart 
normal and daily life sooner (shorter absence from (volunteer) work) 
compared to patients who are not treated according to the new clinical 
pathway. 
3.4 Defining the intervention, comparison treatment and target population 
Details of the clinical pathway must be clearly specified in a future study. 
This means that not only the intervention on the different departments (IC, 
MC and ward) needs to be described in detail but also the care as usual. 
In the description of the IC protocol details of early extubation, frequen-
cies of regular checks, temperature management, sedation and pain 
management are important. The difference between this future study 
and the performed SSIC study is that not only must it focus on the evalua-
tion of an intervention in the first hours of intensive care treatment, but on 
all aspects of the pre-, peri- and postoperative care of CABG patients. An 
important aspect of this new study should be that patients who fulfill the 
IC discharge criteria are immediately transferred to a lower care facility 
(MC or ward). In addition not only discharge after 8 hours IC treatment 
must be considered as an option for transferring patients, but other time 
points in a range of 6 to 12 hours should also be included. These protocols 
must also describe details of, for instance, the preoperative screening 
day, temperature management during surgery, anesthetic doses, mobili-
zation of patients by physiotherapist and nurses. As discussed in the im-
plementation section the care as usual can vary between different hospi-
tals and settings. It is important to compare, if possible, the new clinical 
pathway with the most important comparators of care, which are the 
most realistic policy choices. 
The target population of a future study should contain both low-risk and 
high-risk CABG patients and the eligibility criteria need to be based on 
current standards of risk stratification (Michel, 2003; Nilsson, 2006). 
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3.5 Boundaries and time horizon of the economic evaluation 
The scope of a future study should be the evaluation of the clinical effec-
tiveness and cost-effectiveness of the clinical pathway for all CABG pa-
tients. Aspects that are not primarily related to the abovementioned 
scope, like the influences on quality of life of family members and costs 
made by those relatives due to illness of the patients under study, should 
not be incorporated in the analysis. 
In a future study the follow-up must be until one year after treatment, for 
all relevant study outcomes: clinical outcomes, quality of life and costs. 
One year follow-up can be chosen as the time frame for this study as it is 
a well accepted follow-up for rehabilitation after CABG surgery (Badia, 
2001; Borkon, 2002; Cheng & Barash, 2006). 
4 Choosing quality of life measures for a future study 
4.1 Generic quality of life measures 
In many ways it is important to know the possible effects of a new treat-
ment on quality of life. One of its merits is that it can help clinicians to ex-
plain to patients what they can expect from a specific treatment. Be-
sides, if more than one therapeutic option is available, this knowledge -in 
addition too clinical and cost-effectiveness- contributes to making ra-
tional choices concerning the most appropriate therapy. As the meas-
urement of QoL is subjective it is very important to use validated and reli-
able instruments. The EQ-5D was chosen in the SSIC study as generic 
measure for several reasons. Firstly, it is has good psychometric propor-
tions (Brazier, 1993). Secondly, it is brief, simple and easy to administer (on-
ly 6 items). In addition it is suitable for EE as it can generate a single index 
score for health (utility) by means of population weights (Dolan, 1997). 
Besides using it for the EE (chapter 3) we wanted to use the same instru-
ment for describing patients' quality of life in the five different dimensions, 
so we could use this in the QoL-study (chapter 4). 
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Based on our findings of the validity and reliability study (chapter 5) it may 
be better not to choose the EQ-5D but another generic instrument for the 
evaluation of QoL in evaluation study of the clinical pathway for CABG 
patients. There are several other preference-based measures that can be 
considered. The other questionnaires most commonly used with the same 
possibilities as the EQ-5D are the Short Form-36 (SF-36) and the Health Utili-
ties Index (HUI). The HUI contains 15 questions and classifies patients in ei-
ther HUI2 or HUI3 health states. In our opinion this questionnaire contains 
attributes that are not relevant for the evaluation of the clinical pathway: 
sensation and fertility in the HUI2; vision, hearing, speech and fertility in the 
HUI3. 
Should we then use the SF-36 (and therefore the SF-6D) for a future study 
instead of EQ-5D? A theoretical advantage of the SF-6D is that it contains 
a larger descriptive system (i.e. 18.000 unique health states can be de-
scribed by SF-6D compared to only 243 by EQ-5D), therefore it potentially 
has greater ability to identify small changes (Bryan & Longworth, 2005). 
Another advantage of using the SF-6D is its better ability to detect im-
provements in the upper range of the utility scale in cardiovascular disor-
ders (Moock & Kohlmann, 2008). A disadvantage of the SF-6D is that it 
does not describe health states at the lower end of the scale (Longworth 
& Bryan, 2003). Based on a head-to-head comparison of EQ-5D and SF-
6D in patients with coronary heart disease Van Stel concluded there is no 
clear benefit of using SF-6D in clinical studies instead of EQ-5D (van Stel & 
Buskens, 2006). Others do not prefer one to the other (Kopec & Willison, 
2003) either as both questionnaires have several disadvantages. Some 
authors found no sensitivity to change of SF-6D after the intervention 
(Longworth & Bryan, 2003; Smith, 2000; van Stel & Buskens, 2006). We were 
also not able to demonstrate sensitivity to change for EQ-5D (chapter 5). 
In our opinion based on the above-mentioned advantages and disad-
vantages and the results of our study (chapter 5) either SF-6D or EQ-5D 
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should be chosen for fhe measuremenf of generic qualify of life in a fu-
ture study evaluating the entire clinical pathway for CABG patients. 
4.2 Disease specific quality of life measures 
For the assessment of QoL of people with ischemic heart disease it is rec-
ommended to use a disease specific QoL questionnaire (Dempster & 
Donnelly, 2000) in addition to a generic questionnaire. In the QoL-study 
(chapter 4) we used the Multidimensional index of quality of life (MILQ) as 
disease specific instrument. There were two reasons why we chose this 
questionnaire in our evaluation study: a Dutch version of this question-
naire was already available, and both psychometric proportions (validity 
and reliability) were extensively examined by Avis et al. (Avis, 1996). The 
conclusion of these authors was that this instrument was valid and reli-
able, contrary to our study findings (chapter 5). 
At the moment there are various other options for the evaluation of dis-
ease specific QoL of the clinical pathway of CABG patients. The two most 
commonly used are the Seattle Angina Questionnaire (SAQ) (Dougherty, 
1998; Spertus, 1995) and the MacNew Heart Disease Questionnaire 
(MacNew) (Lim, 1993). The SAQ consists of 19 items, which are grouped in 
five separate domains: physical limitation, angina stability, angina fre-
quency, treatment satisfaction and disease perception. The MacNew 
consists of 27 items, which fall into the following three domains: physical 
limitations, emotional function and social function. All domains of the 
MacNew and SAQ are responsive and their test-retest reliability can also 
be classified as high (Dougherty, 1998; Hofer, 2003; Hofer, 2004; Spertus, 
1994; Spertus, 1995). Furthermore, it was found that none of the SAQ do-
mains and most of the MacNew domains are able to discriminate be-
tween patients in Canadian Cardiovascular Society functional classes l-IV 
(Hofer, 2003). Dougherty et al., however, found that all the SAQ domains 
except for treatment satisfaction were able to discriminate between Ca-
nadian Cardiovascular Society functional classes l-lll. Based on previous 
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findings we can conclude that the psychometric proportions of both 
questionnaires can be classified as good. However, none of the SAQ and 
only a few of the studies evaluating the reliability and validity of the 
MacNew are performed in the Netherlands. In addition to this the study 
population consisted mostly of patients with a stable angina and not of a 
population of CABG patients. Therefore in our opinion further research is 
needed to either prefer the SAQ to the MacNew for the measurement of 
disease specific QoL in a future study evaluating the clinical pathway for 
CABG patients. 
5 Effects of using correction methods for imbalances in baseline utility in 
QALY-calculations on SSIC study findings 
In our EE (chapter 2) we corrected for imbalances in baseline utility by 
means of the delta method. The conclusion of the EE based on using this 
correction method was that the SSIC was a cost-effective treatment. Al-
though this correction method is generally accepted (Cheng, 2000; 
Guthrie, 1999; Hurskainen, 2001; Lee, 2002; Patterson, 1995), it has an im-
portant drawback: it does not correct for regression towards the mean 
phenomenon. In an additional study (chapter 6) we investigated the im-
pact of different correction methods and concluded that the regression-
based QALY adjustment was the preferred correction method. If we cal-
culate the ICERs using the regression-based QALY adjustment, this me-
thod showed more uncertainty about the study findings of the EE com-
pared to calculation of the ICERs using the delta adjustment method. 
When using this correction method after bootstrapping, 98% of the ICERs 
were situated in the Southeast Quadrant compared to 63% using regres-
sion-based QALY adjustment. Can we therefore still say that the SSIC is a 
cost-effective treatment? Yes, because the point estimates indicate 
dominance of the SSIC treatment; there is, however, more uncertainty 
about this, as 33% of the ICERs lay in the Southwest quadrant, indicating 
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that the SSIC intervention is cost saving but not more effective compared 
to care as usual. 
6 Summary of recommendations 
Based on the evidence of this thesis we would recommend: 
1. a before-after multicenter trial that evaluates the entire clinical 
pathway instead of a randomised controlled trial in a single cen-
ter with the focus on an intervention that only evaluates the first 
eight hours of intensive care treatment as study design; 
2. not only a CEA as analysis design, but also outcomes that are 
more relevant to the primary audience, like costs of implementa-
tion; 
3. not only a hospital, but also a societal perspective; 
4. to include both low and high-risk CABG patients instead of low-risk 
on a long-term follow-up (of one year) for all study outcomes in-
stead of the one month follow-up for clinical outcomes and costs 
used in the SSIC study; 
5. the SF-6D or EQ-5D for the measurement of generic QoL; 
6. the SAQ or MacNew instead of the MILQ for the measurement of 
disease specific QoL; 
7. the regression-based QALY adjustment method instead of the 
delta adjustment method, if baseline imbalances in utility occur. 
In conclusion, all the above listed recommendations are important for 
future research of studies evaluating new treatments in CABG pa-
tients, the last recommendation, however, applies to cost-
effectiveness analyses in general, too. 
7 Practical recommendations for future research 
In this last part some practical recommendations for future research will 
be given based on the experience of performing the SSIC study. 
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7.1 Information to healthcare professionals 
• Organize a kick off meeting at the start of the study for all health-
care professionals. 
• Keep the study protocol, summary of treatment protocol, and 
telephone list available and up-to-date at a central place. 
• Inform all healthcare professionals once a month about study 
progress, and immediately about protocol changes. Do not forget 
to inform new employees. 
7.2 Treatment evaluation 
• Perform multidisciplinary meetings once a week to evaluate the 
treatment of control and intervention patients. Record all main 
findings and issues. 
• Give feedback on treatment issues and applications of case re-
cord forms to healthcare professionals as soon as possible. 
7.3 Informed consent procedure and patient guidance 
• Inform patients on the day of admission in the morning hours in an 
individual approach. 
• Ask them to fill in questionnaires and let them write down ques-
tions concerning the study. Collect the questionnaires in the after-
noon, and check missing items therefore. 
• Visit patients frequently during hospital stay. Visit patients also at 
the day of discharge and inform them about their follow-up (e.g. 
questionnaires and hospital visits). 
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Chapter 8 
In dit hoofdstuk worden de belangrijkste bevindingen van dit proefschrift 
samengevat. In het eerste gedeelte van dit hoofdstuk wordt een sa-
menvatting van de verschillende studies gegeven (1). De barrières voor 
implementatie van de short-stay intensive-care interventie worden be-
sproken in het tweede gedeelte (2). In de laatste twee gedeeltes (3 en 
4) wordt een samenvatting van de aanbevelingen voor verder onder-
zoek gegeven. 
1 Samenvatting van de studies in het proefschrift 
1.1 Huidige kennis met betrekking tot fast-track behandeling voor laagri-
sico CABG-patiënten (hoofdstuk 2) 
In het tweede hoofdstuk van dit proefschrift worden de resultaten van 
een systematische literatuurstudie beschreven. 27 gerandomiseerde, 
gecontroleerde studies die fast-track behandelingen evalueerden wer-
den gevonden in de MEDLINE en in de Cochrane databestanden. Om-
dat de verschillende studies heterogeen waren wat betreft de onder-
zochte interventies is een metaregressie analyse uitgevoerd. Hierbij zijn 
de studies ingedeeld op grond van belangrijke kenmerken van fast-track 
behandelingen: type en dosis anestheticum, extubatietijd en tempera-
tuurmanagement. De belangrijkste bevinding van deze metaregressie 
analyse is dat de introductie van een protocol dat gericht is op snelle 
extubatie een belangrijke voorspeller is voor de afname van het totaal 
aantal uren intensive-care verblijf en ziekenhuisverblijf bij laagrisico 
CABG-patiënten. 
In dit hoofdstuk zijn ook de verschillende studies onderzocht op hun me-
thodologische kwaliteit. De epidemiologische kwaliteit van de 27 studies 
was redelijk. Eén studie voldeed aan alle drie methodologische criteria: 
het gebruik van intention-to-treat analyse voor de primaire studie uit-
komst (intensive-care verblijf), allocation concealment (het geheim hou-
den of blinderen van de toewijzing van patiënten aan de verschillende 
onderzoeksgroepen) en blindering van de personen die de lengte van 
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de intensive-care duur bepalen. De kwaliteit van de economische eva-
luaties van de studies is onderzocht aan de hand van de Consensus 
Health Economics Criteria list (CHEC-list). The CHEC-list scores van de 17 
gescoorde items van de studies was laag (gemiddeld 8 punten). Dit was 
met name te wijten aan een verkeerde keuze van het onderzoeksdesign 
en verkeerd gebruik van methoden om de kosten te berekenen. De be-
vindingen van deze literatuurstudie laten zien dat er een noodzaak is om 
zowel de kwaliteit van de initiële studies alsmede die van de economi-
sche evaluaties te verbeteren. 
1.2 Klinische effectiviteit en kosteneffectiviteit van het short-stay intensive 
care protocol (hoofdstuk 3) 
Het effect van een short-stay intensive-care verblijf is onderzocht bij zes-
honderd laagrisico CABG-patiënten door middel van een gerandomi-
seerde, gecontroleerde klinische equivalentie trial en een hieraan ge-
koppelde economische evaluatie. Patiënten die een laagrisico hadden 
op complicaties mochten meedoen in deze studie. Inclusie criteria wa-
ren bijvoorbeeld: jonger dan 78 jaar, een ejectiefractie van meer dan 
30%, geen dialyse nodig hebben, geen pulmonaire hypertensie. De car-
diologische toestand van de patiënten moest eveneens stabiel zijn. Pati-
enten ingedeeld in de SSIC-groep werden binnen 8 uur overgeplaatst 
van de intensive care naar de medium care ais ze voldeden aan de 
volgende ontslagcriteria: extubatie gedurende minstens 30 minuten, 
normale ademhaling, arteriële bloed gassen Pao2 > 10 kPa and Paco2 < 
6.0 kPa, cardiologisch stabiel, vochtbalans onder controle (< 100 ml tho-
rax drain per uur en een diurese > 0.5 ml/kg/uur), geen signalen en symp-
tomen van neurologische complicaties en geen noodzaak voor hemo-
dynamische en ondersteunende therapie. 
De primaire studie uitkomsten waren het aantal intensive-care herop-
names en de totale duur van de ziekenhuisopname. Vier controlegroep 
patiënten (1.34%) en acht (2.68%) SSIC-patiënten werden heropgeno-
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men op de intensive-care afdeling. Het verschil van 1.13% tussen beide 
groepen was niet significant verschillend (P-waarde = .241; 95% be-
trouwbaarheidsinterval: -.9% tot 2.9%). Er werd ook geen verschil gevon-
den in de twee groepen met betrekking tot de totale duur van de zie-
kenhuisopname en de andere secundaire uitkomsten postoperatieve 
morbiditeit en 30 dagen mortaliteit. De patiënten in de SSIC-groep ver-
bleven significant minder uren op de intensive care vergeleken met de 
controlegroep patiënten. In de interventiegroep waren de totale kosten 
gemiddeld €816,- lager vergeleken met de gemiddelde kosten van de 
patiënten in de controlegroep. De kostenbesparing in de SSIC-groep 
werd voornamelijk veroorzaakt door lagere kosten van klinische verrich-
tingen en intensive- care verblijf. De kwaliteit van leven uitgedrukt in -
delta van voor kwaliteit van leven gecorrigeerde levensmaanden (A 
QALM)- was significant verschillend tussen beide groepen, en hoger voor 
de SSIC-patiënten. De incrementele kosteneffectiviteitsratio en de 98% 
van de gebootstrapte ICERs lagen in het zuidwest-kwadrant. Dit geeft 
aan dat de SSIC-interventie dominant is ten opzichte van de standaard 
zorg. De conclusie van deze studie is dat de SSIC een veilige en kosten-
effectieve behandeling is vergeleken met de huidige standaard behan-
deling (24-uur intensive-care zorg). 
1.3 Kwaliteit van leven na een fast-track behandeling (hoofdstuk 4) 
Het doel van deze gerandomiseerde, gecontroleerde equivalentie stu-
die was het evalueren van ziekte specifieke, algemene en domein speci-
fieke kwaliteit van leven tot een jaar na de short-stay intensive-care be-
handeling. Ziekte specifieke kwaliteit van leven werd gemeten met be-
hulp van de Multidimensional Index of Life Quality, de algemene kwaliteit 
van leven door middel van de EQ-5D en de domein specifieke door 
middel van de Beck Depression Inventory en State-Trait Anxiety Inven-
tory. De metingen werden verricht op de dag vóór de operatie en op 
één en twaalf maanden erna. De belangrijkste bevindingen van deze 
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studie zijn dat na een multivariate analyse op één jaar na de operatie 
geen significant verschil in kwaliteit van leven tussen SSIC-patiënten en 
controlegroep patiënten waar te nemen is. Ook na de correctie van 
mogelijke verstorende factoren (zoals bijvoorbeeld co-morbiditeiten en 
leeftijd) was er op één jaar na de operatie geen statistisch significant 
verschil tussen beide groepen waargenomen. De conclusie van deze 
studie is dat op het gebied van de kwaliteit van leven geen van de 
waargenomen verschillen tussen beide behandelingsgroepen klinisch 
relevant verschillend zijn. 
1.4 Het testen van de validiteit en de betrouwbaarheid van de EuroQoL 
en Multidimensional Index of Life Quality (hoofdstuk 5) 
Het doel van deze prospectieve studie was het testen van de validiteit 
en de betrouwbaarheid van de EuroQoL (EQ-5D) en de Multidimensional 
Index of Life Quality (MILQ) in CABG-patiënten. 
De belangrijkste bevindingen van deze studie waren dat de discrimina-
tieve validiteit in de vijf EQ-5D dimensies werd beperkt door plafondef-
fecten (het percentage patiënten met een maximale score). Deze ef-
fecten traden ook op bij twee van de negen MILQ-domeinen. De pre-
dictieve validiteit op één maand na de operatie van het EQ-5D domein 
angst/depressie, EQ-5D VAS, MILQ-domein fysieke gezondheid en de 
MILQ-score waren redelijk. Op 12 maanden na de operatie hadden de 
EQ-5D VAS, de MILQ-score en de twee fysieke dimensies van de MILQ 
een goede predictieve validiteit. Alleen het EQ-5D domein dagelijkse 
activiteiten en de EQ-5D VAS kunnen onderscheid maken tussen patiën-
ten ingedeeld in de verschillende New York Heart Association functional 
classification categorieën (externe criterium validiteit). De test-hertest 
betrouwbaarheid van beide vragenlijsten kan worden geclassificeerd als 
onvoldoende. 
De conclusies van deze studie zijn dat de discriminatieve validiteit van 
de EQ-5D domeinen, de externe criterium validiteit en de predictieve 
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validiteit van zowel de EQ-5D en de MILQ beperkt zijn. Daarnaast is de 
betrouwbaarheid van beide vragenlijsten niet toereikend. Op basis van 
de bevindingen van onze studie kunnen we concluderen dat beide vra-
genlijsten niet de voorkeur hebben bij het evalueren van de kwaliteit van 
leven van CABG-patiënten. 
1.5 Correctiemethoden voor baseline utiliteitsverschillen tussen twee be-
handelingsstrategieën in voor kwaliteit van leven gecorrigeerde levens-
jaar berekeningen (hoofdstuk 6) 
Het doel van deze laatste studie was het evalueren van verschillende 
strategieën die kunnen corrigeren voor baseline utiliteit verschillen in voor 
kwaliteit van leven gecorrigeerde levensjaar (QALY) berekeningen zodat 
er analyses kunnen worden gedaan op patiëntniveau. 
De data van de trial die de short-stay intensive-care behandeling voor 
CABG-patiënten onderzocht, werd gebruikt als case studie. Vijf verschil-
lende methoden werden toegepast: 1) de conventionele QALY bereke-
ning, waarbij geen baseline correctie plaatsvindt; 2) Correctie met de 
verschillen tussen de gemiddelde baseline utiliteit van beide behande-
lingsgroepen; 3) De Delta correctiemethode, waarbij alleen de verande-
ringen in de utiliteit tussen beide metingen wordt gebruikt; 4) een op 
regressie gebaseerde utiliteitscorrectie, waarbij een regressie-model 
wordt gebruikt met daarin de follow-up utiliteit als de afhankelijke 
variabele en de baseline utiliteit als de onafhankelijke variabele; 5) een 
op regressie gebaseerde QALY correctie, waarbij de QALY de afhanke-
lijke en de baseline utiliteit de onafhankelijke variabele is in het regressie-
model. 
De resultaten van deze studie laten zien dat het niet-gebruiken van een 
correctiemethode wanneer er wel baseline utiliteitsverschillen optreden, 
resulteert in verschillende kosteneffectiviteit uitkomsten. De mate van de 
invloed van de correctiemethoden is afhankelijk van welk type correc-
tiemethode er wordt gebruikt. Op basis van de resultaten van deze stu-
die wordt aanbevolen dat wanneer er een baseline verschil in de utiliteit 
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wordt waargenomen deze het beste kan worden gecorrigeerd met be-
hulp van de regressie-gebaseerde QALY correctie. De uitkomsten van 
de andere correctiemethoden kunnen worden gerapporteerd in aanvul-
lende sensitiviteitsanalyses. 
2 Mogelijkheden voor implementatie van het huidige short-stay 
intensive care protocol 
De bevindingen van de SSIC-studie laten zien dat de resultaten aanlei-
ding zouden kunnen zijn om het SSIC-protocol te implementeren in de 
Nederlandse ziekenhuizen. Echter meer dan drie jaar na de publicatie 
van de belangrijkste bevindingen van de SSIC-studie hebben we echter 
geen informatie dat ziekenhuizen op dit moment het SSIC- protocol ge-
bruiken. 
De redenen waarom dit tot op heden nog niet gebeurd is, worden uit-
gebreid besproken in hoofdstuk 7, paragraaf 2. Een van de redenen die 
kan worden geopperd, is dat de implementatie op basis van één onder-
zoek niet voldoende reden is voor beleidsmakers om volgens het SSIC-
protocol te gaan werken. Daarnaast zijn er een heel aantal potentiële 
barrières te bedenken die implementatie van het SSIC-protocol in de 
huidige vorm in de weg kunnen staan. Zoals de infrastructuur van de ver-
schillende intensive en medium care afdelingen in de diverse cardio-
thorale centra in Nederland. Als bijvoorbeeld CABG-patiënten op ge-
mengde IC's liggen, heeft dit direct gevolgen voor de patiëntenlogistiek. 
Een ander voorbeeld van een barrière kan zijn dat er hoge kosten moe-
ten worden gemaakt voor het verbouwen van de IC en MC afdelingen 
als er geen apparte MC aanwezig is. Een belangrijke andere barrière is 
dat het met het huidige protocol niet mogelijk is om exact te bepalen 
hoeveel patiënten wanneer op welke afdeling liggen, waardoor het 
moeilijk is om een personeelsplanning te maken. Daarnaast is het zo dat 
door recente veranderingen in de patiëntenpopulatie er minder laagri-
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sico CABG-patiënten zijn, waardoor het implementeren van een proto-
col specifiek voor deze groep geen hoge prioriteit heeft. 
3 Samenvatting van de aanbevelingen 
Gebaseerd op de bevindingen van dit proefschrift kunnen de volgende 
aanbevelingen worden gedaan: 
1. gebruik een vóór-na trial die de totale behandeling van 
CABG-patiënten evalueert in verschillende ziekenhuizen in 
plaats van een gerandomiseerde, gecontroleerde trial 
die alleen de eerste 8 uur intensive-care behandeling in 
één ziekenhuis evalueert; 
2. neem naast de klinische en kosteneffectiviteit ook uitkom-
sten mee die relevant zijn voor het primaire publiek van 
de studie (managers van de IC's en directie van zieken-
huizen), zoals de kosten van implementatie en scenario 
analyses die de impact van een nieuwe behandeling op 
veranderingen van patiëntstromen en wachtlijsten inzich-
telijk maken; 
3. neem een maatschappelijk en ziekenhuis perspectief als 
uitgangspunt voor de economische evaluatie in plaats 
van alleen een ziekenhuis perspectief; 
4. meet alle studieuitkomsten bij zowel hoog- als laagrisico 
CABG-patiënten met een lange termijn follow-up (1 jaar) 
in plaats van alleen laagrisico en een korte termijn follow-
up voor klinische effecten en kosten zoals in de SSIC-
studie; 
5. gebruik de SF-óD of de EQ-5D voor het meten van alge-
mene kwaliteit van leven; 
6. gebruik de Seatlle Angina of MacNew vragenlijst in plaats 
van de MILQ voor de meting van ziekte specifieke kwali-
teit van leven; 
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7. gebruik, als er baseline verschillen in utilitieitsmetingen op-
treden, de op QALY gebaseerde regressie correctieme-
thode voor de berekening van voor kwaliteit van leven 
gecorrigeerde levensjaren in plaats van de delta correc-
tiemethode. 
Samenvattend: alle aanbevelingen die hierboven zijn opgenoemd 
zijn belangrijk voor toekomstig onderzoek die nieuwe behandelingen 
voor CABG-patiënten evalueren. De laatste aanbeveling is echter 
ook van belang voor kosteneffectiviteitsanalyses in het algemeen. 
4 Praktische aanbevelingen voor toekomstig onderzoek 
In dit laatste gedeelte wordt een aantal praktische aanbevelingen ge-
daan voor toekomstig onderzoek. 
4.1 Informatie voor personeel in de gezondheidszorg 
• Organiseer een kick-off meeting aan het begin van de studie 
vooral het betrokken personeel. 
• Houd het onderzoeksprotocol, een samenvatting van het be-
handelingsprotocol en een up-to-date telefoonlijst beschikbaar 
op een centrale plaats. 
• Informeer al het personeel eens per maand over de studie voort-
gang, en onmiddellijk over wijzigingen in het protocol. Vergeet 
niet nieuwe medewerkers te informeren. 
4.2 Evaluatie van de behandeling 
• Houd wekelijks multidisciplinaire meetings en evalueer de be-
handeling van zowel interventie- alsook controlegroep patiënten. 
Notuleer alle belangrijke bevindingen en onderwerpen. 
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• Geef zo snel als mogelijk feedback aan het personeel over be-
handelingsgerelateerde onderwerpen en het invullen van Case 
Record Forms. 
4.3 Informed consent procedure en patiëntenbegeleiding 
• Informeer patiënten persoonlijk op de dag van de opname, in de 
ochtend. 
• Vraag of ze de vragenlijsten willen invullen en vragen te noteren. 
Verzamel de vragenlijsten in de namiddag en controleer op 
eventueel onbrekende items. 
• Bezoek de patiënten regelmatig gedurende hun verblijf in het 
ziekenhuis. Bezoek hen ook op de dag dat ze naar huis gaan en 
informeer ze dan over de follow-up (bijvoorbeeld vragenlijsten en 
poliklinische bezoeken). 
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